Preparation method of chiral amino acid
Through asymmetric decarboxylation reaction catalyzed by chiral phosphoric acid, the enantiomer excess rate and multiple side chain problems in the preparation of chiral amino acids in the prior art are solved, and efficient and diversified chiral amino acid preparation is achieved.
Patent Information
- Application Number
- CN202410557097.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-18
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to efficiently prepare chiral amino acids, especially in obtaining chiral amino acids with high enantiomer excess and multiple side chains.
Chiral phosphoric acid is used as a catalyst to convert amino-malonic acid into chiral amino acids with multiple side chains through asymmetric decarboxylation reactions. Chiral phosphoric acid is used to achieve selective protonation in the decarboxylation process, achieving high optical purity and high yield. Rate.
Chiral amino acid preparation with high enantiomer excess (at least 70% ee value) and high yield (at least 80%) is achieved to meet a variety of side chain needs.
Smart Images

Figure CN118993926A_ABST
Abstract
Description
Cross-references to Related Patent Applications
[0001] This application claims priority to U.S. Provisional Application No. 63 / 503,061, filed May 18, 2023, the entire contents of which are incorporated herein by reference. Technical Field
[0002] The present disclosure relates generally to the field of chiral amino acids. Background Art
[0003] Organic synthesis often uses active methylene compounds to build complex structures. When the methylene bridge is located between two electron-withdrawing groups, the methylene bridge is easily deprotonated and doubly substituted. When these substitution reactions are combined with further derivatization reactions of the tetrasubstituted carbon, multifunctional structures can be quickly provided. Malonate synthesis is an example of this paradigm, which has been implemented for more than a century to produce α-substituted carboxylic acids through a series of substitutions, hydrolysis and decarboxylation (J. Wislicenus, Liebigs Ann. Chem. 186, 161-228 (1877); ACCope et al., Org. React. 107-331 (1957); and H.O. House, Modern Synthetic 2nd ed W.A. Benjamin, inc., 1972, pp. 492-623). When combined with the phthalimide-based Gabriel amine synthesis (S. Gabriel, Ber. 20, 2224-2236 (1887); MS Gibson and RW Bradshaw, Angew. Chem., Int. Ed. Engl. 7, 919-930 (1968)), this synthetic approach can further produce α-amino acids (SK Mitra, J. Ind. Chem. Soc. 7, 799-802 (1930)). Although the malonic acid-based approach has the advantages of easy substrate preparation and high modularity, its ability to stereoselectively access these acids is limited.
[0004] Asymmetric malonate synthesis requires a fast and stereoselective decarboxylation pathway that can outperform the self-decarboxylation of racemic acids by delivering a small proton precisely to one face of the enol intermediate after CO2 extrusion. These challenges can be addressed by the enzyme catalysis of arylmalonate decarboxylase (AMDase, EC 4.1.1.76, K.Miyamoto and Kourist, R., Appl.Microbiol.Biotechnol.100, 8621-8631 (2016); M.Wilding et al., Comprehensive Chirality, H.Yamamoto and EMCarreira, eds. (Elsevier, 2012) pp.402-409). In alkaline media, the diacid substrate is deprotonated to its conjugate base, which has an inhibited self-decarboxylation and can enter the active site of arylmalonate decarboxylase (AMDase), which contains two polar pockets of different sizes and a dioxyanion hole (WH Richardson and H.E.O. Neal, Comprehensive Chemical Kinetics: Decomposition and Isomerization of Organic Compounds, edited by CH Bamford and CFH Tipper (Elsevier, 1972) pp.381-565). The anion hole is composed of four residues and six hydrogen bond donors, which lower the decarboxylation barrier by stabilizing the negative charge. Subsequently, the nearby cysteine protonates the fixed dianion in a stereoinverted manner. This enzymatic method has a special selectivity for the decarboxylation of malonates with an aryl group and a small alkyl group. However, the amino acids obtained using this method (ie, compounds 10a and 10b in K. Okrasa et al., Angew. Chem. Int. Ed. 48, 7691-7694 (2009)) were only moderately enantiomeric enriched (ie, enantiomeric excess of 61%).
[0005] Also attempted to carry out asymmetric decarboxylation by chemical catalysis (J.Blanchet et al., Eur.J.Org.Chem.5493-5506 (2008)). Early studies of malonic acid show that decarboxylation rate is higher in alkaline solvents such as tertiary amine and pyridine, which suggests that there may be base catalysis (WHRichardson and HEO'Neal, Comprehensive Chemical Kinetics:Decomposition and Isomerization of Organic Compounds, CHBamford & C.FHTipper edit (Elsevier, 1972), pp.381-565). Therefore, people have carried out a large amount of research on organic bases, particularly cinchona alkaloids. However, these alkalis can only produce limited enantioinduction, so ee value is lower. For example, H. Brunner and MA Baur found the best results for the organic base-catalyzed decarboxylation of aminomalonic acid (H. Brunner and MA Baur, Eur. J. Org. Chem. 2854-2862 (2003)), where malonate 4 gave amino acid ee values of 8.1 and 11.9%.
[0006] There is still a need to develop better methods for preparing chiral amino acids, such as high enantiomeric excess (ee).
[0007] Therefore, one object of the present invention is to provide a method for preparing chiral amino acids with high enantiomeric excess (ee).
[0008] Another object of the present invention is to provide a method for preparing chiral amino acids with various side chains.
[0009] Another object of the present invention is to provide chiral amino acids with various side chains. Summary of the Invention
[0010] The inventors have developed a method for preparing chiral α-amino acids using chiral phosphoric acid as a catalyst. The method disclosed herein can use amino-malonic acid as a substrate to generate chiral amino acids with a variety of side chains in high optical purity (e.g., an ee value of at least 70%) and high yield (i.e., a yield of at least 80%, for example, in the range of about 80% to about 99%) through an asymmetric decarboxylation reaction. The decarboxylation reaction of the method is catalyzed by chiral phosphoric acid, and selective protonation can be achieved during the decarboxylation process, which is considered to be one of the most difficult processes in asymmetric catalysis. In some forms, the catalyst can be a chiral phosphoric acid supported on a suitable carrier.
[0011] In general, the method for preparing chiral amino acid comprises: (i) the first reaction mixture is maintained at a first temperature, maintaining a first time period sufficient to form a product containing chiral amino acid. The first reaction mixture comprises substrate, catalyst and solvent. The solvent is preferably an ether, such as cyclopentyl methyl ether (CPME). The catalyst is typically chiral phosphoric acid. In some forms, the catalyst is a chiral phosphoric acid supported on a carrier. Typically, the amount of the catalyst in the first reaction mixture ranges from about 1mol% to about 20mol%, about 1mol% to about 10mol%, about 2mol% to about 20mol%, about 2mol% to about 10mol%, or about 2.5mol% to about 10mol%, such as about 10mol% or about 2.5mol%.
[0012] Generally speaking, the first reaction mixture can be maintained at a temperature in the range of about 50°C to about 100°C, about 60°C to about 100°C, or about 70°C to about 100°C, for example, a temperature of about 80°C, for a period of time ranging from about 1 hour to about 12 hours, about 1 hour to about 10 hours, about 1 hour to about 8 hours, about 1 hour to about 5 hours, or about 1 hour to about 3 hours, for example, about 2 hours, to produce a product containing a chiral amino acid.
[0013] Typically, the substrate is malonate. In some forms, malonate can have a structure of Formula I or Formula I': The chiral amino acid in the product can have the structure of Formula II or Formula II': Wherein P1 can be an amino protecting group, and R1 can be any suitable functional group or biomolecule moiety.
[0014] In some forms, the method of the present disclosure further comprises: (ii) adding an alkylation reactant (e.g., a methylation reactant, such as trimethylsilyldiazomethane, or an ethylation reactant) or an acid (e.g., HCl) to the product to form a second reaction mixture; (iii) maintaining the second reaction mixture at a second temperature for a second period of time sufficient to form an alkylation product (e.g., a methylation or ethylation product) or a hydrolysis product. The alkylation product or the hydrolysis product contains an alkylated chiral amino acid or a hydrolyzed chiral amino acid. In some forms, the alkylated chiral amino acid can have a structure of Formula VIII or Formula VIII', and the hydrolyzed chiral amino acid can have a structure of Formula V or Formula V': Wherein P1 and R1 may be as defined above, R 26 It can be a substituted or unsubstituted alkyl group, such as C1-C 12 Unsubstituted alkyl, C1-C 10 unsubstituted alkyl, C1-C8 unsubstituted alkyl, C1-C6 unsubstituted alkyl, or C1-C4 unsubstituted alkyl, such as methyl or ethyl, A1 can be an acid molecule (such as HCl),
[0015] In some forms, the second reaction mixture undergoes a methylation reaction. In these forms, the second reaction mixture is maintained at a temperature range of about 50°C to about 100°C, about 60°C to about 100°C, or about 70°C to about 100°C, for a duration of about 30 minutes to about 2 hours, or about 30 minutes to about 1 hour, to produce a methylated chiral amino acid; or the second reaction mixture is maintained at a temperature range of about 90°C to about 120°C, or about 90°C to about 110°C, for a duration of about 12 hours to about 36 hours, or about 12 hours to about 24 hours, to produce a hydrolyzed chiral amino acid. In some forms, after step (i), the product is cooled to room temperature or about 0°C before adding the alkylation reactant or the acid.
[0016] In some forms, P1 can be Where L1 can be: R2 can be hydrogen, hydroxy, halide, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, alkoxy, thiol, amino, amido, carbonyl, cyano, isocyano, nitro, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono; R3-R 10 can be independently hydrogen, or substituted or unsubstituted alkyl (e.g., unsubstituted alkyl, such as C1-C 10unsubstituted alkyl, C1-C8 unsubstituted alkyl, C1-C6 unsubstituted alkyl, or C1-C4 unsubstituted alkyl); when the substituents are present, the substituents may independently be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl, or phosphono.
[0017] In some forms, L1 can be R2 can be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, alkoxy, thiol, amino, amide, or carbonyl.
[0018] In some forms, R2 can be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, or substituted or unsubstituted aralkyl. In some forms, R2 can be where R 11 -R 15 R can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, nitro, amino, amido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono. In some forms, R 11 -R 15 can independently be hydrogen, halogen, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted phenyl, unsubstituted haloalkyl, unsubstituted aralkyl, cyano, isocyano, nitro, where R 16 -R 18 can be independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted phenyl, unsubstituted halogenated alkyl, or unsubstituted aralkyl, R' 18 An unsubstituted alkyl group may be used.
[0019] In some forms, R2 can be where R 12 -R 14 Can be independently a halide (such as F, Cl or I), an unsubstituted alkyl, an unsubstituted haloalkyl (such as a fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), a cyano group, an isocyano group, a nitro group, R 16 and R 18 can be independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or unsubstituted aralkyl (e.g., benzyl), R' 18 An unsubstituted alkyl group may be used.
[0020] In some forms, R2 can be where R 12 Can be R 13 It can be a halide (such as F, Cl or I), unsubstituted alkyl, unsubstituted haloalkyl (such as -CF3), cyano, isocyano, nitro, R 16 and R 18 can be independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or unsubstituted aralkyl (e.g., benzyl), R' 18 Can be unsubstituted alkyl. In some forms, R 13 Could be nitro.
[0021] In some forms, R1 can be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, wherein when substituents are present, the substituents can independently be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, azido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl, or phosphono. In some forms, when substituents are present, the substituents can independently be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, azido, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, or nitro. In some forms, when substituents are present, the substituents can independently be a biomolecule moiety.
[0022] In some forms, one or more carbons, one or more nitrogens, and / or one or more hydrogens of the substrate may be 13 C. 14 C. 15 N and / or D form.
[0023] In some forms, the chiral phosphoric acid can be BINOL phosphoric acid or a derivative thereof, H8BINOL phosphoric acid or a derivative thereof, SPINOL phosphoric acid or a derivative thereof, Biphenol phosphoric acid or a derivative thereof, dithiophosphoric acids or a derivative thereof, TADDOL phosphoric acid or a derivative thereof, paracyclophane or a derivative thereof, TiPSY phosphoric acid or a derivative thereof, or TRIP phosphoric acid or a derivative thereof. In some forms, the chiral phosphoric acid can have a structure of Formula III or Formula III': where R 19 、R 20 , R' 19 , and R' 20 R may independently be a substituted or unsubstituted aryl group, or a substituted or unsubstituted polyaryl group; 21 -R 24 and R' 21 -R' 24may independently be hydrogen or unsubstituted alkyl; when the substituents are present, the substituents may independently be substituted or unsubstituted alkyl, substituted or unsubstituted aryl (e.g. phenyl), substituted or unsubstituted polyaryl (e.g. naphthyl), substituted or unsubstituted haloalkyl (e.g. fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or R 25 It can be a substituted or unsubstituted alkyl group, a substituted or unsubstituted haloalkyl group (for example, a fluorine-substituted C1-C6 haloalkyl group, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), a substituted or unsubstituted aryl group (for example, a phenyl group), or a substituted or unsubstituted aralkyl group (for example, a benzyl group).
[0024] In some forms, R 19 and R 20 At least one of R' 19 and R' 20 At least one of the can be independently substituted aryl or substituted polyaryl, optionally, wherein the substituted aryl or polyaryl has three or more substituents (such as 2,4,6-substituted phenyl). In some forms, the chiral phosphoric acid has the following structure:
[0025] In some forms, the disclosed method may further comprise one or more of the following steps: purifying the product after step (i), and / or purifying the alkylated or hydrolyzed product after step (iii); preparing the substrate before step (i); recovering the amino protecting agent and the catalyst after step (i) and / or step (iii); and / or derivatizing the chiral amino acid or the alkylated or hydrolyzed chiral amino acid into a derivative compound, such as a cyclic amino acid, a drug-amino acid conjugate, or a DNA gyrase inhibitor, after step (i) and / or step (iii).
[0026] In some forms, the derivatization step can be performed by an oxidation reaction, a coupling reaction (eg, a click reaction), a nucleophilic / electrophilic substitution, or a metathesis reaction, or a combination thereof.
[0027] In some forms, the substrate can be prepared using a commercially available malonate as a starting compound, such as a malonate having the structure of Formula VI; this starting material is converted to an amino-protected compound of Formula VII: wherein T1 and T2 can independently be unsubstituted alkyl groups, and P1 can be any amino protecting group, such as any of the amino protecting groups described above for the substrate. After the protection step, the amino protected compound of Formula VII can be converted to the substrate of Formula I or I' by substitution and hydrolysis, which can be performed sequentially or simultaneously. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 is a schematic diagram of an exemplary asymmetric decarboxylation reaction using chiral phosphoric acid.
[0029] Figure 2A The enantiomeric excess (ee) of 14 and the yield of 14 are plotted against different solvents. Figure 2B Schematic diagram of asymmetric decarboxylation using different amine protecting groups. aThe results were obtained using the same conditions as those shown in Scheme 19, except that the concentration of aminomalonic acid in the solvent was 0.05 M and the reaction time was 5 hours instead of 0.2 M and 2 hours.
[0030] Figures 3A-3D Schematic diagram of the synthesis of amino acids with different alkyl chains. Yield and enantiomeric excess are given after recrystallization.
[0031] Figures 4A-4C Schematic diagram of the preparation of different functionalized phenylalanines. Yield and enantiomeric excess were obtained after recrystallization.
[0032] Figure 5 Schematic diagram of the preparation of a DNA gyrase B inhibitor (79) containing a non-natural alanine residue. Yield and enantiomeric excess were obtained after recrystallization.
[0033] Figure 6 This is a schematic diagram of the crystal structure of (+)-17. Specific implementation plan
[0034] I. Definition
[0035] It should be understood that the disclosed compounds, compositions and methods are not limited to specific synthetic methods, specific analytical techniques or specific reagents, unless otherwise indicated, and therefore may vary. It should also be understood that the terminology used herein is only used to describe specific forms and embodiments and is not intended to be limiting.
[0036] As used herein, "substituted" refers to all permissible substituents of the compounds or functional groups described herein. In the broadest sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. Exemplary substituents include, but are not limited to, halogens, hydroxyl groups, or any other organic group containing any number of carbon atoms (preferably 1-14 carbon atoms), and optionally one or more heteroatoms, such as oxygen, sulfur, or nitrogen groups, in linear, branched, or cyclic structures. Representative substituents include substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, halogen, hydroxyl, alkoxy, alkylthio, substituted alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, substituted or unsubstituted carbonyl, carboxyl, amino, amido, oxo, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphanyl, phosphoryl, phosphonyl, and amino acid.Such substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, halogen, hydroxy, alkoxy, phenoxy, aryloxy, silyl, thiol, alkylthio, substituted alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, substituted or unsubstituted carbonyl, carboxyl, amino, amide, oxo, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphono and amino acid may be further substituted.
[0037] The heteroatoms (e.g., nitrogen) may have hydrogen substituents and / or any permissible substituents of organic compounds described herein that satisfy the valences of the heteroatoms. It is understood that "substituted" or "substituted" includes the implicit restriction that such substitution is based on the permissible valences of the substituted atom and substituents, and that the substitution results in a stable compound, i.e., a compound that does not spontaneously undergo transformations such as rearrangement, cyclization, elimination, etc.
[0038] As used herein, "alkyl" refers to a group of saturated aliphatic radicals, including straight-chain alkyl, branched-chain alkyl, and cycloalkyl (alicyclic) groups. In some forms, a straight-chain or branched-chain alkyl group has 30 or fewer carbon atoms in its backbone (e.g., a straight-chain C1-C1 30 , branched C3-C 30 ), 20 or less, 15 or less, 10 or less. Alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, etc. Similarly, cycloalkyl is a non-aromatic carbon-based ring composed of at least three carbon atoms, for example, a non-aromatic monocyclic ring or non-aromatic polycyclic ring containing 3-30 carbon atoms, 3-20 carbon atoms, or 3-10 carbon atoms in its ring structure, preferably having 5, 6, or 7 carbons in the ring structure. Cycloalkyl containing a polycyclic system can have two or more non-aromatic rings, wherein two or more carbon atoms are shared by two adjacent rings (i.e., a "fused cycloalkyl ring"). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.
[0039] "Substituted alkyl" refers to an alkyl moiety having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. These substituents can be any of the substituents described above, for example, a halogen (e.g., fluorine, chlorine, bromine, or iodine), a hydroxyl group, a carbonyl group (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), a thiocarbonyl group (e.g., thioester, thioacetate, or thioformate), an aryl group, an alkoxyl group, an aralkyl group, a phosphonium group, a phosphanyl group, a phosphonyl group, a phosphoryl group, a phosphate group, a phosphonate group, a phosphinate ... e), amino, amido, amidine, imine, cyano, nitro, azido, oxo, sulfhydryl, thiol, alkylthio, silyl, sulfinyl, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aromatic, or heteroaromatic. -NRR', wherein R and R' each independently represent hydrogen, alkyl or aryl, wherein the nitrogen atom is optionally quaternized; -SR, wherein R is phosphono, sulfinyl, silyl, hydrogen, alkyl or aryl; -CN; -NO2; -COOH; carboxylate; -COR, -COOR or -CON(R)2, wherein R is hydrogen, alkyl or aryl; imino, silyl, ether, haloalkyl (such as -CF3, -CH2-CF3, -CCl3); -CN; -NCOCOCH2CH2; -NCOCOCHCH; and -NCS; and combinations thereof.
[0040] It will be appreciated by those skilled in the art that the substituted portion of the hydrocarbon chain itself may also be substituted, if appropriate. For example, the substituents of the substituted alkyl group may include halogen, hydroxyl, nitro, thiol, amino, aralkyl, azido, imino, amide, phosphonium, phosphino, phosphoryl (including phosphonate and phosphinate), oxo, sulfonyl (including sulfate, sulfonamido, sulfonamido and sulfonate) and silyl groups, as well as ether, alkylthio, carbonyl (including ketone, aldehyde, carboxylate and ester), haloalkyl (haloalkyls), -CN, etc. Cycloalkyl groups may be substituted in the same manner.
[0041] Unless the number of carbon atoms is otherwise specified, "lower alkyl" as used herein refers to an alkyl group as defined above but having 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms in its backbone structure. Similarly, "lower alkenyl" and "lower alkynyl" also have similar chain lengths.
[0042] As used herein, "heteroalkyl" refers to a linear or branched, or cyclic carbon-containing alkyl group containing at least one heteroatom in the carbon backbone, or a combination thereof. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized. For example, the term "heterocycloalkyl" is a cycloalkyl group as defined above, wherein at least one carbon atom of the ring is substituted with a heteroatom, such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
[0043] As used herein, the term "alkenyl" refers to a hydrocarbon group having 2 to 24 carbon atoms and a structural formula containing at least one carbon-carbon double bond. Alkenyl groups include straight-chain alkenyls, branched alkenyls, and cycloalkenyls. A cycloalkenyl group is a non-aromatic carbon-based ring composed of at least three carbon atoms and at least one carbon-carbon double bond, such as a non-aromatic monocyclic ring or a non-aromatic polycyclic ring containing 3-30 carbon atoms and at least one carbon-carbon double bond, 3-20 carbon atoms and at least one carbon-carbon double bond, or 3-10 carbon atoms and at least one carbon-carbon double bond in the ring structure, preferably containing 5, 6, or 7 carbon atoms and at least one carbon-carbon double bond in the ring structure. Cycloalkenyl groups containing polycyclic ring systems may have two or more non-aromatic rings in which two or more carbon atoms are shared by two adjacent rings (i.e., a "fused cycloalkenyl ring") and contain at least one carbon-carbon double bond. Asymmetric structures, such as (AB)C=C(C'D), are meant to include both E and Z isomers. This can be inferred from the presence of asymmetric olefins in the structural formula herein, or explicitly indicated by the bond symbol C. The term "alkenyl" as used throughout the specification, examples, and claims includes both "unsubstituted alkenyl" and "substituted alkenyl," the latter of which refers to alkenyl groups having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. The term "alkenyl" also includes "heteroalkenyl."
[0044] The term "substituted alkenyl" refers to an alkenyl group having one or more substituents replacing one or more hydrogen atoms on one or more carbon atoms of the hydrocarbon backbone. The substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphonium, phosphonyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, oxo, thiol, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0045] As used herein, "heteroalkenyl" refers to a straight or branched chain or cyclic carbon-containing alkenyl group containing at least one heteroatom, or a combination thereof. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized. For example, the term "heterocycloalkenyl" refers to a cycloalkenyl group in which at least one carbon atom of the ring is substituted with a heteroatom such as nitrogen, oxygen, sulfur, or phosphorus.
[0046] As used herein, the term "alkynyl" refers to a hydrocarbon group having 2 to 24 carbon atoms and containing at least one carbon-carbon triple bond in the structural formula. Alkynyl groups include straight-chain alkynyl groups, branched-chain alkynyl groups, and cycloalkynyl groups. A cycloalkynyl group is a non-aromatic carbyl ring composed of at least three carbon atoms and at least one carbon-carbon triple bond, such as a non-aromatic monocyclic ring or a non-aromatic polycyclic ring containing 3-30 carbon atoms and at least one carbon-carbon triple bond, wherein the ring structure has 3-20 carbon atoms and at least one carbon-carbon triple bond, or wherein the ring structure has 3-10 carbon atoms and at least one carbon-carbon triple bond, preferably wherein the ring structure has 5, 6, or 7 carbon atoms and at least one carbon-carbon triple bond. Cycloalkynyl groups containing polycyclic ring systems can have two or more non-aromatic rings, wherein two or more carbon atoms are shared by two adjacent rings (i.e., a "fused cycloalkynyl ring"), and contain at least one carbon-carbon triple bond. Asymmetric structures, such as (AB)C≡C(C"D), are meant to include E and Z isomers. This may be inferred from the presence of asymmetric alkynes in the formula herein, or may be explicitly indicated by the bond symbol C. The term "alkynyl" as used throughout the specification, examples, and claims includes both "unsubstituted alkynyl" and "substituted alkynyl," the latter of which refers to alkynyl groups having one or more substituents replacing hydrogen atoms on one or more carbons of the hydrocarbon backbone. The term "alkynyl" also includes "heteroalkynyl."
[0047] The term "substituted alkynyl" refers to an alkynyl group having one or more substituents replacing one or more hydrogen atoms on one or more carbon atoms of the hydrocarbon backbone. The substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphonium, phosphonyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0048] As used herein, "heteroalkynyl" refers to a linear or branched, or cyclic carbon-containing alkynyl group containing at least one heteroatom, or a combination thereof. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized. For example, the term "heterocycloalkynyl" refers to a cycloalkynyl group wherein at least one carbon atom of the ring is substituted with a heteroatom such as nitrogen, oxygen, sulfur, or phosphorus.
[0049] As used herein, "aryl" refers to a C5-C 26 Examples of aromatic groups include benzene, naphthalene, anthracene, phenanthrene, (chrysene), pyrene, corannulene, coronene, etc.
[0050] The term "substituted aryl" refers to an aryl group in which one or more hydrogen atoms on one or more aromatic rings are replaced by one or more substituents, including but not limited to halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, alkoxy, carbonyl (e.g., ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl (e.g., CF3, -CH2-CF3, -CCl3), -CN, aryl, heteroaryl, and combinations thereof.
[0051] "Heterocycle" and "heterocyclyl" are used interchangeably and refer to a cyclic group attached through a carbon atom or nitrogen atom in the ring, which is a non-aromatic monocyclic or polycyclic ring containing 3-30 ring atoms, 3-20 ring atoms, 3-10 ring atoms, or 5-6 ring atoms, wherein each ring contains carbon and 1 to 4 heteroatoms, each heteroatom selected from: non-peroxide oxygen, sulfur and N(Y), wherein Y is absent or is H, O, C1-C 10 Alkyl, phenyl or benzyl, and optionally containing 1-3 double bonds, optionally substituted by one or more substituents. By definition, heterocyclyl is different from heteroaryl. The heterocycle can be a heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, and the like, for example, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, dihydrofuro[2,3-b]tetrahydrofuran, morpholinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyranyl, 2H-pyrrolyl, 4H-quinolizinyl, quinuclidinyl, tetrahydrofuranyl, and 6H-1,2,5-thiadiazinyl. The heterocyclic group may be optionally substituted by one or more substituents as defined above for alkyl and aryl groups.
[0052] The term "heteroaryl" refers to a C5-C 26
[0014] The term "heteroaryl" refers to a monocyclic aromatic or fused aromatic ring system in which one or more carbon atoms in one or more aromatic ring structures are replaced by heteroatoms. Suitable heteroatoms include, but are not limited to, oxygen, sulfur, and nitrogen. Examples of heteroaryl groups include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine. Examples of heteroaryl rings include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisothiazolyl, benzmidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, and chromanyl. olinyl), decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl,Isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, naphthyridinyl, octahydroisoquinolinyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl diazolyl), oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl pyrazinyl), pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl uinazolinyl), quinolinyl, quinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,Thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, and xanthenyl. One or more of these rings may be substituted as defined below for "substituted heteroaryl".
[0053] The term "substituted heteroaryl" refers to a heteroaryl group in which one or more hydrogen atoms on one or more heteroaryl rings are replaced by one or more substituents including, but not limited to, halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, alkoxy, carbonyl (e.g., ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl (e.g., CF3, -CH2-CF3, -CCl3), -CN, aryl, heteroaryl, and combinations thereof.
[0054] The term "polyaryl" refers to a chemical molecule that includes two or more fused aromatic groups. When two or more fused heteroaryl groups are involved, the chemical molecule may be referred to as a "polyheteroaryl."
[0055] The term "substituted polyaryl" refers to a polyaryl in which one or more aryl groups are substituted with one or more substituents, including but not limited to halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (or quaternized amino), amido, amidino, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof. When referring to a polyheteroaryl, the chemical molecule may be referred to as a "substituted polyheteroaryl."
[0056] The term "cyclic ring" or "cyclic group" refers to a substituted or unsubstituted monocyclic ring or a substituted or unsubstituted polycyclic ring (e.g., a polycyclic ring formed by a monocyclic ring or a fused ring system), such as a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted cycloalkynyl, or a substituted or unsubstituted heterocyclyl, having from 3 to 30 carbon atoms, where geometric constraints permit. Substituted cycloalkyl, cycloalkenyl, cycloalkynyl, and heterocyclyl groups are substituted as defined above for alkyl, alkenyl, alkynyl, and heterocyclyl groups, respectively.
[0057] The term "aralkyl" as used herein refers to an aryl or heteroaryl group having an alkyl, alkynyl or alkenyl group as defined above, attached to an aromatic group, such as an aryl, heteroaryl, polyaryl or polyheteroaryl group. An example of an aralkyl group is a benzyl group.
[0058] The terms "alkoxyl" or "alkoxy" and "aroxy" or "aryloxy" generally describe a group consisting of the formula -OR v A compound represented by vThe alkyl radicals include, but are not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, and substituted or unsubstituted polyheteroaryl. Alkoxyl includes alkyl, aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, phosphonium, phosphanyl, phosphonyl, sulfinyl, silyl, thiol, amido and amino. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like. "Lower alkoxy" is an alkoxy group containing 1 to 6 carbon atoms. "Ether" is two functional groups covalently linked by oxygen as defined below. Thus, the alkyl substituent that makes the alkyl an ether is or is similar to an alkoxy group, and can be represented, for example, by one of -O-alkyl, -O-alkenyl, -O-alkynyl, -O-aralkyl, -O-aryl, -O-heteroaryl, -O-polyaryl, -O-polyheteroaryl, -O-heterocyclyl, etc.
[0059] The term "substituted alkoxy" refers to an alkoxy group in which one or more hydrogen atoms on one or more carbon atoms of the alkoxy backbone are replaced by one or more substituents. The substituents can be any of the above substituents, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphonium, phosphonyl, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, oxo, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0060] The term "ether" as used herein is a compound of formula A. 2 OA 1 Indicates that A 2 and A 1 and alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, phosphonium, phosphino, phosphono, sulfinyl, silyl, thiol, substituted or unsubstituted carbonyl, alkoxy, amide, or amino, as described above.
[0061] The term "polyether" as used herein is represented by the formula: Among them A 3 can independently represent a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted polyaryl, a substituted or unsubstituted polyheteroaryl, a phosphonium, a phosphino, a substituted or unsubstituted carbonyl, an alkoxy, an amide or an amino group, as described above; and g can be a positive integer from 1 to 30.
[0062] The term "phenoxy" is art-recognized and refers to a group of the formula -OR v A compound wherein R v It is C6H5 (i.e. -O-C6H5). Those skilled in the art will recognize that phenoxy is a type of aryloxy.
[0063] The term "substituted phenoxy" refers to a phenoxy group as defined above in which one or more hydrogen atoms on one or more carbon atoms of a phenyl ring are replaced by one or more substituents. The substituents include, but are not limited to, halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphonium, phosphino, phosphono, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof.
[0064] The terms "aroxy" and "aryloxy" used interchangeably herein are represented by -O-aryl or -O-heteroaryl, wherein aryl and heteroaryl are as defined herein.
[0065] The terms "substituted aroxy" and "substituted aryloxy" used interchangeably herein represent an -O-aryl or -O-heteroaryl group in which one or more hydrogen atoms on one or more ring atoms of the aryl and heteroaryl groups, as defined herein, are replaced with one or more substituents. The substituent can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphonium, phosphino, phosphono, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0066] As used herein, the term "amino" includes the group wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heterocyclyl, wherein R x 、R xi and R xii and E, each independently represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group (e.g., a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group), a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, a substituted or unsubstituted heterocyclic group, a hydroxyl group, an alkoxy group, a phosphonium group, a phosphino group, a phosphono group, a sulfinyl group, a silyl group, a thiol group, an amide group, an amino group, or —(CH 2 ) m-R"'; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphino group, an amide group or an amino group; m is zero or an integer from 1 to 8. The term "quaternary amino" also includes groups wherein nitrogen, R x、 R xi and R xii The N + The heterocyclic or heteroaryl groups have 3 to 14 atoms in the ring structure. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0067] The terms "amide" or "amido" are used interchangeably to refer to both "unsubstituted amido" and "substituted amido" and are represented by the general formula: wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heterocyclyl, wherein R and R' are independent of E and each independently represent hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl , substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic, hydroxy, alkoxy, phosphonium, phosphino, phosphono, sulfinyl, silyl, thiol, acylamino, amino, or -(CH2)m R', or R and R' together with the N atom to which they are attached, form a heterocycle having from 3 to 14 atoms in the ring structure; R' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; m is zero or an integer from 1 to 8. In some forms, when E is oxygen, a carbamate is formed. It will be understood by those of ordinary skill in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0068] As used herein, "Carbonyl" is art-recognized and includes moieties that can be represented by the following general formula: wherein X is a bond or represents oxygen or sulfur, and R represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphino, amide, amino, or -(CH2) m-R", or a pharmaceutically acceptable salt; E" is either absent or E" is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl; R' represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphino, amido, amino, or -(CH2) m-R"; R" represents a hydroxyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphino group, an amide group or an amino group; m is zero or an integer from 1 to 8. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, and combinations thereof. It will be understood by those of ordinary skill in the art that the "E" groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl). When X is oxygen and R is as defined above, the molecule is also referred to as a carboxyl group. When X is oxygen and R is hydrogen, the formula represents a "carboxylic acid." When X is oxygen and R' is hydrogen, the formula represents a "formate." When X is oxygen and R or R' is not hydrogen, the formula represents an "ester." Generally speaking, when the oxygen atom in the above formula is replaced by a sulfur atom, the formula represents a "thiocarbonyl" group. When X is sulfur and R or R' is not hydrogen, the formula represents a "thioester." When X is sulfur and R is hydrogen, the formula represents a "thiocarboxylic acid." When X is sulfur and R' is hydrogen, the formula represents a "thioformate." When X is a bond and R is not hydrogen, the formula represents a "ketone." When X is a bond and R is hydrogen, the formula represents an "aldehyde."
[0069] The term "phosphanyl" is represented by the formula wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heterocyclyl, wherein R vi and R viiand E, each independently represents hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group (e.g., a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group, etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, a substituted or unsubstituted heterocyclic group, a hydroxyl group, an alkoxy group, a phosphonium group, a phosphino group, a phosphono group, a sulfinyl group, a silyl group, a thiol group, an amide group, an amino group, or -(CH2) m -R"', or R vi and R vii Together with the P atom to which they are attached, they form a heterocycle having 3 to 14 atoms in the ring structure; R' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; m is zero or an integer from 1 to 8. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acyl) alkyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. One of ordinary skill in the art will appreciate that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0070] The term "phosphonium" is represented by the formula wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heterocyclyl, wherein R vi 、R vii and R viiiand E, each independently represents hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group (e.g., a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group, etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, a substituted or unsubstituted heterocyclic group, a hydroxyl group, an alkoxy group, a phosphonium group, a phosphino group, a phosphono group, a sulfinyl group, a silyl group, a thiol group, an acylamino group, an amino group, or -(CH2) m -R"', or R vi 、R vii and R viii The P to which they are connected + The atoms together form a heterocycle having 3 to 14 atoms in the ring structure; R' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; m is zero or an integer from 1 to 8. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acyl), formyl, Silane, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. One of ordinary skill in the art will appreciate that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0071] The term "phosphonyl" is represented by the formula wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, oxygen, alkoxy, aryloxy, or substituted alkoxy or substituted aryloxy, wherein Rvi 、R vii E is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphino, phosphono, sulfinyl, silyl, thiol, amide, amino, or -(CH2) m -R"', or R vi and R vii Together with the P atom to which they are attached, they form a heterocycle having 3 to 14 atoms in the ring structure; R' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; m is zero or an integer from 1 to 8. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acyl) alkyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. One of ordinary skill in the art will appreciate that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0072] The term "phosphoryl" defines a phosphonyl group, as defined above, wherein E is absent or is oxygen, alkoxy, aryloxy, substituted alkoxy or substituted aryloxy, and R vi and R vii Independent of E, is independently hydroxy, alkoxy, aryloxy, substituted alkoxy or substituted aryloxy, as defined above. When E is oxygen, as understood by those of ordinary skill in the art, the phosphoryl group cannot be attached to another chemical species, such as to form an oxygen-oxygen bond or other unstable bond. When E, R vi and R viiWhen substituted, the substituents include, but are not limited to, halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0073] The term "sulfinyl" is represented by the formula wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, wherein R, independent of E, represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted hetero ... unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphino, phosphono, silyl, thiol, amide, amino, or -(CH2) m-R"', or E and R together with the S atom to which they are attached form a heterocycle having 3 to 14 atoms in the ring structure; R"' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; m is zero or an integer from 1 to 8. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0074] The term "sulfonyl" is represented by the formula wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, wherein R, independent of E, represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphino, amide, amino, or -(CH2) m-R"', or E and R together with the S atom to which they are attached form a heterocycle having 3 to 14 atoms in the ring structure; R"' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; m is zero or an integer from 1 to 8. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0075] The term "sulfonic acid" refers to a sulfonyl group as defined above, wherein R is hydroxy and E is either absent or E is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heteroaryl. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0076] The term "sulfate" refers to a sulfonyl group as defined above, wherein E is either absent or is oxygen, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy, as defined above, and R is independently hydroxy, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy, as defined above. When E is oxygen, the sulfate cannot be attached to another chemical species, such as to form an oxygen-oxygen bond or other unstable bond, as understood by those of ordinary skill in the art. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0077] The term "sulfonate" refers to a sulfonyl group as defined above, wherein E is oxygen, alkoxy, aryloxy, substituted alkoxy, or substituted aryloxy as defined above, and R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, -(CH2) m-R'", R'' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, an aryl group, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, an amide group, an amino group, or a polycyclic ring; m is zero or an integer ranging from 1 to 8. When E is oxygen, the sulfonate ester cannot be attached to another chemical species, such as to form an oxygen-oxygen bond or other unstable bond, as understood by those of ordinary skill in the art. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0078] The term "sulfamoyl" refers to a sulfonamide represented by the formula wherein E is either absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein R and R' are independent of E and each independently represent hydrogen, substituted or unsubstituted unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphino, amido, amino or -(CH2) m-R"', or R and R' together with the N atom to which they are attached form a heterocycle having 3 to 14 atoms in the ring structure; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphino group, an amide group or an amino group; m is zero or an integer from 1 to 8. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof. It will be understood by those skilled in the art that the E groups listed above are divalent (e.g., methylene, ethane-1,2-diyl, ethylene-1,2-diyl, 1,4-phenylene, cyclohexane-1,2-diyl).
[0079] The term "silyl group" as used herein is represented by the formula SiRR'R", wherein R, R' and R" can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted carbonyl, phosphonium, phosphino, phosphono, sulfinyl, thiol, amido, amino, alkoxy or oxo, as described above. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0080] The term "thiol" may be represented by -SR and used interchangeably, where R may be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted carbonyl, phosphonium, phosphino, amido, amino, alkoxy, oxo, phosphono, sulfinyl, or silyl. These substituents can be any of the substituents described above, such as halogen, azido, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0081] Disclosed compounds and substituents can independently have two or more of the groups listed above. For example, if the compound or substituent is a straight chain alkyl group, one hydrogen atom in the alkyl group can be replaced by a hydroxyl group, an alkoxy group, etc. Depending on the selected group, the first group can be combined in the second group, or the first group can be pendant (i.e., connected) to the second group. For example, for the phrase "an alkyl group comprising an ester group", the ester group can be contained in the main chain of the alkyl group. Or, the ester group can be connected to the main chain of the alkyl group. The nature of the selected group will determine whether the first group is embedded in the second group or is connected to the second group.
[0082] The compounds and substituents may independently be substituted with substituents as defined above for "substituted".
[0083] Numerical ranges individually disclose every possible value that the range can reasonably contain, as well as any subranges and combinations of subranges contained therein. For example, in a given carbon range of C3-C9, the range also discloses C3, C4, C5, C6, C7, C8, and C9, as well as any subranges between these numbers (e.g., C4-C6), and any possible range combinations between these values. In another example, a given temperature range can be about 25°C to 30°C, wherein the range also discloses temperatures independently selected from about 25°C, 26°C, 27°C, 28°C, 29°C, and 30°C, as well as any ranges between these numbers (e.g., 26 to 28°C), and any possible range combinations between these values.
[0084] The term "about" is used to describe values above or below the indicated numerical value, and the term "about" modifies a numerical range that is approximately within + / - 10%. When the term "about" is used before a numerical range (i.e., about 1-5) or before a series of numbers (i.e., about 1, 2, 3, 4, etc.), unless otherwise indicated, it is intended to modify both ends of the numerical range and / or each number listed in the entire series.
[0085] The disclosed compounds and substituents can independently have two or more of the groups listed above. For example, if the compound or substituent is a straight chain alkyl, one of the hydrogen atoms of the alkyl can be substituted by a hydroxyl group, an alkoxy group, etc. Depending on the selected group, the first group can be incorporated into the second group, or the first group can be pendantly connected (i.e., connected) to the second group. For example, for the phrase "an alkyl group comprising an ester group", the ester group can be contained in the main chain of the alkyl group. Alternatively, the ester group can be connected to the main chain of the alkyl group. The nature of the selected group will determine whether the first group is embedded in the second group or connected to the second group.
[0086] The compounds and substituents may be independently substituted with substituents as described above in the definition of "substituted".
[0087] The following table provides the full names of some abbreviations used in this document:
[0088] II. Preparation of Chiral Amino Acids
[0089] Methods for preparing chiral α-amino acids using chiral phosphoric acids as catalysts have been developed. The chiral α-amino acids prepared using the disclosed methods can be natural or non-natural and have different side chains and functionalities.
[0090] The disclosed methods can use amino-malonic acids as substrates to generate chiral amino acids with various side chains through asymmetric decarboxylation reactions, optionally with high purity (e.g., an ee value of at least 70%). The decarboxylation reaction of these methods is catalyzed by chiral phosphoric acid, which can achieve selective protonation during the decarboxylation process (e.g., see Figure 1 ), which is generally one of the most difficult processes in asymmetric catalysis. In some forms, the catalyst can be a chiral phosphoric acid supported on a suitable support.
[0091] Without being bound by any theory, we believe that the selective protonation achieved by using chiral phosphoric acid in the method of the present invention is not only due to the high acidity of chiral phosphoric acid, which allows for rapid protonation, but also due to the ability of chiral phosphoric acid to form a rich hydrogen bond network in its pocket, especially with heteroatom-rich substrates or intermediates (such as Figure 1 8 and 9 in the phosphate group) to form a hydrogen bond network, thereby achieving stereo control. Therefore, chiral phosphoric acid can interrupt the internal hydrogen bonds of malonate (such as Figure 1 8 in ), and initiates decarboxylation via intermolecular proton transfer (e.g. Figure 1 10 in). It is also possible to directly intercept the intermediate (such as Figure 1 In either case, stereoselective protonation within the chiral pocket (e.g. Figure 1 11) will produce chiral amino acids (such as Figure 1 12).
[0092] In some forms, the amino-malonic acid substrate (also referred to herein as " substrate ") used in the disclosed methods is prepared using commercially available malonate / ester as a starting material. The starting material can be converted by connecting a suitable functional group or biomolecule part to the methylene carbon of the malonate / ester, for example, via a substitution reaction between the starting material and an alkyl halide (for example, see Scheme 2), which is then hydrolyzed to provide a substrate (for example, see Scheme 3). Then, using chiral phosphoric acid as a catalyst, the amino-malonic acid substrate can be directly converted into the corresponding chiral amino acid (for example, see Scheme 10) by asymmetric decarboxylation. Therefore, the functional group or biomolecule part introduced during the substrate preparation process becomes the side chain or partial side chain of the chiral amino acid produced thereby. Using the disclosed method, a large number of side chains with different shapes and different functional groups can be connected to the final chiral amino acid product by decarboxylation, and ultimately incorporated into the final chiral amino acid product. Thus, the disclosed method provides a general, selective, and efficient approach to provide chiral α-amino acids with diverse side chains and functional groups (natural or unnatural), which is currently lacking using existing methods.
[0093] Generally speaking, the method of producing a chiral amino acid disclosed herein comprises: (i) maintaining a first reaction mixture at a first temperature for a first period of time sufficient to form a product, wherein the product comprises a chiral amino acid. The first reaction mixture comprises a substrate, a catalyst, and a solvent. The catalyst is preferably a chiral phosphoric acid. Typically, in step (i), the chiral amino acid is produced by an asymmetric decarboxylation reaction of the substrate catalyzed by the chiral phosphoric acid.
[0094] In some forms, the chiral amino acid in the product formed in step (i) further reacts with a reactant to produce an alkylated chiral amino acid or a hydrolyzed amino acid. In these forms, the method of the present disclosure further comprises: (ii) adding an alkylating reactant (such as a methylating or ethylating reactant) or an acid to the product to form a second reaction mixture, and (iii) maintaining the second reaction mixture at a second temperature for a sufficiently long second period of time to form an alkylated product (such as a methylated or ethylated product) or a hydrolyzed product. The alkylated product or the hydrolyzed product contains an alkylated chiral amino acid (such as a methylated or ethylated chiral amino acid) or a hydrolyzed chiral amino acid.
[0095] In some forms, the disclosed methods further comprise: purifying the product after step (i), and / or purifying the alkylated or hydrolyzed product after step (iii); preparing a substrate before step (i); recovering the amino protecting agent and catalyst after step (i) and / or step (iii); and / or derivatizing the chiral amino acid or the alkylated or hydrolyzed chiral amino acid into a derivative compound after step (i) and / or step (iii).
[0096] A. Maintaining the reaction mixture at a temperature for a sufficient period of time to allow the product to form
[0097] In general, in a suitable solvent, a first reaction mixture containing a substrate and a catalyst (preferably a chiral phosphoric acid) is maintained at a suitable temperature for a period of time sufficient to form a product containing a chiral amino acid, which is formed by asymmetric decarboxylation of the substrate. Typically, the reaction conditions for carrying out the reaction are very simple. For example, at 1 atm, the temperature range for carrying out the asymmetric decarboxylation reaction can be from about 50°C to about 100°C, from about 60°C to about 100°C, or from about 70°C to about 100°C, such as about 80°C; the time period for carrying out the reaction within any of the above temperature ranges can be from about 1 hour to about 12 hours, from about 1 hour to about 10 hours, from about 1 hour to about 8 hours, from about 1 hour to about 8 hours, from about 1 hour to about 8 hours, from about 5 hours, or from about 1 hour to about 3 hours, such as about 2 hours.
[0098] The first reaction mixture can be formed by mixing the substrate and the chiral phosphoric acid in a solvent before the reaction. Examples of solvents suitable for step (i) of the disclosed method include, but are not limited to, ethyl acetate, t BuOMe, THF, 2-MeTHF, 1,4-dioxane, cyclopentylmethylether (CPME) and (MeOCH2CH2)2O, and combinations thereof. In a preferred form, the solvent for forming the first reaction mixture in step (i) is an ether, such as CPME.
[0099] 1. Substrate
[0100] In step (i) of the disclosed method, the catalyst catalyzes the asymmetric decarboxylation reaction of the substrate to generate a chiral amino acid. Typically, the substrate is a malonate substrate. In some forms, the malonate substrate has a structure of Formula I or Formula I': Where P1 can be an amino protecting group, and R1 can be any suitable functional group or biomolecule moiety, as long as it can be attached to the methylene carbon of the substrate. The term "biomolecule moiety" refers to the portion of a biomolecule that comprises the chiral amino acid structure. A biomolecule can be any natural or synthetic compound with biological activity. Generally, the biomolecule moiety of a chiral amino acid is the portion of the biomolecule responsible for the biomolecule's activity.
[0101] In some forms, the amino protecting group P1 can be where L1 can be R2 can be hydrogen, hydroxy, halide, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, alkoxy, thiol, amino, amido, carbonyl, cyano, isocyano, nitro, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono; R3-R 10 can be independently hydrogen, or substituted or unsubstituted alkyl (e.g., unsubstituted alkyl, such as C1-C 10unsubstituted alkyl, C1-C8 unsubstituted alkyl, C1-C6 unsubstituted alkyl, or C1-C4 unsubstituted alkyl); when substituents are present, the substituents may independently be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl, or phosphono.
[0102] In a preferred form, L1 is
[0103] In some forms, R can be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, alkoxy, thiol, amino, amide or carbonyl. In some forms, R is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl or substituted or unsubstituted aralkyl.
[0104] In some forms, R2 can be where R 11 -R 15 and may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aralkyl, carbonyl (e.g., aldehyde, ketone, carboxylic acid, ester, etc.), alkoxy, halide, hydroxyl, thiol, cyano, isocyano, nitro, amino, amide, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono.
[0105] In some forms, R 11 -R 15 can independently be hydrogen, halide, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted phenyl, unsubstituted haloalkyl, unsubstituted aralkyl, cyano, isocyano, nitro, where R 16 -R 18 can be independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted phenyl, unsubstituted haloalkyl, or unsubstituted aralkyl, wherein R'18 is an unsubstituted alkyl group.
[0106] In some forms, R2 can be where R 12 -R 14 It can be independently a halide (such as F, Cl or I), an unsubstituted alkyl, an unsubstituted haloalkyl (such as a fluoride substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF2-CF3), a cyano group, an isocyano group, a nitro group, R 16 and R 18 can be independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or unsubstituted aralkyl (e.g., benzyl), wherein R' 18 An unsubstituted alkyl group may be used.
[0107] In some forms, R2 can be where R 12 Can be R 13 It can be a halide (such as F, Cl or I), unsubstituted alkyl, unsubstituted haloalkyl (such as -CF3), cyano, isocyano, nitro, R 16 and R 18 can be independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or unsubstituted aralkyl (e.g., benzyl), wherein R' 18 Can be unsubstituted alkyl. In some forms, R 13 Could be nitro.
[0108] In some forms, the functional group or biomolecule moiety R1 attached to the methylene carbon of the malonate substrate can be a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, or a substituted or unsubstituted alkynyl, wherein the substituents, when present, can independently be a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted aryl, a substituted or unsubstituted polyaryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteropolyaryl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aralkyl, a carbonyl, an alkoxy, a halide, a hydroxyl, a thiol, a cyano, an isocyano, a nitro, an amino, an amido, an azido, an oxo, a silyl, a sulfinyl, a sulfonyl, a phosphonium, a phosphino, a phosphoryl, or a phosphono group. In some forms, when substituents are present, they are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, azido, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, or nitro. In some forms, when substituents are present, they are independently a biomolecule moiety, such as a cholic acid moiety (e.g., see Figure 3D (+)-39) or estrone moiety (e.g. see Figure 3D (+)-40).
[0109] In some forms, a substrate, such as a malonate substrate of Formula I or I', contains one or more isotopes. For example, one or more carbons, one or more nitrogens, and / or one or more hydrogens of a substrate (such as a malonate substrate of Formula I or I') can be 13 C. 14 C. 15 N, and / or D forms.
[0110] For any of the above substrate forms, when an alkyl group is present, it can be a straight chain alkyl group, a branched chain alkyl group, or a cyclic alkyl group (monocyclic or polycyclic). The terms "cyclic alkyl" and "cycloalkyl" are used interchangeably herein. Exemplary alkyl groups include straight chain C1-C 30 Alkyl, branched C4-C 30 Alkyl, cyclic C3-C 30 Alkyl, straight chain C1-C 20 Alkyl, branched C4-C 20 Alkyl, cyclic C3-C 20 Alkyl, straight chain C1-C 10 Alkyl, branched C4-C 10 Alkyl, cyclic C3-C10 Alkyl, linear C1-C6 alkyl, branched C4-C6 alkyl, cyclic C3-C6 alkyl, linear C1-C4 alkyl, cyclic C3-C4 alkyl, for example linear C1-C 10 C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, or C1-C2 alkyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, or C3-C4 alkyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, or C3-C4 alkyl groups. The cyclic alkyl group can be a monocyclic or polycyclic alkyl group, such as a C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic alkyl groups.
[0111] For any of the above substrate forms, when alkenyl is present, it can be a straight chain alkenyl, a branched chain alkenyl, or a cyclic alkenyl (monocyclic or polycyclic). The terms "cyclic alkenyl" and "cycloalkenyl" are used interchangeably herein. Exemplary alkenyl groups include linear C2-C 30 Alkenyl, branched C4-C 30 Alkenyl, cyclic C3-C 30 Alkenyl, straight chain C2-C 20 Alkenyl, branched C4-C 20 Alkenyl, cyclic C3-C 20 Alkenyl, straight chain C2-C 10 Alkenyl, branched C4-C 10 Alkenyl, cyclic C3-C 10 Alkenyl, straight-chain C2-C6 alkenyl, branched-chain C4-C6 alkenyl, cyclic C3-C6 alkenyl, straight-chain C2-C4 alkenyl, cyclic C3-C4 alkenyl, for example straight-chain C2-C 10C2-C9, C2-C8, C2-C7, C2-C6, C2-C5, C2-C4, C2-C3, C2 alkenyl groups, branched C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkenyl groups, or cyclic C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkenyl groups. Cyclic alkenyl groups can be monocyclic or polycyclic alkenyl groups, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18 、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6, or C4-C5 monocyclic or polycyclic alkenyl groups.
[0112] For any of the above substrate forms, the alkynyl group can be a straight chain alkynyl group, a branched chain alkynyl group, or a cyclic alkynyl group (monocyclic or polycyclic). The terms "cyclic alkynyl" and "cycloalkynyl" are used interchangeably herein. Exemplary alkynyl groups include straight chain C2-C 30 Alkynyl, branched C4-C 30 Alkynyl, cyclic C3-C 30 Alkynyl, straight chain C2-C 20 Alkynyl, branched C4-C 20 Alkynyl, cyclic C3-C 20 Alkynyl, straight chain C2-C 10 Alkynyl, branched C4-C 10 Alkynyl, cyclic C3-C 10 Alkynyl, straight chain C2-C6 alkynyl, branched chain C4-C6 alkynyl, cyclic C3-C6 alkynyl, straight chain C2-C4 alkynyl, cyclic C3-C4 alkynyl, for example straight chain C2-C 10 C2-C9, C2-C8, C2-C7, C2-C6, C2-C5, C2-C4, C2-C3, C2 alkynyl groups, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkynyl groups, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkynyl groups. The cyclic alkynyl group can be a monocyclic or polycyclic alkynyl group, such as C4-C 30 、C4-C 25 、C4-C 20 、C4-C 18、C4-C 16 、C4-C 15 、C4-C 14 、C4-C 13 、C4-C 12 、C4-C 10 , C4-C9, C4-C8, C4-C7, C4-C6 or C4-C5 monocyclic or polycyclic alkynyl groups.
[0113] It will be understood that any of the exemplary alkyl, alkenyl, and alkynyl groups can be heteroalkyl, heteroalkenyl, and heteroalkynyl, respectively.
[0114] For any of the above substrates, the aryl group can be C5-C 30 Aryl, C5-C 20 Aryl, C5-C 12 Aryl, C5-C 11 Aryl, C5-C9 aryl, C6-C 20 Aryl, C6-C 12 Aryl, C6-C 11 It should be understood that the aryl group can be a heteroaryl group, such as a C5-C 30 Heteroaryl, C5-C 20 Heteroaryl, C5-C 12 Heteroaryl, C5-C 11 Heteroaryl, C5-C9 heteroaryl, C6-C 30 Heteroaryl, C6-C 20 Heteroaryl, C6-C 12 Heteroaryl, C6-C 11 heteroaryl, or C6-C9 heteroaryl.
[0115] For any of the above substrates, the polyaryl group can be C 10 -C 30 Polyaryl, C 10 -C 20 Polyaryl, C 10 -C 12 Polyaryl, C 10 -C 11 Polyaryl or C 12 -C 20 It is understood that aryl can be polyheteroaryl, such as C 10 -C 30 Polyheteroaryl, C 10 -C 20 Polyheteroaryl, C 10 -C 12 Polyheteroaryl, C 10 -C 11 Polyheteroaryl or C 12 -C 20Polyheteroaryl.
[0116] 2. Catalyst
[0117] The catalyst used in the first reaction mixture of step (i) to catalyze the asymmetric decarboxylation of the substrate to produce the chiral amino acid is preferably chiral phosphoric acid. Without being bound by any theory, we believe that the selective protonation achieved by using chiral phosphoric acid in the method of the present invention is not only due to the high acidity of chiral phosphoric acid, which allows for rapid protonation, but also due to the chiral phosphoric acid forming a rich hydrogen bond network in its pocket, especially with heteroatom-rich substrates or intermediates (such as Figure 1 8 and 9 in the phosphate group) to form a hydrogen bond network, thereby achieving stereo control. Therefore, chiral phosphoric acid can interrupt the internal hydrogen bonds of malonate (such as Figure 1 8 in ), and initiates decarboxylation via intermolecular proton transfer (e.g. Figure 1 10 in). It is also possible to directly intercept the intermediate (such as Figure 1 In either case, stereoselective protonation within the chiral pocket (e.g. Figure 1 11) will produce chiral amino acids (such as Figure 1 12).
[0118] Any suitable chiral phosphoric acid ((R)- and (S)-chiral phosphoric acid), such as commercially available chiral phosphoric acids, can be used in the disclosed method. Examples of chiral phosphoric acids suitable for use in step (i) of the disclosed method include, but are not limited to, BINOL phosphoric acids and their derivatives, H8BINOL phosphoric acids and their derivatives, SPINOL phosphoric acids and their derivatives, Biphenol phosphoric acid and their derivatives, dithiophosphoric acid and their derivatives, TADDOL phosphoric acid and their derivatives, paracyclophane and their derivatives, TiPSY phosphoric acid and their derivatives, TRIP phosphoric acid and their derivatives. Exemplary structures of chiral phosphoric acids are disclosed in https: / / www.sigmaaldrich.com / US / en / technical-documents / technical-article / chemistry- and-synthesis / reaction-design-and-optimization / chiral-phosphoric and website daicelchiraltech.cn / en / reagents / list02.aspx?pid=72621643502977024&cid= 72620543991349248&sid=72626041549488128 .
[0119] In some forms, the catalyst can be a chiral phosphoric acid supported on a support for recycling after the asymmetric decarboxylation and / or subsequent alkylation reaction or hydrolysis. The support can be any material suitable for supporting the chiral phosphoric acid and not interfering with the asymmetric decarboxylation reaction, such as polystyrene, metal organic frameworks, covalent organic frameworks, etc.
[0120] In some forms, the chiral phosphate used in the first reaction mixture to catalyze the asymmetric decarboxylation of the substrate to produce the chiral amino acid can have the structure of Formula III or Formula III': where R 19 、R 20 , R' 19 and R' 20 R may independently be a substituted or unsubstituted aryl group, or a substituted or unsubstituted polyaryl group; 21 -R 24 and R' 21 -R' 24 may independently be hydrogen, or unsubstituted alkyl; substituents (when present) may independently be substituted or unsubstituted alkyl, substituted or unsubstituted aryl (such as phenyl), substituted or unsubstituted polyaryl (such as naphthyl), substituted or unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF2-CF3), or R 25 It can be a substituted or unsubstituted alkyl group, a substituted or unsubstituted haloalkyl group (e.g., a fluoride-substituted C1-C6 haloalkyl group, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), a substituted or unsubstituted aryl group (e.g., phenyl), or a substituted or unsubstituted aralkyl group (e.g., benzyl).
[0121] In some forms, R 19 and R 20 At least one of R' 19 and R' 20 At least one of can independently be a substituted aryl or substituted polyaryl, optionally wherein the substituted aryl or polyaryl has three or more substituents (e.g., 2,4,6-substituted phenyl). In some forms, R 19 and R 20 Both and R' 19 and R' 20 Both may independently be substituted aryl or substituted polyaryl, optionally wherein the substituted aryl or polyaryl has three or more substituents (eg, 2,4,6-substituted phenyl).
[0122] In some forms, R 19 、R 20 , R' 19 , R' 20The substituents on the aryl or polyaryl groups can be unsubstituted alkyl (e.g., methyl, ethyl, isopropyl, n-propyl, etc.), unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or alkoxy (e.g., methoxy, ethoxy, aryloxy, anisole, etc.). In some forms, R 19 、R 20 , R' 19 , R' 20 The substituent on the aryl or polyaryl group may be an unsubstituted alkyl group (eg, methyl, ethyl, isopropyl, n-propyl, etc.).
[0123] In some forms, the chiral phosphate can have the following structure:
[0124] Typically, the catalyst is present in the first reaction mixture in an amount from about 1 mol% to about 20 mol%, from about 1 mol% to about 10 mol%, from about 2 mol% to about 20 mol%, from about 2 mol% to about 10 mol%, or from about 2.5 mol% to about 10 mol%, e.g., about 10 mol% or about 2.5 mol%.
[0125] 3. Chiral amino acids
[0126] The product formed in step (i) contains a chiral amino acid, which is produced by the asymmetric decarboxylation reaction of the substrate. Therefore, the functional group or biomolecule part (except the protected amino group) attached to the methylene carbon of the malonate substrate becomes the side chain or part of the side chain of the chiral amino acid thus produced.
[0127] In some forms, when the substrate is a malonate substrate of Formula I or Formula I', the chiral amino acid produced thereby has the structure of Formula II or Formula II': wherein P1 can be any amino protecting group as defined above for the substrate, and R1 can be any functional group or biomolecule moiety as defined above for the substrate.
[0128] When the chiral amino acid produced in step (i), such as the chiral amino acid of Formula II or Formula II', is further reacted with an alkylating reactant (e.g., a methylating or ethylating reactant), the carboxyl group of the chiral amino acid is alkylated to generate an alkylated chiral amino acid (e.g., a methylated chiral amino acid or an ethylated amino acid). In some forms, the alkylated chiral amino acid may have a structure of Formula VIII or Formula VIII': where R 26 It can be a substituted or unsubstituted alkyl group, such as C1-C 12 Unsubstituted alkyl, C1-C 10 unsubstituted alkyl, C1-C8 unsubstituted alkyl, C1-C6 unsubstituted alkyl or C1-C4 unsubstituted alkyl, such as methyl or ethyl; P1 can be any amino protecting group as defined above for the substrate; R1 can be any functional group or biomolecule part as defined above for the substrate.
[0129] In some forms, the alkylated chiral amino acid can be a methylated chiral amino acid having the structure of Formula IV or Formula IV': wherein P1 can be any amino protecting group as defined above for the substrate, and R1 can be any functional group or biomolecule moiety as defined above for the substrate.
[0130] In some forms, P1 of Formula VIII, VIII', IV and IV' can be where R 12 Can be R 13 Can be cyano, isocyano, nitro or R 16 and R 18 can be independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3) or unsubstituted aralkyl (e.g., benzyl), wherein R' 18 Can be unsubstituted alkyl. In some forms, R 13 Can be nitro, R 12 Can be where R 16 It can be an unsubstituted haloalkyl group (e.g., a fluoride-substituted C1-C6 haloalkyl group, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3). In some forms, R 13 Can be nitro, R 12 Can be where R 16 It can be -CH2-CH2-CF3, -CH2-CF2-CF3, or -CH2-CF2-CF2-CF3.
[0131] In some forms, the functional group or biomolecule moiety R1 of Formulas VIII, VIII', IV and IV' can be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, wherein the substituents (when present) can independently be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, nitro, amino, amido, azido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono. In some forms, the substituents (when present) can independently be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, azido, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, or nitro. In some forms, the substituents (when present) are independently a biomolecule moiety, such as a bile acid moiety (e.g., Figure 3D (+)-39) or the estrone portion (e.g. Figure 3D (+)-40).
[0132] In some forms, the alkylated chiral amino acid produced using the disclosed methods can have any of the following structures:
[0133] When the chiral amino acid produced in step (i), such as the chiral amino acid of Formula II or Formula II', is further reacted with an acid, the protected amino group of the chiral amino acid is hydrolyzed to generate a hydrolyzed chiral amino acid. In some forms, the hydrolyzed chiral amino acid may have a structure of Formula V or Formula V': Wherein R1 can be any functional group or biomolecule moiety as defined above for the substrate, and A1 can be any suitable acid molecule. Examples of acids suitable for hydrolyzing chiral amino acids include, but are not limited to, hydrochloric acid (HCl), sulfuric acid, nitric acid, carbonic acid, formic acid, acetic acid, citric acid, and acetylsalicylic acid. In some forms, A1 is HCl.
[0134] a. Enantiomeric excess
[0135] In general, the enantiomeric excess ("ee") of the chiral amino acid in the product produced by the asymmetric decarboxylation reaction using the disclosed methods can be at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, in the range of about 70% to 100%, about 75% to 100%, about 80% to 100%, about 85% to 100%, about 90% to 100%, about 75% to 99%, about 80% to 99%, about 85% to 99%, or about 90% to 99%, as determined by chiral HPLC. The ee value of the chiral amino acid in the product can be calculated as follows: ee = [(moles of one enantiomer - moles of the other enantiomer) / total moles of both enantiomers] x 100%. The ee value of a chiral amino acid can be determined using known methods, such as using chiral HPLC or a polarimeter. In some forms, the ee of the chiral amino acid is determined using chiral HPLC.
[0136] In some forms, the chiral amino acid of Formula II, the alkylated chiral amino acid of Formula VIII, the methylated chiral amino acid of Formula IV, or the hydrolyzed chiral amino acid of Formula V in the product formed by the asymmetric decarboxylation reaction catalyzed by a chiral phosphoric acid (such as a chiral phosphoric acid of Formula III or CPA-8) using the disclosed methods has an ee of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, ranging from about 70% to 100%, about 75% to 100%, about 80% to 100%, about 85% to 100%, about 90% to 100%, about 75% to 99%, about 80% to 99%, about 80% to 99%, about 85% to 99%, or about 90% to 99%, as determined by chiral HPLC.
[0137] In some forms, the ee value of the chiral amino acid of Formula II', the alkylated chiral amino acid of Formula VIII', the methylated chiral amino acid of Formula IV', or the hydrolyzed chiral amino acid of Formula V' in the product formed by the asymmetric decarboxylation reaction catalyzed by a chiral phosphoric acid (such as a chiral phosphoric acid of Formula III') using the disclosed methods can be at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, in the range of about 70% to 100%, about 75% to 100%, about 80% to 100%, about 85% to 100%, about 90% to 100%, about 75% to 99%, about 80% to 99%, about 85% to 99%, or about 90% to 99%, as determined by chiral HPLC.
[0138] b. Yield
[0139] In general, using the disclosed methods, the yield of the chiral amino acid in the product formed by the asymmetric decarboxylation reaction is at least 80%, for example, in the range of about 80% to about 99%. The yield of the chiral amino acid in the product can be calculated as follows: Chiral amino acid yield = (total moles of chiral amino acid obtained experimentally) / (total moles of chiral amino acid obtained theoretically) × 100%. The total moles of chiral amino acids obtained experimentally can be determined using known methods, such as using NMR (e.g. 1 H NMR, 19 F NMR and / or 31 P NMR) spectral analysis and a known amount of an internal standard, such as a known amount of PhTMS as an internal standard.
[0140] In some forms, using the disclosed methods, the yield of the chiral amino acid of Formula II, the alkylated chiral amino acid of Formula VIII, the methylated chiral amino acid of Formula IV, or the hydrolyzed chiral amino acid of Formula V in the product formed by the asymmetric decarboxylation reaction catalyzed by a chiral phosphoric acid (e.g., a chiral phosphoric acid of Formula III or CPA-8) can be at least 80%, for example, in the range of about 80% to about 99%.
[0141] In some forms, using the disclosed methods, the yield of the chiral amino acid of Formula II', the alkylated chiral amino acid of Formula VIII', the methylated chiral amino acid of Formula IV', or the hydrolyzed chiral amino acid of Formula V' in the product formed by the asymmetric decarboxylation reaction catalyzed by a chiral phosphoric acid (e.g., a chiral phosphoric acid of Formula III') can be at least 80%, for example, in the range of about 80% to about 99%.
[0142] B. Optional Steps
[0143] The disclosed methods may include one or more optional steps, such as: (ii) adding an alkylating reactant (e.g., a methylating or ethylating reactant) or an acid to the product to form a second reaction mixture, (iii) maintaining the second reaction mixture at a second temperature for a second period of time sufficiently long to form an alkylated product (e.g., a methylated or ethylated product) or a hydrolysis product; purifying the product after step (i), and / or purifying the alkylated or hydrolysis product after step (iii); preparing a substrate before step (i); recovering the amino protecting agent and catalyst after step (i) and / or step (iii); and / or derivatizing the chiral amino acid or the alkylated or hydrolyzed chiral amino acid into a derivative compound after step (i) and / or step (iii).
[0144] In some forms, the disclosed method includes the steps of: after the asymmetric decarboxylation reaction (i.e., step (i)), purifying the product to remove impurities in the product, such as catalyst, unwanted isomers and / or unreacted substrate, thereby obtaining a purified chiral amino acid. The product can be purified by known methods, for example, using column chromatography on silica gel or recrystallization in a suitable solvent.
[0145] In some forms, after the asymmetric decarboxylation reaction (i.e., step (i)), and / or after the alkylation / hydrolysis reaction (i.e., step (ii)), the catalyst and / or amino-protecting agent can be recovered from the product. For example, after hydrolysis of the chiral amino acid produced in the asymmetric decarboxylation reaction, the catalyst and amino-protecting agent can be recovered by extraction.
[0146] 1. Formation of alkylation or hydrolysis products
[0147] In some forms, after the asymmetric decarboxylation reaction (i.e., step (i)), the chiral amino acid produced in the asymmetric decarboxylation reaction is further treated with an alkylating reactant (e.g., a methylating or ethylating reactant) or an acid to form an alkylated chiral amino acid (e.g., a methylated or ethylated chiral amino acid) or a hydrolyzed chiral amino acid. The alkylating reactants and reaction conditions for converting a carboxylic acid group into an ester are known, for example, see Matsumoto et al., "Recent Advances in the Synthesis of Carboxylic Acid Esters" DOI: 10.5772 / intechopen.74543.
[0148] For example, a chiral amino acid of Formula II or Formula II' (as described above) is reacted with a methylating reactant to form a methylated chiral amino acid of Formula IV or Formula IV' (as described above) through a methylation reaction. The methylating reactant can be any suitable chemical substance that can react with the chiral amino acid and convert its carboxyl group into an ester. Examples of methylating reactants suitable for the methylation reaction include, but are not limited to, trimethylsilyldiazomethane, iodomethane, dimethyl sulfate, dimethyl carbonate, or tetramethylammonium chloride, methyl triflate, diazomethane, and methyl fluorosulfonate. In a preferred form, the methylating reactant used to form the methylated chiral amino acid in the methylation reaction is trimethylsilyldiazomethane. Typically, the methylation reaction is carried out at a temperature ranging from about 50°C to about 100°C, from about 60°C to about 100°C, or from about 70°C to about 100°C, for a duration of about 30 minutes to about 2 hours, or from about 30 minutes to about 1 hour.
[0149] For example, the chiral amino acid of formula II or formula II ' (as mentioned above) and acid reaction are formed into the hydrolysis chiral amino acid of formula V or formula V ' (as mentioned above) by hydrolysis.This acid can be any suitable acid, and its acidity can make the protected amino deprotection of chiral amino acid, as any one of those acids described above for A1.In preferred form, the acid that is used to make protected amino deprotection and form hydrolysis chiral amino acid in the hydrolysis reaction is HCl.Generally speaking, the hydrolysis reaction is carried out at a temperature of approximately 90 ℃ to approximately 120 ℃ or approximately 90 ℃ to approximately 110 ℃, and the duration is approximately 12 hours to approximately 36 hours or approximately 12 hours to approximately 24 hours.
[0150] For example, a chiral amino acid of Formula II or II' (as described above) is reacted with an ethylating reactant to form an ethylated chiral amino acid through an ethylation reaction (such as the reaction of the chiral amino acid of Formula II or II' with thionyl chloride in ethanol solution).
[0151] In some forms, the product containing the chiral amino acid is cooled to room temperature or about 0°C before adding the alkylating reactant (e.g., methylating or ethylating reactant) or acid (i.e., step (ii)), and then the alkylating reactant (e.g., methylating or ethylating reactant) or acid is added to the cooled product at room temperature (e.g., for methylation reaction) or 0°C (for hydrolysis), and the reaction mixture is then heated to a suitable temperature (such as the temperature described above) to react.
[0152] 2. Preparation of Substrate
[0153] In some forms, before the asymmetric decarboxylation reaction (i.e., step (i)), the starting material is converted into a substrate using known reactions (such as substitution reactions and hydrolysis) to prepare the substrate. Typically, the starting material is readily available, such as commercially available malonic acid or esters.
[0154] In some forms, the starting material is a commercially available malonate having the structure of Formula VI: Wherein T1 and T2 can be independently unsubstituted alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, etc. For example, T1 and T2 are both methyl or ethyl.
[0155] In these forms, the starting material can be reacted with an amino protecting agent P1X1 via a substitution reaction to form an amino protected malonate having the structure of Formula VII: Wherein X1 is a halide (such as fluoride, chloride, iodide, etc.), P1 can be any suitable amino protecting group, such as any of those described above for the substrate.
[0156] The amino protected malonate of formula VII can then be subjected to a substitution reaction and hydrolysis to form a substrate of formula I or formula I' as described above. For example, the amino protected malonate of formula VII is reacted with a substitution reactant R1X2, wherein X2 is a halide (such as fluoride, chloride, iodide, etc.), and R1 is a functional group or a biomolecule moiety (such as any of those described above for the substrate), so that R1 is attached to the methylene carbon of the malonate, and then hydrolyzed to form a malonate substrate of formula I or formula I'. In some forms, the substitution reaction and hydrolysis can be carried out simultaneously, i.e., the substitution reaction to attach R1 and the hydrolysis of the ester group to form the carboxyl group are completed in a single step.
[0157] 3. Further derivatization of chiral amino acids
[0158] Since chiral amino acids introduce various functional groups through their side chains, they can be further derivatized to generate a variety of useful compounds, such as cyclic amino acids, drug-amino acid conjugates, DNA gyrase inhibitors, etc.
[0159] Further derivatization of the chiral amino acid can be performed using any known reaction, such as oxidation, coupling reaction (eg, click reaction), nucleophilic / electrophilic substitution, metathesis reaction, and combinations thereof.
[0160] For example, chiral amino acids containing a p-methoxybenzyl group in the side chain produced using the disclosed method can be derivatized to form cyclic amino acids (e.g. Figure 3D , 41-44). For example, the chiral amino acids produced using the disclosed methods contain alkynyl or azide groups, which can react with drugs containing azide or alkyne groups to form drug-amino acid conjugates through click chemistry reactions. For example, when the amino protecting group of the chiral amino acids produced using the disclosed methods is 3-alkoxy-4-nitrobenzamides, they can be further derivatized to form DNA gyrase B inhibitors through hydrogenation, acylation, and ester hydrolysis (see Figure 5 ).
[0161] Specific exemplary substrates, chiral phosphates, chiral amino acids, alkylated chiral amino acids (such as methylated chiral amino acids), hydrolyzed chiral amino acids, further derivatized chiral amino acids, and their corresponding yields and enantiomeric ratios are described in the examples below.
[0162] The disclosed methods and compositions can be further understood through the following numbered paragraphs.
[0163] 1. A method for preparing a chiral amino acid, comprising: (i) maintaining the first reaction mixture at a first temperature for a first period of time sufficient to form a product, wherein the first reaction mixture comprises a substrate, a catalyst and a solvent, wherein the catalyst is chiral phosphoric acid, and wherein the product comprises a chiral amino acid. 2. The method according to paragraph 1, wherein the substrate is malonic acid. 3. The method according to paragraph 2, wherein the malonic acid has a structure of Formula I or Formula I': The chiral amino acid in the product has a structure of Formula II or Formula II': Wherein P1 is an amino protecting group and R1 is a functional group or a biomolecule moiety. 4. The method according to any one of paragraphs 1-3, further comprising: (ii) adding an alkylation reactant or acid to the product to form a second reaction mixture, and (iii) maintaining the second reaction mixture at a second temperature for a second period of time sufficient to form an alkylated product or a hydrolyzed product, The alkylation product or hydrolysis product comprises an alkylated chiral amino acid or a hydrolyzed chiral amino acid. 5. The method according to paragraph 4, wherein the alkylated chiral amino acid has a structure of Formula VIII or Formula VIII', and the hydrolyzed chiral amino acid has a structure of Formula V or Formula V': Where P1 and R1 are as defined in paragraph 3, R 26 is a substituted or unsubstituted alkyl group, such as C1-C 12 Unsubstituted alkyl, C1-C 10 unsubstituted alkyl, C1-C8 unsubstituted alkyl, C1-C6 unsubstituted alkyl, or C1-C4 unsubstituted alkyl, such as methyl or ethyl, A1 is an acid molecule (e.g., HCl), Alternatively, the alkylated chiral amino acid is a methylated chiral amino acid having a structure of Formula IV or Formula IV': wherein P1 and R1 are as defined in paragraph 3. 6. The method of paragraph 4 or 5, wherein the alkylating reactant in the second reaction mixture is a methylating reactant (such as trimethylsilylated diazomethane) and the acid in the second reaction mixture is HCl. 7. The method according to any one of paragraphs 3-6, wherein P1 is where L1 is: R2 is hydrogen, hydroxy, halide, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, alkoxy, thiol, amino, amido, carbonyl, cyano, isocyano, nitro, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono; R3-R 10 are independently hydrogen, or substituted or unsubstituted alkyl (e.g., unsubstituted alkyl, such as C1-C 10 unsubstituted alkyl, C1-C8 unsubstituted alkyl, C1-C6 unsubstituted alkyl, or C1-C4 unsubstituted alkyl); and When present, the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl, or phosphono, 8. The method according to paragraph 7, wherein L1 is 9. The method of paragraph 7 or 8, wherein R2 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, alkoxy, thiol, amino, amide or carbonyl. 10. The method according to any one of paragraphs 7 to 9, wherein R2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, or substituted or unsubstituted aralkyl. 11. The method according to any one of paragraphs 7-10, wherein R2 is where R 11 -R 15 and R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl, or phosphono. 12. The method according to paragraph 11, wherein R 11 -R 15 are independently hydrogen, halide, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted phenyl, unsubstituted haloalkyl, unsubstituted aralkyl, cyano, isocyano, nitro, where R 16 -R 18 are independently hydrogen, hydroxy, -OR' 18 , unsubstituted alkyl, unsubstituted phenyl, unsubstituted halogenated alkyl or unsubstituted aralkyl, R' 18 is an unsubstituted alkyl group. 13. The method according to any one of paragraphs 7-12, wherein R2 is: where R 12 -R 14 are independently halide (e.g., F, Cl or I), unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), cyano, isocyano, nitro, where R 16 and R 18 are independently hydrogen, hydroxy, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or unsubstituted aralkyl (e.g., benzyl), R' 18 is an unsubstituted alkyl group. 14. The method according to any one of paragraphs 7-13, wherein R2 is where R 12 yes R 13 is a halide (such as F, Cl or I), an unsubstituted alkyl group, an unsubstituted haloalkyl group (such as -CF3), a cyano group, an isocyano group, a nitro group, R 16 and R 18 are independently hydrogen, hydroxy, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or unsubstituted aralkyl (e.g., benzyl), R' 18 is an unsubstituted alkyl group. 15. The method according to paragraph 14, wherein R 13 It's nitro. 16. The method of any one of paragraphs 3-15, wherein R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, and wherein when the substituents are present, the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, nitro, amino, amido, azido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono. 17. The method of paragraph 16, wherein the substituents, when present, are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, azide, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, or nitro. 18. The method of paragraph 16 or 17, wherein the substituents, when present, are independently biomolecule moieties. 19. The method according to any one of paragraphs 1-18, wherein the one or more carbons, one or more nitrogens and / or one or more hydrogens of the substrate are 13 C. 14 C. 15 N and / or D form. 20. The method of any one of paragraphs 1-19, wherein the chiral phosphoric acid is BINOL phosphoric acid or a derivative thereof, H8BINOL phosphoric acid or a derivative thereof, SPINOL phosphoric acid or a derivative thereof, Biphenol phosphoric acid or a derivative thereof, dithiophosphoric acids or a derivative thereof, TADDOL phosphoric acid or a derivative thereof, paracyclophane or a derivative thereof, TiPSY phosphoric acid or a derivative thereof, or TRIP phosphoric acid or a derivative thereof. 21. The method according to any one of paragraphs 1-20, wherein the chiral phosphoric acid has a structure of Formula III or Formula III': in: R 19 、R 20 , R' 19 , and R' 20 are independently substituted or unsubstituted aryl, or substituted or unsubstituted polyaryl; R 21 -R 24 and R' 21-R' 24 are independently hydrogen, or unsubstituted alkyl; and When the substituents are present, the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted polyaryl (e.g., naphthyl), substituted or unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF2-CF3), or R 25 It is a substituted or unsubstituted alkyl group, a substituted or unsubstituted haloalkyl group (for example, a fluorine-substituted C1-C6 haloalkyl group, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), a substituted or unsubstituted aryl group (for example, a phenyl group), or a substituted or unsubstituted aralkyl group (for example, a benzyl group). 22. The method according to paragraph 21, wherein R 19 and R 20 At least one of R' 19 and R' 20 At least one of the groups is independently a substituted aryl group or a substituted polyaryl group, optionally wherein the substituted aryl group or polyaryl group has three or more substituents (such as 2,4,6-substituted phenyl). 23. The method of any one of paragraphs 1-22, wherein the chiral phosphoric acid has the following structure: 24. The process of any of paragraphs 1-23, wherein the catalyst is present in the first reaction mixture in an amount ranging from about 1 mol% to about 20 mol%, about 1 mol% to about 10 mol%, about 2 mol% to about 20 mol%, about 2 mol% to about 10 mol%, or about 2.5 mol% to about 10 mol%, e.g., about 10 mol% or about 2.5 mol%. 25. The method of any of paragraphs 1-24, wherein the solvent is an ether. 26. The process according to paragraph 25, wherein the ether is ethyl acetate, t BuOMe, THF, 2-MeTHF, 1,4-dioxane, cyclopentyl methyl ether (CPME), or (MeOCH2CH2)2O, or a combination thereof. 27. The process of any of paragraphs 1-26, wherein the first reaction mixture is maintained at a temperature in the range of about 50°C to about 100°C, about 60°C to about 100°C, or about 70°C to about 100°C, for example, at a temperature of about 80°C, for a duration in the range of about 1 hour to about 12 hours, about 1 hour to about 10 hours, about 1 hour to about 8 hours, about 1 hour to about 5 hours, or about 1 hour to about 3 hours, for example, for about 2 hours. 28. The method of any one of paragraphs 4-27, wherein the second reaction mixture (e.g., for the methylation reaction) is maintained at a temperature in the range of about 50°C to about 100°C, about 60°C to about 100°C, or about 70°C to about 100°C, for a time in the range of about 30 minutes to about 2 hours, or about 30 minutes to about 1 hour, or The second reaction mixture (for hydrolysis) is maintained at a temperature ranging from about 90°C to about 120°C, or about 90°C to about 110°C, for a time ranging from about 12 hours to about 36 hours, or about 12 hours to about 24 hours. 29. The process of any of paragraphs 4-28, wherein after step (i), the product is cooled to room temperature or about 0°C before adding the alkylation reactant (eg, methylation reactant) or the acid. 30. The process of any of paragraphs 1-29, wherein the chiral amino acid is produced in a yield of at least 80%, or in a yield ranging from about 80% to about 99%. 31. The method of any of paragraphs 1-30, wherein the enantiomeric excess (ee) of the chiral amino acid is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, in the range of about 70% to 100%, about 75% to 100%, about 80% to 100%, about 85% to 100%, about 90% to 100%, about 75% to 99%, about 80% to 99%, about 85% to 99%, or about 90% to 99%, as determined by chiral HPLC. 32. The method according to any one of paragraphs 1 to 31, further comprising: purifying the product after step (i), and / or purifying the alkylated or hydrolyzed product after step (iii); preparing the substrate before step (i); recovering the amino protecting agent and the catalyst after step (i) and / or step (iii); and / or derivatizing the chiral amino acid or the alkylated or hydrolyzed chiral amino acid into a derivative compound after step (i) and / or step (iii). 33. The method of paragraph 32, wherein the derivatization step is performed by oxidation reaction, coupling reaction (eg, click reaction), nucleophilic / electrophilic substitution, or metathesis reaction, or a combination thereof. 34. The method of paragraph 32 or 33, wherein the derivative compound is a cyclic amino acid, a drug-amino acid conjugate, or a DNA gyrase inhibitor. 35. The method of any one of paragraphs 32-34, wherein the substrate is prepared by the following steps: (a) converting a starting compound having the structure of formula VI into an amino-protected compound of formula VII: wherein T1 and T2 are independently unsubstituted alkyl groups, and P1 is an amino protecting group; (b) converting the amino protected compound of formula VII into a substrate of formula I or I'. 36. A chiral amino acid having a structure of Formula VIII or Formula VIII': where R 26 is a substituted or unsubstituted alkyl group, such as C1-C 12 Unsubstituted alkyl, C1-C 10 unsubstituted alkyl, C1-C8 unsubstituted alkyl, C1-C6 unsubstituted alkyl, or C1-C4 unsubstituted alkyl, such as methyl or ethyl; P1 is where R 12 yes R 13 Is cyano, isocyano, nitro, or R 16 and R 18 are independently hydrogen, hydroxy, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C1-C6 haloalkyl, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), or unsubstituted aralkyl (e.g., benzyl), wherein R' 18 is an unsubstituted alkyl group; R1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, wherein the substituents, when present, are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, azido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphonyl, phosphoryl, or phosphono. 37. The chiral amino acid according to paragraph 36, wherein R 26 is methyl or ethyl; R 13 is nitro; R 12 yes R 16 is an unsubstituted haloalkyl group (e.g., a fluoride-substituted C1-C6 haloalkyl group, such as -CF3, -CH2-CF3, -CH2-CH2-CF3, -CH2-CF2-CF3, -CH2-CF2-CF3), optionally, wherein R 16 It is -CH2-CH2-CF3, -CH2-CF2-CF3, or -CH2-CF2-CF2-CF3. 38. The chiral amino acid of paragraph 36 or 37, wherein the substituents, when present, are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, azido, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, or nitro. 39. The chiral amino acid of any of paragraphs 36-38, wherein the substituents, when present, are independently biomolecule moieties (eg, cholic acid moieties, estrone moieties, etc.). 40. The chiral amino acid according to any one of paragraphs 36-39, wherein R 26 is methyl; R 13 is nitro; R 12 yes R 16 It is -CH2-CF2-CF3. 41. The chiral amino acid according to any one of paragraphs 36-40, having any one of the following structures:
[0164] Examples
[0165] Example 1: Synthesis of α-amino acids using asymmetric malonates Materials and methods Reagents and instruments
[0166] Unless otherwise noted, all reactions were performed under nitrogen. (R)- or (S)-chiral phosphoric acid (CPA) (purity ≥98%) was purchased from Daicel Chiral Technology (China) Co., Ltd. and used as received. Cyclopentyl methyl ether (CPME) was purchased from Shanghai MacLean Biochemical Co., Ltd. and used as received. Thin-layer chromatography (TLC) was performed using silica gel plates from Yantai Huanghai Silica Gel Development Co., Ltd.
[0167] 1 H NMR, 13 C NMR and 19 F NMR spectra were obtained on a Bruker 400, 500, or 600 spectrometer ( 1 H is 400 / 500 / 600MHz, 13 C is 100 / 125 / 150MHz, 19 F is 376 / 471MHz). 15 N NMR spectra were obtained on a Bruker 400 spectrometer ( 15 N is 40MHz). All 1 All H NMR experiments were performed using tetramethylsilane (0 ppm) in CDCl3, using the residual DMSO (2.50 ppm) signal in DMSO-d6, the residual CH3OH (3.31 ppm) signal in CD3OD, or the residual CH3CN (1.94 ppm) signal in CD3CN as internal references. 13 C NMR experiments were performed on CDCl3 signal (77.0 ppm), DMSO-d6 signal (39.52 ppm), CD3OD signal (49.00 ppm), or CD3CN signal (1.32, 118.3 ppm). 1 H NMR, 13 CNMR and 19 F NMR data are shown as follows: chemical shift (δ, ppm), multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, hept = septet, dd = doublet of doublets, tt = triplet of triplets, td = triplet of doublets, m = multiplet), coupling constant (Hz), and integration. Chiral high-performance liquid chromatography (HPLC) spectra were measured on an Agilent 1260 Infinity II. [α] DThe infrared absorption spectra were recorded on a PerkinElmer UATR two Fourier transform infrared spectrometer and the data were expressed as cm -1 ). High-resolution EI mass spectra were recorded on a Thermo Scientific DFS high-resolution magnetic sector mass spectrometer. High-resolution ESI-MS measurements were performed on a Bruker Impact II high-resolution LC-QTOF mass spectrometer. Molecular ions [M+H] are reported. + The accurate mass of high-resolution mass spectrometry.
[0168] General procedure for substrate synthesis Preparation of common intermediate 16
[0169] Scheme 1. Synthetic steps of intermediate 16
[0170] Step I: To a suspension of NaH (32.4 g, 810 mmol, 311 mol%, 60% dispersion in mineral oil) in THF (600 mL) was added 2,2,3,3,3-pentafluoro-1-propanol (58.5 g, 390 mmol, 150 mol%) dropwise at room temperature. The resulting mixture was stirred at room temperature for 30 minutes, and then 3-fluoro-4-nitrobenzoic acid (60.0 g, 324 mmol, 125 mol%) was added portionwise. The mixture was stirred at room temperature for 4 hours and monitored by TLC. After complete consumption of the acid starting material, 1 M aqueous HCl (500 mL) was slowly added to the reaction mixture. The organic phase (THF) was separated, concentrated in vacuo, and redissolved in EtOAc. The aqueous phase was extracted with EtOAc (100 mL x 3). The organics were combined, washed with water and brine, dried over Na2SO4, filtered and concentrated to give 4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzoic acid which was used directly in the next step without further purification.
[0171] Step II: To a solution of the crude 4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzoic acid synthesized above in DCM (600 mL) was added oxalyl chloride (33.4 mL, 390 mmol, 150 mol%) at room temperature. 2 mL of DMF was slowly added dropwise to the reaction mixture. The reaction mixture was stirred at room temperature until all solids dissolved and the mixture became clear. The reaction mixture was concentrated in vacuo to afford the acid chloride, which was used directly in the next step without purification.
[0172] Step III: To a solution of diethylaminomalonate hydrochloride (55.1 g, 260 mmol, 100 mol%) in DCM (600 mL) was added triethylamine (150 mL) under vigorous stirring at 0°C. A 200 mL DCM solution of the above-synthesized 4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzoyl chloride was then added dropwise to the reaction mixture. The reaction mixture was stirred at the same temperature for 1 hour and monitored by TLC. After completion, the mixture was poured into 500 mL of water and stirred vigorously for 5 minutes. The organic phase was separated and washed with water (500 mL × 3). The organic solution was concentrated in vacuo to approximately 200 mL. The precipitate was collected by filtration and washed with hexane (200 mL × 3). The solid was dried in vacuo to give a light yellow solid 16 (109.69 g, 89% yield), which was used in the next step without further purification.
[0173] Representative substitution steps
[0174] Scheme 2. Intermediate 16 a Examples of substitution reactions a R represents each group on the amino acid products shown in Figures 3 and 4.
[0175] At room temperature, CsCO (200mol%) and RI or RBr (150mol%) were added to a solution of 16 (100mol%) in CHCN (0.1M). The resulting mixture was stirred at room temperature until complete conversion and monitored by TLC. The CHCN was then removed in vacuo and a 1M aqueous HCl solution (0.1M to 16) was added to the residue. The mixture was stirred for 5 minutes and extracted with EtOAc. The combined organic solvents were washed with water and brine, dried over NaSO, filtered, and concentrated. The residue was subjected to flash column chromatography (hexane / ethyl acetate) to obtain disubstituted malonic esters.
[0176] Representative hydrolysis steps
[0177] Scheme 3. Example of hydrolysis reaction of R-substituted 16
[0178] To a solution of disubstituted diethyl 2-(4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzamide)malonate (100 mol%) in 1,4-dioxane (0.5 M) at 0°C was added a 2M aqueous NaOH solution (400 mol%) dropwise. The resulting mixture was warmed to room temperature and then stirred at 40°C until hydrolysis was complete, which was monitored by TLC. 1,4-Dioxane was removed in vacuo, and the aqueous layer was acidified to pH 6-7 with 1M aqueous HCl and washed with diethyl ether to remove unreacted malonic acid half esters and 4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzoic acid until only malonic acid remained in the aqueous layer, as monitored by TLC. The aqueous phase was then acidified to pH 2-3 with 1M aqueous HCl and extracted three times with diethyl ether. The organic phase was washed with brine, dried over MgSO4, filtered, and evaporated in vacuo to yield aminomalonic acid without further purification.
[0179] Synthesis of exemplary substrates
[0180] Scheme 4.α- 13 Synthesis process of C-68
[0181] Step a: diethyl malonate-2- 13 C(Diethyl malonate-2- 13 C) (1.0 g, 6.3 mmol) was dissolved in a mixture of water (2.0 mL) and acetic acid (1.5 mL) and cooled to 0 ° C. Sodium nitrite (2.20 g, 31.5 mmol, 500 mol%) was added portionwise to the reaction mixture. The mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, the reaction mixture was poured into 30 mL of water and extracted with ether (30 mL × 3). The combined organic phases were carefully treated with saturated sodium bicarbonate solution and stirred until the aqueous layer turned light yellow. The organic layer was separated (retention factor ("R f”) = 0.4 (hexane / EtOAc 5:1)), washed with brine, dried over Na2SO4, filtered and concentrated to give the corresponding oxime (1.2267 g, quantitative yield). The oxime was used directly in the next step without further purification.
[0182] Step b: Mix the above-synthesized oxime and Pd / C (10%, 100 mg) in a 50 mL round-bottom flask. Seal the flask with a rubber septum and purge with nitrogen for 10 minutes. Under a nitrogen balloon, 15 mL of methanol was added to the reaction mixture. The reaction mixture was purged with hydrogen for 15 minutes and stirred at room temperature with hydrogen overnight. Filter the reaction mixture with a diatomaceous earth plug and elute with EtOAc. The filtrate was concentrated to obtain diethyl aminomalonate-2- 13 C(diethyl aminomalonate-2- 13 C) (0.9067 g, 82% yield). The amine was used directly in the next step without further purification. f =0.2 (hexane / EtOAc 1:1).
[0183] Step c: Dissolve the above synthesized diethyl aminomalonate (0.9067 g, 5.2 mmol) and triethylamine (2.0 mL, 14 mmol, 270 mol%) in 50 mL DCM. Add Bz in 20 mL DCM dropwise to the reaction mixture at 0°C. 7 OH (according to the general procedure, 7.3 mmol Bz 7 OH). The reaction mixture was stirred at 0°C and monitored by TLC. After completion, the mixture was poured into 50 mL of water and extracted with DCM (25 mL x 3). The combined organics were washed with water and brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash column chromatography to give α- 13 C-16 (1.7428 g, 71% yield). f =0.2 (hexane / EtOAc 4:1).
[0184] Step d: At room temperature, 13To a solution of C-16 (1.7428 g, 3.7 mmol) in 50 mL of CH3CN were added Cs2CO3 (2.41 g, 7.4 mmol, 200 mol%) and iodomethane (781 mg, 5.5 mmol, 150 mol%). The resulting mixture was stirred at room temperature until complete conversion, which was monitored by TLC. The CH3CN was then removed in vacuo and a 1 M aqueous HCl solution (50 mL) was added to the residue. The mixture was stirred for 5 minutes and extracted with EtOAc (25 mL×3). The combined organic solvents were washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was subjected to flash column chromatography to give α- 13 C-68 diester (1.3762 g, 77% yield). f =0.5 (hexane / EtOAc 3:1).
[0185] The α- 13 C-68 (2.5 mmol hydrolysis ratio, 0.8426 g, 78% yield) white solid. f =0.1 (DCM / MeOH 5:1).
[0186] Option 5. 15 Synthesis steps of N-68
[0187] Step a: Diethyl malonate (1.0 g, 6.3 mmol) was dissolved in a mixture of water (2.0 mL) and acetic acid (1.5 mL) and cooled to 0°C. Sodium nitrite- 15 N (2.0 g, 28.6 mmol, 450 mol%) was added to the reaction mixture in batches. The mixture was stirred at room temperature overnight. After TLC showed that the reaction was complete, the reaction mixture was poured into 30 mL of water and extracted with ether (30 mL × 3). The combined organic phases were carefully treated with saturated sodium bicarbonate solution and stirred until the aqueous layer turned light yellow. The organic layer was separated, washed with brine, dried over Na2SO4, filtered and concentrated to give the corresponding oxime (1.1771 g, 99% yield). The oxime was used directly in the next step without further purification. f =0.4 (hexane / EtOAc 5:1).
[0188] Step b: Mix the above-synthesized oxime and Pd / C (10%, 100 mg) in a 50 mL round-bottom flask. Seal the flask with a rubber septum and purge with nitrogen for 10 minutes. Add 15 mL of methanol under a nitrogen balloon. Purge the reaction mixture with hydrogen for 15 minutes and stir with hydrogen at room temperature overnight. Filter the reaction mixture through a celite plug and elute with EtOAc. Concentrate the filtrate to obtain diethyl aminomalonate- 15 N(diethyl aminomalonate- 15 N) (0.8805 g, 80% yield). The amine was used directly in the next step without further purification. f =0.2 (hexane / EtOAc 1:1).
[0189] Step c: The aminomalonate synthesized above (0.8805 g, 5.0 mmol) and triethylamine (2.0 mL, 14 mmol, 270 mol%) were dissolved in 50 mL of DCM. At 0° C., Bz7Cl (prepared from 7.3 mmol of Bz7OH as described in the general procedure) in 20 mL of DCM was added dropwise to the reaction mixture. The reaction mixture was stirred at 0° C. and monitored by TLC. After completion, the mixture was poured into 50 mL of water and extracted with DCM (25 mL×3). The combined organics were washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography to give a colorless oil. 15 N-16 (1.4331 g, 61% yield). f =0.2 (hexane / EtOAc 4:1).
[0190] Step d: At room temperature, 13 To a solution of C-16 (1.4331 g, 3.0 mmol) in 40 mL of CH3CN were added Cs2CO (1.96 g, 6.0 mmol, 200 mol%) and iodomethane (639 mg, 4.5 mmol, 150 mol%). The resulting mixture was stirred at room temperature until complete conversion, as monitored by TLC. The CH3CN was then removed in vacuo, and a 1 M aqueous HCl solution (50 mL) was added to the residue. The mixture was stirred for 5 minutes and extracted with EtOAc (25 mL×3). The combined organic solvents were washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was subjected to flash column chromatography to give a colorless oil. 15 N-68 diester (897.3 mg, 61% yield). f =0.5 (hexane / EtOAc 3:1).
[0191] Scheme 6. Synthetic steps of S73
[0192] Step I: To a solution of Lamivudine (2.2972 g, 10 mmol, 100 mol%) and TBSCl (tert-butyldimethylsilyl chloride) (1.8097 g, 12 mmol, 120 mol%) in DCM (80 mL) was added imidazole (1.0332 g, 15 mmol, 150 mol%). The reaction mixture was stirred at room temperature for 12 hours and monitored by TLC. After the reaction was completed, the mixture was poured into 100 mL of water, and the aqueous phase was extracted with DCM (50 mL×3). The combined organic phases were washed with brine, dried over MgSO4, filtered, and evaporated in vacuo to give S73-SM-1 as a light yellow oil, which was used in the next step without further purification. f =0.7 (DCM / MeOH 5:1).
[0193] Step II: To all the S73-SM-1 from step I in DCM (50 mL) was added triethylamine (2.8 mL, 20 mmol, 200 mol%) with vigorous stirring at 0°C. BzCl (1.4 mL, 12 mmol, 120 mol%) was added dropwise to the reaction mixture. The reaction mixture was warmed to room temperature and stirred for 2 hours, monitored by TLC. After completion of the reaction, the mixture was poured into 50 mL of water, and the aqueous phase was extracted with DCM (50 mL×3). The combined organic phases were washed with brine, dried over MgSO4, filtered, and evaporated in vacuo to give S73-SM-2 as a light yellow oil, which was used in the next step without further purification. f =0.2 (hexane / EtOAc 1:1).
[0194] Step III: To a solution of all S73-SM-2 from step II in THF (20 mL) was added TBAF (tetrabutylammonium fluoride) (20 mL, 1.0 M in THF) dropwise at 0°C under argon over 10 minutes. The resulting mixture was stirred at room temperature for 18 hours and monitored by TLC. The mixture was concentrated under reduced pressure to afford S73-SM-3 as a light yellow oil, which was used in the next step without further purification.
[0195] Step IV: To a solution of all S73-SM-3 from step III in DMF (50 mL) was added NaH (0.6005 g, 15 mmol, 150 mol% (60% dispersion in mineral oil)) at 0°C with vigorous stirring. The reaction mixture was warmed to room temperature and stirred for 0.5 hours. 3-bromopropyne (1.3 mL, 15 mmol, 150 mol%) was added dropwise to the reaction mixture at 0°C. The reaction mixture was warmed to room temperature and stirred for 2 hours and monitored by TLC. After completion of the reaction, the mixture was quenched with 10 mL of saturated aqueous NH4Cl solution and extracted with EtOAc (50 mL×3). The combined organic phases were washed with brine, dried over MgSO4, filtered, and evaporated in vacuo without further purification to afford S73 as a light yellow oil.
[0196] Scheme 7. Synthesis of (±)-80
[0197] To a solution of S17-diesters (1.4592 g, 3 mmol, 100 mol%) in 1,4-dioxane (0.5 M) at 0°C was added 2 M aqueous NaOH (2.25 mL, 4.5 mmol, 150 mol%) dropwise. The resulting mixture was warmed to room temperature and stirred at 40°C until hydrolysis was complete, which was monitored by TLC. 1,4-dioxane was removed in vacuo. The aqueous layer was washed three times with diethyl ether to remove unreacted starting materials and acidified with 1 M aqueous HCl to 40°C. The 4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzoic acid was removed by washing with ether until only the malonic acid remained in the aqueous phase (monitored by TLC). The aqueous phase was then acidified to pH 3-4 with 1M aqueous HCl and extracted three times with ether. The organic phase was washed with brine, dried over MgSO₄, filtered, and evaporated in vacuo without further purification to yield (±)-80.
[0198] Scheme 8. Synthesis of 84
[0199] To a solution of 16 (0.9966 g, 2.1 mmol, 100 mol%) in CH3CN (0.1 M) was added Cs2CO3 (2.6125 g, 8.0 mmol, 400 mol%) and MeI (0.5 mL, 8.0 mmol, 400 mol%) at room temperature. The resulting mixture was stirred at room temperature until complete conversion, which was monitored by TLC. The CH3CN was then removed in vacuo and a 1 M aqueous HCl solution (0.1 M to 16) was added to the residue. The mixture was stirred for 5 minutes and extracted with EtOAc. The combined organic solvents were washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography (hexane / ethyl acetate) to give disubstituted malonic ester 84-SM (1.0012 g, 95% yield). f =0.5 (hexane / EtOAc 2:1).
[0200] To a 0.5 M solution of 84-SM (1.0012 g, 2 mmol, 100 mol%) in 1,4-dioxane was added 2 M aqueous NaOH (4 mL, 8 mmol, 400 mol%) dropwise at 0°C. The resulting mixture was warmed to room temperature and then stirred at 40°C until hydrolysis was complete, as monitored by TLC. 1,4-Dioxane was removed in vacuo, and the aqueous layer was acidified to pH 6-7 with 1 M aqueous HCl. The unreacted malonate half-ester and 4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzoic acid were washed with ether until only malonate remained in the aqueous phase (as monitored by TLC). The aqueous phase was then acidified to pH 2-3 with 1 M aqueous HCl and extracted three times with ether. The organic phase was washed with brine, dried over MgSO4, filtered, and evaporated in vacuo without further purification to afford 84.
[0201] Scheme 9. Synthesis of 85
[0202] To a CH3CN (0.1M) solution of 16 (7.0845 g, 15 mmol, 100 mol%) were added Cs2CO3 (9.7850 g, 30 mmol, 200 mol%) and 1,3-dibromopropane (3 mL, 30 mmol, 200 mol%) at room temperature. The resulting mixture was stirred at room temperature until complete conversion, which was monitored by TLC. The CH3CN was then removed in vacuo, and a 1M aqueous HCl solution (0.1 M to 16) was added to the residue. The mixture was stirred for 5 minutes and extracted with EtOAc. The combined organic solvents were washed with water and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography (hexane / ethyl acetate) to give the disubstituted malonate 85-SM (6.5103 g, 73% yield). f =0.7 (hexane / EtOAc 2:1).
[0203] To a 0.5 M solution of 85-SM (2.1522 g, 3.6 mmol, 100 mol%) in 1,4-dioxane was added 2 M aqueous NaOH (7.2 mL, 14.4 mmol, 400 mol%) dropwise at 0°C. The resulting mixture was warmed to room temperature and then stirred at 40°C until hydrolysis was complete, as monitored by TLC. 1,4-Dioxane was removed in vacuo, and the aqueous layer was acidified to pH 6-7 with 1 M aqueous HCl. The unreacted malonate half ester and 4-nitro-3-(2,2,3,3,3-pentafluoropropoxy)benzoic acid were washed with ether until only malonate remained in the aqueous phase (as monitored by TLC). The aqueous phase was then acidified to pH 2-3 with 1 M aqueous HCl and extracted three times with ether. The organic phase was washed with brine, dried over MgSO4, filtered, and evaporated in vacuo without further purification to afford 85.
[0204] General process of asymmetric catalytic reaction
[0205] Scheme 10. Examples of asymmetric catalytic reactions
[0206] Malonic acid (0.2 mmol, 100 mol%) and (R)-CPA-8 (11.0 mg, 0.02 mmol, 10 mol%) were added to a oven-dried 25 mL Schlenk tube. The tube was sealed with a rubber septum and evacuated / filled with nitrogen three times. Under a nitrogen atmosphere, 4 mL of CPME was added to the tube via syringe, and the reaction mixture was stirred at 80°C for 5-20 hours. After the reaction mixture was cooled to room temperature, 0.8 mL of MeOH and 0.8 mL of 2M TMSCHN2 (800 mol%) were added to the reaction mixture, and the reaction mixture was stirred for another hour. The solvent was removed in vacuo, and the filtrate was purified by flash column chromatography (hexane / ethyl acetate) to obtain the decarboxylated product.
[0207] Large-Scale Synthesis of Alanine Hydrochloride
[0208] Scheme 11. Example of the synthetic steps for alanine hydrochloride
[0209] To an oven-dried 100 mL round-bottom flask was added (R)-CPA-8 (41.8 mg, 0.075 mmol, 2.5 mol%). The flask was sealed with a rubber septum and evacuated / filled with nitrogen three times. Under nitrogen, 12 mL of CPME was added via syringe, and the flask was then stirred in an 80°C oil bath.
[0210] S17 (3.0 mmol, 1.2912 g, 100 mol%) was dissolved in 48 mL of CPME and added dropwise to the reaction mixture over 24 hours using a syringe pump. The reaction mixture was stirred at the same temperature for an additional 12 hours. The reaction mixture was cooled to room temperature and the solvent was removed in vacuo. The residue was used directly in the next step.
[0211] The residue was dissolved in 1,4-dioxane (6 mL). 6M HCl (20 mL, 4000 mol%) was added to the reaction mixture at 0°C. The reaction mixture was warmed to room temperature and then stirred at 100°C for 24 hours. The reaction mixture was cooled to room temperature and washed with diethyl ether (10 mL x 3). The aqueous phase was concentrated in vacuo to obtain a solid amino acid hydrochloride (+)-18. 58 (0.3136 g, 83% yield). f =0.2 (DCM / MeOH 1:1).
[0212] Scheme 12. Synthesis of (+)-42
[0213] To an oven-dried 25 mL Schlenk tube was added (+)-41 (226.0 mg, 0.4 mmol, 91% ee, 100 mol%), sealed with a rubber septum, and evacuated / filled with nitrogen three times. Under nitrogen, 2 mL of DCM was added to the tube via syringe. The reaction mixture was cooled to 0°C, and then DDQ (273.2 mg, 1.2 mmol, 300 mol%) was added. The reaction mixture was stirred at room temperature for 10 hours. 1 mL of saturated aqueous NaHCO3 was then added to quench the reaction, followed by extraction with DCM (5 mL x 6), washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to afford (+)-42 (151.5 mg, 85% yield) as a colorless oil. f =0.2 (hexane / EtOAc 1:1).
[0214] Scheme 13. Synthesis of (+)-43
[0215] To an oven-dried 25 mL Schlenk tube were added (+)-42 (88.6 mg, 0.2 mmol, 91% ee, 100 mol%), PPh3 (63.2 mg, 0.24 mmol, 120 mol%), and imidazole (16.4 mg, 0.24 mmol, 120 mol%), sealed with a rubber septum, and evacuated / refilled with nitrogen three times. Under nitrogen, 1 mL of DCM was added to the tube via syringe. The reaction mixture was cooled to 0°C, and then I2 (60.8 mg, 0.24 mmol, 120 mol%) was added. The reaction mixture was stirred at room temperature for 16 hours. 1 mL of saturated aqueous Na2S2O3 was then added to quench the reaction, and the mixture was extracted with DCM (5 mL×6), washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to afford (+)-43 (96.6 mg, 87% yield) as a white solid. f =0.6 (hexane / EtOAc 1:1).
[0216] Scheme 14. Synthesis of (-)-44
[0217] To a oven-dried 25 mL Schlenk tube was added (+)-43 (110.5 mg, 0.2 mmol, 91% ee, 100 mol%), sealed with a rubber septum, and evacuated / filled with nitrogen three times. 1 mL of DMF was added to the tube via syringe under nitrogen. The reaction mixture was cooled to 0°C, and then Cs2CO3 (130.8 mg, 0.4 mmol, 200 mol%) was added. The reaction mixture was stirred at room temperature for 2 hours. 1 mL of H2O was then added to quench the reaction, and the mixture was extracted with ethyl acetate (5 mL x 3), washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to afford (-)-44 (75.2 mg, 88% yield) as a white solid. f =0.3 (hexane / EtOAc 2:1).
[0218] Scheme 15. Synthesis of (+)-72
[0219] To a oven-dried 25 mL Schlenk tube were added (+)-29 (63.7 mg, 0.15 mmol, 98% ee, 100 mol%) and zidovudine (54.1 mg, 0.225 mmol, 150 mol%). The tube was sealed with a rubber septum and evacuated / filled with nitrogen three times. Under nitrogen, 3 mL of DCM was added via syringe. Sodium ascorbate (9 mg, dissolved in 1.5 mL of water, 0.045 mmol, 30 mol%) and CuSO4·5H2O (3.8 mg, dissolved in 1.5 mL of water, 0.015 mmol, 10 mol%) were then added. The reaction mixture was stirred at 30°C for 40 h, extracted with DCM (5 mL x 3), washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to afford (+)-72 (95.4 mg, 92% yield) as a colorless oil. The crude product was chromatographed using CH2Br2 (10.5 μL) as an internal standard. 1 H NMR analysis confirmed that its dr>20:1. f =0.3 (ethyl acetate 100%).
[0220] Scheme 16. Synthesis of (+)-73
[0221] To a dried 25 mL Schlenk tube were added (+)-57 (77.6 mg, 0.15 mmol, 97% ee, 100 mol%) and a lamivudine-derived terminal alkyne (67.5 mg, 0.18 mmol, 120 mol%). The tube was sealed with a rubber septum and evacuated / filled with nitrogen three times. Under a nitrogen atmosphere, 1.5 mL of DCM was added to the tube via syringe. Sodium ascorbate (9.1 mg, dissolved in 0.75 mL of water, 0.045 mmol, 30 mol%) and CuSO₄·H₂O (3.9 mg, dissolved in 0.75 mL of water, 0.015 mmol, 10 mol%) were added sequentially. The reaction mixture was stirred at room temperature for 24 hours, extracted with DCM (5 mL x 3), washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to give (+)-73 (115.3 mg, 86% yield) as a colorless oil. The crude product was chromatographed using CH2Br2 (10.5 μL) as an internal standard. 1 H NMR analysis confirmed dr>20:1. f =0.4 (hexane / EtOAc 1:3).
[0222] Scheme 17. Synthesis of (+)-74
[0223] To an oven-dried 25 mL Schlenk tube were added (+)-57 (77.5 mg, 0.15 mmol, 97% ee, 100 mol%) and a diacetone-D-glucose-derived terminal alkyne (53.5 mg, 0.18 mmol, 120 mol%). The tube was sealed with a rubber septum and evacuated / filled with nitrogen three times. Under nitrogen, 1.5 mL of DCM was added to the tube via syringe. Sodium ascorbate (9 mg, dissolved in 0.75 mL of water, 0.045 mmol, 30 mol%) and CuSO₄·H₂O (3.8 mg, dissolved in 0.75 mL of water, 0.015 mmol, 10 mol%) were added sequentially. The reaction mixture was stirred at room temperature for 12 h, extracted with DCM (5 mL x 3), washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to give (+)-74 (114.9 mg, 94% yield) as a colorless oil. The crude product was chromatographed using CH2Br2 (10.5 μL) as an internal standard. 1 H NMR analysis confirmed that dr>20:1.f =0.2 (hexane / EtOAc 2:1).
[0224] Scheme 18. Synthesis of (-)-79
[0225] Step I: (-)-77 (232.5 mg, 0.75 mmol, 94% ee) and Pd / C powder (10%, 50 mg) were added to a oven-dried 100 mL flask, sealed with a rubber septum, and evacuated / filled with nitrogen three times. 40 mL of MeOH was added to the flask via a syringe under nitrogen. The reaction mixture was purged with H2 for 5 minutes using a H2 balloon, then sealed with a H2 balloon under H2 and stirred. After stirring at room temperature for 12 hours, the reaction mixture was filtered through celite, the filtrate was concentrated in vacuo, and purified by flash column chromatography to give 78 (176.2 mg, 84% yield) as a colorless oil, which was used directly in the next step. f =0.3 (hexane / EtOAc 1:1).
[0226] Step II: To an oven-dried 100 mL flask was added 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (116.7 mg, 0.6 mmol, 100 mol%) and dry DCM (18 mL). The mixture was sealed with a rubber septum and evacuated / filled with nitrogen three times. Oxalyl chloride (254 μL in 4 mL of dry DCM, 3 mmol, 500 mol%) was added to the flask via syringe under nitrogen. Five drops of DMF were carefully added to the reaction mixture, which was stirred at room temperature for 24 hours. The solvent was then removed in vacuo, and the residue (79-SM-1) was redissolved in 4 mL of DCM and used in the next step without further purification.
[0227] Step III: To a dried 50 mL flask, 78 (168.2 mg, 0.6 mmol, 100 mol%) and dry DCM (4 mL) were added, sealed with a rubber septum, and evacuated / filled with nitrogen three times. Under nitrogen, 79-SM-1 (dissolved in 4 mL of dry DCM from Step II) and anhydrous pyridine (4 mL) were added to the flask in sequence. After stirring at room temperature for 24 hours, the reaction mixture was concentrated in vacuo, then dissolved in DCM (50 mL), washed with 1 M HCl and brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to give 79-SM-2 (72.7 mg, 27% yield) as a yellow oil, which was used directly in the next step. f =0.5 (hexane / EtOAc 1:1).
[0228] Step IV: To a stirred solution of 79-SM-2 (60.0 mg, 0.13 mmol, 100 mol%) in THF / H2O (1.2 mL of a 4:1 mixture) was added LiOH·H2O (11.5 mg, 0.26 mmol, 200 mol%). After stirring at room temperature for 3 hours, the reaction mixture was concentrated in vacuo to remove THF, then redissolved in H2O (5 mL) and washed with ether (5 mL×3). The aqueous layer was acidified to pH=2-3 with 1 M aqueous HCl and extracted with ether (5 mL×3). The organic layer was washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo and purified by flash column chromatography to give (-)-79 (41.1 mg, 71% yield) as a white solid. f =0.3 (DCM / MeOH 5:1).
[0229] Results and Discussion Characterization data Substrate characterization
[0230] 16 (260 mmol scale, 109.69 g, 89% yield) pale yellow solid. f =0.4 (hexane / EtOAc 2:1). 1 HNMR (400MHz, CDCl3) δ7.94(d,J=8.0Hz,1H),7.66(s,1H),7.57(d,J=8.0Hz,1H),7.26(s,1 H), 5.30 (d, J = 6.4Hz, 1H), 4.61 (t, J = 11.8Hz, 2H), 4.46-4.20 (m, 4H), 1.34 (t, J = 6.8Hz, 6H). 13C NMR (150MHz, CDCl3) δ 166.0, 164.3, 150.2, 142.4, 138.1, 126.0, 120.7, 115.1, 66.2 (t, J=28.5Hz), 63.0, 56.9, 13.9. 19 F NMR (376MHz, CDCl3) δ -83.4 (s), -123.2 (t, J = 11.8Hz). IR(neat, cm -1 )3293, 2992, 1748, 1530, 1190. HRMS (ESI) calculated value CalcdC 17 H 18 F5N2O8 + [M+H] + : 473.0978. Found: 473.0977.
[0231] S17-diester (13.0 mmol scale, 5.4544 g, 88% yield) was obtained as a white solid. f =0.6 (hexane / EtOAc 2:1). 1 H NMR(400MHz, CDCl3) δ7.94(d,J=8.4Hz,1H),7.75-7.60(m,2H),7.54(d,J=8.0Hz,1H ), 4.62 (t, J = 11.8Hz, 2H), 4.30 ( q, J = 7.1Hz, 4H), 1.87 ( s, 3H), 1.29 ( t, J = 7.0Hz, 6H). 13 C NMR (150MHz, CDCl3) δ168.3, 163.2, 150.3, 142.3, 138.7, 126.1, 120.4, 115.0, 66.2 (t, J = 28.2Hz), 63.4, 62.9, 20.5, 13.9. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.2(t,J=12.4Hz).IR(neat,cm -1 )3405,2987,1743,1534,1190. HRMS (ESI) calculated value calcd C 10 H 20 F5N2O8 + [M+H] + :487.1134. Measured value Found:487.1135.
[0232] S17 (11.2 mmol hydrolysis scale, 3.8477 g, 80% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 H NMR (400MHz, DMSO-d6) δ8.55(s,1H),8.02(d,J=8.4Hz,1H),7.87(s,1H),7.66(d,J=8.4Hz,Hz,1H),5.19(t,J=13.0Hz,2H),1.69(s,3H). 13 C NMR (150MHz, DMSO-d6) δ170.0,163.7,149.0,141.4,138.7,125.3,121.7,118.4(qt,J1=284. 6Hz, J2=34.8Hz), 115.0, 112.7 (tq, J1=252.8Hz, J2=37.4Hz), 65.1 (t, J=27.5Hz), 63.2, 21.0. 19 F NMR(376MHz, CDCl3)δ-82.7,-122.5(t,J=11.7Hz).IR(neat,cm -1 )3460(br),3414,1693,1520,1196.HRMS(ESI)calcd C 14 H 12 F5N2O8 + [M+H] + :431.0508. Measured value Found:431.0506.
[0233] S19 (5.9 mmol hydrolysis scale, 1.8778 g, 73% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.92(d,J=8.4Hz,1H),7.83(s,1H),7.69(s,1H),7.62(d,J =8.0Hz,1H),4.84(t,J=12.6Hz,2H),2.30(q,J=7.1Hz,2H),0.91(t,J=7.2Hz,3H). 13 C NMR (100MHz, CD3CN) δ170.6, 165.6, 150.6, 143.2, 139.2, 126.6, 122.4, 115.8, 67.6, 66.7 (t, J = 27.8Hz), 27.4, 8.4. 19F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=13.2Hz).IR(neat,cm -1 )3384,3091,1733,1516,1149. HRMS (ESI) calculated value calcd C 15 H 14 F5N2O8 + [M+H] + :445.0665. Measured value Found:445.0668.
[0234] S20 (5.3 mmol hydrolysis scale, 1.6774 g, 69% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.92(d,J=8.4Hz,1H),7.81(s,1H),7.69(s,1H),7.62(d,J=8.0Hz,1 H), 4.84 (t, J = 12.6Hz, 2H), 2.23 (t, J = 8.2Hz, 2H), 1.38-1.25 (m, 2H), 0.93 (t, J = 7.2Hz, 3H). 13 C NMR (100MHz, CD3CN) δ170.8, 165.6, 150.6, 143.1, 139.2, 126.6, 122.3, 115.8, 67.1, 66.7 (t, J = 28.2Hz), 36.1, 18.0, 14.1. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3395,2977,1739,1530,1194.HRMS (ESI) calculated value calcdC 16 H 16 F5N2O8 + [M+H] + :459.0821. Found:459.0819.
[0235] S21 (9.3 mmol hydrolysis scale, 3.4190 g, 78% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1HNMR(500MHz,CD3CN)δ7.92(d,J=8.0Hz,1H),7.84(s,1H),7.69(s,1H),7.62(d,J=8.5Hz,1 H), 4.84 (t, J = 12.5Hz, 2H), 2.26 (t, J = 8.0Hz, 2H), 1.41-1.20 (m, 4H), 0.88 (t, J = 7.0Hz, 3H). 13 C NMR (100MHz, CD3CN) δ170.7, 165.5, 150.7, 143.2, 139.2, 126.6, 122.4, 115.8, 67.1, 66.7 (t, J = 27.5Hz), 33.7, 26.6, 23.2, 14.1. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3312,29731756,1538,1207.HRMS(ESI)calcdC 17 H 18 F5N2O8 + [M+H] + :473.0978. Found:473.0976.
[0236] S22 (8.3 mmol hydrolysis scale, 2.3683 g, 54% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.92(d,J=8.4Hz,1H),7.84(s,1H),7.69(s,1H),7.62(d,J=8.4Hz, 1H), 4.84 (t, J = 12.6Hz, 2H), 2.37-2.12 (m, 2H), 1.37-1.16 (m, 12H), 0.85 (t, J = 6.6Hz, 3H). 13 C NMR (100MHz, CD3CN) δ170.7,165.5,150.6,143.2,139.2,126.6,122.3,115. 8,67.1,66.7(t,J=27.8Hz),33.9,32.5,30.0,29.9,29.8,24.4,23.3,14.4. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.6Hz).IR(neat,cm-1 )3316,2929,1760,15411203.HRMS (ESI) calcd C 21 H 26 F5N2O8 + [M+H] + :529.1604. Measured value Found:529.1604.
[0237] S23 (3.9 mmol hydrolysis scale, 0.7891 g, 43% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ8.05-7.84(m,2H),7.69(s,1H),7.62(d,J=8.4Hz,1H),4.84(t,J=12.6H z,2H),2.21(d,J=7.2Hz,2H),0.76-0.62(m,1H),0.44(q,J=6.0Hz,2H),0.11(q,J=4.9Hz,2H). 13 C NMR (100MHz, CD3CN) δ171.0, 165.4, 150.6, 143.1, 139.3, 126.6, 122.3, 115.8, 67.0, 66.7 (t, J = 28.9Hz), 38.6, 6.5, 4.4. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3400,3116,1731,1531,1193. HRMS (ESI) calculated value calcdC 17 H 16 F5N2O8 + [M+H] + :471.0821. Measured value Found:471.0819.
[0238] S24 (10.9 mmol hydrolysis scale, 1.0992 g, 22% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1H NMR (400MHz, CD3CN) δ7.92(d,J=8.0Hz,1H),7.85(s,1H),7.71-7.61(m,2H),4.83(t,J=12.4Hz,2H),2.64-2.46(m,1H),1.09(d,J=6.8Hz,6H). 13 C NMR (100MHz, CD3CN) δ171.8, 166.7, 150.6, 143.1, 138.9, 126.6, 122.5, 115.8, 69.7, 66.7 (t, J = 27.5Hz), 34.6, 18.2. 19 FNMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3274,2977,1734,1534,1199. HRMS (ESI) calculated value calcd C 16 H 16 F5N2O8 + [M+H] + :459.0821. Found:459.0818.
[0239] S25 (19.2 mmol hydrolysis scale, 5.4429 g, 62% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 H NMR(400MHz,CD3CN)δ7.91(d,J=8.4Hz,1H),7.74(s,1H),7.68(s,1H),7.59(d,J=8.0Hz, 1H),5.79-5.68(m,1H),5.21-5.11(m,2H),4.83(t,J=12.6Hz,2H),3.05(d,J=7.6Hz,2H). 13 C NMR (100MHz, CD3CN) δ 169.5, 165.4, 150.6, 143.2, 139.3, 132.1, 126.6, 122.3, 120.8, 115.8, 67.0, 66.7 (t, J = 27.8Hz), 38.0. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3383,2951,1730,1524,1195.HRMS (ESI) calculated value calcdC 16 H14 F5N2O8 + [M+H] + :457.0665. Measured value Found:457.0664.
[0240] S26 (4.9 mmol hydrolysis scale, 1.8927 g, 73% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89(d,J=8.4Hz,1H),7.81(s,1H),7.66(s,1H),7.60(d,J=8.4Hz,1H),7.35(d,J=7.2Hz,2H),7.29(t, J=7.4Hz,2H),7.23(t,J=7.0Hz,1H),6.52(d,J=16.0Hz,1H),6.20-6.10(m,1H),4.77(t,J=12.6Hz,2H),3.21(d,J=7.2Hz,2H). 13 C NMR (100MHz, CD3CN) δ169.5,165.6,150.6,143.1,139.4,137.9,135.7,129. 6,128.7,127.2,126.6,123.5,122.4,115.8,67.3,66.7(t,J=27.8Hz),37.4. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.6Hz).IR(neat,cm -1 )3379,2979,1729,1529,1193. HRMS (ESI) calculated value calcd C 22 H 18 F5N2O8 + [M+H] + :533.0978. Measured value Found:533.0975.
[0241] S27 (19.7 mmol hydrolysis scale, 3.3933 g, 32% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1H NMR(400MHz,CD3CN)δ7.91(d,J=8.4Hz,1H),7.81(s,1H),7.67(s,1H),7.60(d ,J=8.4Hz,1H),5.69(s,1H),5.60(s,1H),4.84(t,J=12.6Hz,2H),3.57(s,2H). 13 C NMR (100MHz, CD3CN) δ168.4, 165.3, 150.6, 143.2, 139.4, 126.9, 126.6, 123.7, 122.3, 115.8, 66.8, 66.7 (t, J = 27.8Hz), 43.3. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.6Hz).IR(neat,cm -1 )3390,2992,1734,1530,1199.HRMS (ESI) calculated value calcdC 16 H 13 F5N2O8 79 Br + [M+H] + :534.9770. Measured value Found:534.9766.
[0242] S28 (7.2 mmol hydrolysis scale, 2.8503 g, 82% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.91(d,J=8.4Hz,1H),7.77(s,1H),7.67(s,1H),7.58(d,J=8.0Hz,1H), 5.05(t,J=7.4Hz,1H),4.83(t,J=12.6Hz,2H),3.02(d,J=7.6Hz,2H),1.69(s,3H),1.55(s,3H). 13 C NMR (100MHz, CD3CN) δ170.0,165.5,150.7,143.2,139.3,138.8,126.6,122.3,116.9,115.8,66.8,66.7(t,J=27.8Hz),32.7,26.0,18.1. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.6Hz).IR(neat,cm -1)3392,2978,1729,1529,1193. HRMS (ESI) calculated value calcd C 18 H 18 F5N2O8 + [M+H] + :485.0978. Found:485.0977.
[0243] S29 (17.3 mmol hydrolysis scale, 5.3877 g, 69% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 H NMR (400MHz, CD3CN) δ7.99-7.82(m,2H),7.69(s,1H),7.61(d,J=8.4Hz,1H),4.84(t,J=12.6Hz,2H),3.01(d,J=1.6Hz,2H),2.32(s,1H). 13 C NMR (100MHz, CD3CN) δ168.0, 165.4, 150.7, 143.3, 139.0, 126.7, 122.3, 115.8, 78.7, 73.4, 66.7 (t, J = 27.8Hz), 66.2, 24.3. 19 FNMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.6Hz).IR(neat,cm -1 )3391,3293,1953,1733,1521,1198. HRMS (ESI) calculated value calcd C 16 H 12 F5N2O8 + [M+H] + :455.0510. Measured value Found:455.0508.
[0244] S30 (7.4 mmol hydrolysis scale, 2.6497 g, 67% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ7.99 (s, 1H), 7.91 (d, J = 8.4Hz, 1H), 7.70 (s, 1H), 7.63 (d, J = 8.4Hz, 1H), 7.39-7.25 (m, 5H), 4.80 (t, J = 12.4Hz, 2H), 3.53 (s, 2H). 13C NMR(100MHz,CD3CN)δ168.3,165.4,150.7,143.2,139.2,132.5,129.51,129 .46,126.7,123.7,122.3,115.8,84.5,84.4,66.7(t,J=27.9Hz),66.6,25.3. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3405,2924,1739,1530,1199.HRMS (ESI) calculated value calcdC 22 H 16 F5N2O8 + [M+H] + :531.0821. Measured value Found:531.0823.
[0245] S31 (5.8 mmol hydrolysis scale, 1.9438 g, 60% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.90(d,J=8.4Hz,1H),7.79(s,1H),7.68(s,1H),7.57(d,J=8.4Hz,1H),5.12-4. 97(m,2H),4.83(t,J=12.6Hz,2H),3.03(d,J=7.6Hz,2H),2.06-1.94(m,4H),1.63(s,3H),1.55(s,6H). 13 C NMR(100MHz,CD3CN)δ170.1,165.6,150.7,143.2,142.4,139.2,132.5,126.6,124.9 ,122.2,116.9,115.8,66.8,66.7(t,J=27.8Hz),40.5,32.6,27.2,25.8,17.8,16.4. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.4Hz).IR(neat,cm -1 )3383,2951,1731,1525,1195. HRMS (ESI) calculated value calcd C 23 H 26 F5N2O8 + [M+H]+ :553.1604. Measured value Found:553.1606.
[0246] S32 (4.0 mmol hydrolysis scale, 0.7862 g, 35% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.82(s,1H),7.73(d,J=8.4Hz,1H),7.61(s,1H),7.55(d,J=8.0Hz,1H),7.32 -7.17(m,3H),7.11(d,J=7.2Hz,2H),5.55(s,1H),5.42(s,1H),4.66(t,J=12.4Hz,2H),3.34(s,2H). 13 C NMR(100MHz,CD3CN)δ168.7,164.9,150.5,143.0,139.0,132.1,129.5,129.3,127 .4,126.5,126.4,123.4,122.3,115.7,90.7,90.2,67.3,66.5(t,J=27.8Hz),39.4. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.6Hz).IR(neat,cm -1 )3396,2928,2157,1737,1530,1195. HRMS (ESI) calculated value calcdC 24 H 18 F5N2O8 + [M+H] + :557.0978. Measured value Found:557.0979.
[0247] S33 (8.3 mmol hydrolysis scale, 2.5487 g, 57% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1HNMR(400MHz,CD3CN)δ7.91(d,J=8.0Hz,1H),7.81(s,1H),7.67(s,1H),7.60(d,J=8.0Hz,1H),7.32-7.22(m,2 H),7.21-7.08(m,3H),4.83(t,J=12.6Hz,2H),2.64(t,J=6.8Hz,2H),2.27(t,J=7.8Hz,2H),1.71-1.48(m,2H). 13 C NMR (100MHz, CD3CN) δ170.4,165.5,150.6,143.1,142.7,139.1,129.4,126.9,126.6,122.4,115.8,67.0,66.7(t,J=27.8Hz),35.8,33.4,26.4. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3385,2936,1729,1531,1193. HRMS (ESI) calculated value calcd C 22 H 20 F5N2O8 + [M+H] + :535.1134. Measured value Found:535.1131.
[0248] S34 (1.2 mmol hydrolysis scale, 0.4657 g, 68% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ7.83(d,J=8.4Hz,1H),7.72(s,1H),7.52(s,1H),7.47(d,J=8.0Hz,1H),7.39(d,J=8.4Hz,1H),7.21(d,J=8.4Hz,1 H),7.12(t,J=7.6Hz,1H),7.01(t,J=7.4Hz,1H),6.92(s,1H),4.77(t,J=12.6Hz,2H),3.62(s,3H),2.81-2.74(m,2H),2.74-2.66(m,2H). 13C NMR (100MHz, CD3CN) δ170.1,165.2,150.5,143.0,138.9,138.1,128.4,127.6,126.4,122. 3,121.9,119.51,119.47,115.5,113.8,110.3,67.3,66.6(t,J=27.8Hz),33.9,32.8,20.4. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.4Hz).IR(neat,cm -1 )3405,2929,1736,1534,1199. HRMS (ESI) calculated value calcd C 24 H 21 F5N3O8 + [M+H] + :574.1243. Measured value Found:574.1246.
[0249] S35 (1.8 mmol hydrolysis scale, 0.5831 g, 55% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ8.58(s,1H),7.90-7.84(m,2H),7.71-7.66(m,1H),7.59-7.49(m,2H),7.42 (d,J=7.2Hz,1H),7.32-7.23(m,1H),4.79(t,J=12.2Hz,2H),3.49-3.33(m,2H),2.66-2.52(m,2H). 13 C NMR(100MHz,CD3CN)δ172.0,170.0,168.3,166.2,150.6,143.0,138.9,138.1,133.2,1 31.3,131.0,130.1,128.7,126.6,122.5,115.8,66.6(t,J=27.8Hz),66.2,36.2,33.4. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.0(t,J=12.4Hz).IR(neat,cm -1 )3347,2943,1714,1534,1199. HRMS (ESI) calculated value calcd C 23 H 17 F5N3O10 + [M+H] + :590.0829. Found:590.0833.
[0250] S36 (9.5 mmol hydrolysis scale, 2.9939 g, 60% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.92(d,J=8.0Hz,1H),7.79(s,1H),7.69(s,1H),7.62( d,J=8.0Hz,1H),4.84(t,J=12.6Hz,2H),2.60-2.16(m,4H),1.75-1.45(m,2H). 13 C NMR (100MHz, CD3CN) δ169.5, 165.5, 150.6, 143.2, 139.2, 126.6, 122.4, 120.8, 115.8, 66.9, 66.7 (t, J = 27.5Hz), 32.5, 21.0, 17.3. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3395,2982,2190,1738,1520,1194. HRMS (ESI) calculated value calcd C 17 H 15 F5N3O8 + [M+H] + :484.0774. Measured value Found:484.0774.
[0251] S37 (9.7 mmol hydrolysis scale, 3.8063 g, 76% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.97-7.86(m,2H),7.70(d,J=1.2Hz,1H),7.62(dd,J1=8.2,J1=1.4Hz,1H) ,4.92-4.75(m,3H),3.95-3.84(m,2H),3.83-3.71(m,2H),2.44-2.30(m,2H),1.69-1.54(m,2H). 13C NMR (100MHz, CD3CN) δ170.0,165.6,150.6,143.2,139.1,126.6,122.3,115.8,104.0,66.8,66.7(t,J=27.5Hz),65.8,28.8,28.0. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=13.2Hz).IR(neat,cm -1 )3395,2290,1739,1534,1194. HRMS (ESI) calculated value calcd C 18 H 18 F5N2O 10 + [M+H] + :517.0876. Found:517.0878.
[0252] S38 (2.0 mmol hydrolysis scale, 0.4997 g, 50% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.91(d,J=8.4Hz,1H),7.84(s,1H),7.69(s,1H),7.62(d,J=8.0Hz, 1H), 4.84 (t, J = 12.4Hz, 2H), 3.33 (t, J = 6.6Hz, 2H), 2.51-2.21 (m, 2H), 1.63-1.42 (m, 2H). 13 C NMR (100MHz, CD3CN) δ170.0, 165.5, 150.6, 143.1, 139.2, 126.6, 122.4, 115.8, 67.0, 66.7 (t, J = 27.8Hz), 51.6, 30.9, 24.2. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.6Hz).IR(neat,cm -1 )3390,2943,2098,1739,1534,1199.HRMS (ESI) calculated value calcdC 16 H 15 F5N5O8 + [M+H] + :500.0835. Found:500.0837.
[0253] S39 (0.46 mmol hydrolysis scale, 0.2571 g, 68% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 H NMR (400MHz, CD3CN) δ7.93(d,J=8.0Hz,1H),7.84(s,1H),7.70(s,1H),7.63(d,J=8.4Hz,1H),4.84(t,J=12.6Hz,2H),3.37(s,1H),3.27(s,3H),3. 22(s,3H),3.19(s,3H),3.14(s,1H),3.04-3.93(m,1H),2.36-2.08(m,2H ),2.02-1.94(m,3H),1.88-0.96(m,21H),0.91-0.82(m,6H),0.64(s,3H). 13 C NMR (100MHz, CD3CN) δ170.7,170.6,165.4,150.7,143.2,139.2,126.6,122.3,115.8,83.0,81.4,78.2,67.1,66.7(t,J=27.8Hz),56.2, 56.0,55.5,47.7,46.9,43.5,42.7,40.4,36.4,36.1,35.8,35.6,35.5,34.3,28.6,28.5,28.2,27.7,23.9,23.2,22.7,21.1,18.2,12.8. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3395,2934,1739,1530,1199.HRMS (ESI) calculated value calcdC 40 H 56 F5N2O 11 + [M+H] + :835.3799. Measured value Found:835.3795.
[0254] S40 (1.7 mmol hydrolysis scale, 0.7305 g, 57% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1HNMR(400MHz,DMSO-d6)δ8.40(s,1H),8.01(d,J=8.0Hz,1H),7.86(s,1H),7.66(d,J= 8.0Hz,1H),7.10(d,J=8.0Hz,1H),6.61(d,J=7.2Hz,1H),6.54(s,1H),5.20(t,J=12. 8Hz,2H),3.87-3.84(m,2H),2.75(s,2H),2.46-2.38(m,1H),2.36-2.22(m,3H),2.16 -2.02(m,2H),1.98-1.86(m,2H),1.78-1.62(m,3H),1.56-1.26(m,8H),0.81(s,3H). 13 C NMR(100MHz,DMSO-d6)δ219.7,169.3,163.4,156.5,148.9,141.4,138.4,137.4,131.7,126.2,125.2,121.7,115.0,114.3 ,112.1,67.0,66.7,65.1(t,J=28.3Hz),49.6,47.4,43.4,37.9,35.4,32.0,31.4,29.1,28.7,26.1,25.5,21.2,20.3,13.5. 19 F NMR(376MHz, DMSO-d6)δ-82.5(s),-122.4(t,J=12.6Hz).IR(neat,cm -1 )3400,2939,1743,1539,1199. HRMS (ESI) calculated value calcd C 35 H 38 F5N2O 10 + [M+H] + :741.2441. Measured value Found:741.2444.
[0255] S41 (6.0 mmol hydrolysis scale, 2.6009 g, 73% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1HNMR(400MHz,CD3CN)δ8.01(s,1H),7.86(d,J=8.0Hz,1H),7.65(s,1H),7.55(d,J=8.0Hz,1H),7.20(d,J=7.2Hz,2H),6.83( d,J=7.2Hz,2H),4.80(t,J=12.2Hz,2H),4.37(s,2H),3.74(s,3H),3.53-3.42(m,2H),3.45-3.23(m,2H),1.70-1.50(m,2H). 13 C NMR(100MHz,CD3CN)δ170.5,165.7,160.2,150.6,143.1,139.2,131.5,130.4,12 6.6,122.3,115.8,114.6,73.1,70.1,66.9,66.7(t,J=27.9Hz),55.8,31.3,24.8. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3395,2934,1743,1515,1194. HRMS (ESI) calculated value calcd C 24 H 24 F5N2O 10 + [M+H] + :595.1346. Measured value Found:595.1349.
[0256] S45 (6.1 mmol hydrolysis scale, 1.9894 g, 64% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.88(d,J=8.0Hz,1H),7.62(d,J=1.2Hz,1H),7.52(s,1H),7.45(dd,J1= 8.2, J2=1.4Hz,1H),7.30-7.22(m,3H),7.15-7.04(m,2H),4.81(t,J=12.6Hz,2H),3.65(s,2H). 13C NMR (100MHz, CD3CN) δ169.2,165.6,150.6,143.1,139.4,135.9,131.0,129.4,128.4,126.7,122.1,115.8,68.1,66.7(t,J=27.8Hz),38.6. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.4Hz).IR(neat,cm -1 )3382,2983,1729,1525,1195. HRMS (ESI) calculated value calcd C 20 H 16 F5N2O8 + [M+H] + :507.0821. Found:507.0819.
[0257] S46 (5.0 mmol hydrolysis scale, 1.9277 g, 75% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89(d,J=8.4Hz,1H),7.62(s,1H),7.52-7.45(m,2H) ,7.14-7.07(m,2H),7.04-6.96(m,2H),4.81(t,J=12.6Hz,2H),3.64(s,2H). 13 C NMR(100MHz,CD3CN)δ169.0,165.5,163.2(d,J=241.9Hz),150.6,143.2,139.4,132.8(d,J=8.0Hz ), 132.0 (d, J = 2.9Hz), 126.6, 122.2, 116.2, 115.9 (d, J = 19.5Hz), 68.1, 66.7 (t, J = 27.5Hz), 37.7. 19 FNMR(376MHz,CD3CN)δ-84.2(s),-117.0--117.1(m),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3387,2953,1730,1510,1193. HRMS (ESI) calculated value calcd C 20 H 15 F6N2O8 + [M+H] +:525.0727. Measured value Found:525.0726.
[0258] S47 (4.8 mmol hydrolysis scale, 1.7392 g, 67% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89(d,J=8.4Hz,1H),7.61(s,1H),7.52-7.43(m,2H),7. 27(d,J=8.4Hz,2H),7.07(d,J=8.4Hz,2H),4.81(t,J=12.6Hz,2H),3.64(s,2H). 13 C NMR (100MHz, CD3CN) δ168.8,165.5,150.6,143.2,139.4,134.9,133.8,132.7,129.4,126.6,122.3,115.8,68.0,66.7(t,J=27.8Hz),37.8. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3389,2926,1729,1526,1193.HRMS (ESI) calculated value calcdC 20 H 15 F5N2O8 35 Cl + [M+H] + :541.0432. Measured value Found:541.0437.
[0259] S48 (5.6 mmol hydrolysis scale, 2.0157 g, 62% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.88(d,J=8.4Hz,1H),7.61(s,1H),7.52-7.45(m,2H),7. 41(d,J=8.0Hz,2H),7.01(d,J=8.0Hz,2H),4.81(t,J=12.6Hz,2H),3.62(s,2H). 13C NMR (100MHz, CD3CN) δ168.8,165.5,150.6,143.2,139.3,135.4,133.0,132.4,126.6,122.3,121.9,115.8,67.9,66.7(t,J=27.8Hz),37.9. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.1(t,J=13.2Hz).IR(neat,cm -1 )3386,2927,1730,1526,1194.HRMS (ESI) calculated value calcdC 20 H 15 F5N2O8 79 Br + [M+H] + :584.9926. Measured value Found:584.9923.
[0260] S49 (4.2 mmol hydrolysis scale, 1.4281 g, 64% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89(d,J=8.4Hz,1H),7.62(s,1H),7.52-7.40(m,2H),7.01(d, J=8.0Hz,2H),6.81(d,J=8.0Hz,2H),4.81(t,J=12.6Hz,2H),3.74(s,3H),3.57(s,2H). 13 CNMR(100MHz,CD3CN)δ169.3,165.4,160.1,150.6,143.1,139.5,132.1,127.6,126.7,122.2,115.8,114.7,68.1,66.7(t,J=27.8Hz),55.8,37.9. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=11.8Hz).IR(neat,cm -1 )3366,2964,1733,1511,1202. HRMS (ESI) calculated value calcd C 21 H 18 F5N2O9 + [M+H] + :537.0927. Measured value Found:537.0928.
[0261] S50 (5.2 mmol hydrolysis scale, 2.1458 g, 67% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.88(d,J=8.4Hz,1H),7.64(s,1H),7.56-7.26(m,7H),7.02(d, J=8.0Hz,2H),6.88(d,J=8.0Hz,2H),5.03(s,2H),4.82(t,J=12.4Hz,2H),3.59(s,2H). 13 CNMR(100MHz,CD3CN)δ169.3,165.4,159.2,150.6,143.1,139.5,138.3,132.1,129.5, 128.9,128.7,128.0,126.7,122.1,115.8,115.7,70.6,68.1,66.7(t,J=27.8Hz),37.8. 19 FNMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.4Hz).IR(neat,cm -1 )3390,2939,1739,1515,1199. HRMS (ESI) calculated value calcd C 27 H 22 F5N2O9 + [M+H] + :613.1240. Measured value Found:613.1241.
[0262] S51 (6.5 mmol hydrolysis scale, 2.0763 g, 56% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3OD)δ8.05(s,1H),7.90(d,J=8.4Hz,1H),7.63(s,1H),7.49(d,J=7.6Hz,1H), 7.40(d,J=7.6Hz,2H),7.03(d,J=7.2Hz,2H),4.86(t,J=12.0Hz,2H),3.69(s,2H),2.08(s,3H). 13C NMR (100MHz, CD3OD) δ171.6,170.4,166.6,151.0,143.5,140.1,139.0,132. 5,131.4,126.7,122.3,121.1,115.8,69.1,66.8(t,J=27.5Hz),38.1,23.7. 19 F NMR(376MHz,CD3OD)δ-84.8(s),-124.7(t,J=12.4Hz).IR(neat,cm -1 )3313,2929,1763,1515,1209. HRMS (ESI) calculated value calcd C 22 H 19 F5N3O9 + [M+H] + :564.1036. Measured value Found:564.1034.
[0263] S52 (4.3 mmol hydrolysis scale, 1.3536 g, 57% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ8.09(d,J=8.4Hz,2H),7.88(d,J=8.4Hz,1H),7.60(s,1H) ,7.52-7.43(m,2H),7.31(d,J=8.0Hz,2H),4.81(t,J=12.4Hz,2H),3.79(s,2H). 13 C NMR (100MHz, CD3CN) δ168.5,165.6,150.6,148.5,144.1,143.2,139.3,132.2,126.6,124.4,122.3,115.8,67.9,66.7(t,J=27.8Hz),38.2. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=13.2Hz).IR(neat,cm -1 )3356,2977,1749,1521,1349,1199. HRMS (ESI) calculated value calcdC 20 H 15 F5N3O 10 + [M+H] + :552.0672. Measured value Found:552.0675.
[0264] S53 (4.0 mmol hydrolysis scale, 0.7493 g, 32% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.88(d,J=8.4Hz,1H),7.80(d,J=7.6Hz,2H),7.62(s,1H),7.53 -7.44(m,2H),7.33(d,J=7.6Hz,2H),4.82(t,J=12.4Hz,2H),3.77(s,2H),3.03(s,3H). 13 CNMR(100MHz,CD3CN)δ168.7,165.5,150.6,143.2,142.6,141.0,139.3,132.0,128.2,126.6,122.3,115.8,68.0,66.7(t,J=27.8Hz),44.5,38.3. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=13.2Hz).IR(neat,cm -1 )3390,2934,1734,1539,1204. HRMS (ESI) calculated value calcd C 21 H 18 F5N2O 10 S + [M+H] + :585.0597. Measured value Found:585.0596.
[0265] S54 (4.7 mmol hydrolysis scale, 1.5121 g, 56% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ7.89(d,J=8.4Hz,1H),7.63-7.55(m,3H),7.51-7.46(m,2H),7.28(d,J=8.0Hz,2H),4.81(t,J=12.6Hz,2H),3.74(s,2H). 13C NMR(100MHz,CD3CN)δ168.7,165.6,150.6,143.2,140.8,139.3,131.8,129.9(q,J=32.0Hz),1 26.6,126.2(q,J=3.8Hz),125.5(q,J=269.6Hz),122.3,115.8,68.0,66.7(t,J=27.8Hz),38.2. 19 F NMR(376MHz,CD3CN)δ-63.0(s),-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3389,2957,1730,1530,1195. HRMS (ESI) calculated value calcd C 21 H 15 F8N2O8 + [M+H] + :575.0695. Measured value Found:575.0697.
[0266] S55 (6.6 mmol hydrolysis scale, 1.7377 g, 48% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ7.92-7.80(m,3H),7.62(s,1H),7.53-7.42(m,2H),7.21(d,J=8.0Hz,2H),4.81(t,J=12.6Hz,2H),3.73(s,2H),2.52(s,3H). 13 C NMR (100MHz, CD3CN) δ198.9,168.8,165.6,150.6,143.2,141.6,139.4,137. 3,131.3,129.3,126.6,122.2,115.8,67.9,66.7(t,J=27.8Hz),38.4,27.0. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.6Hz).IR(neat,cm -1 )3395,2934,1739,1534,1194. HRMS (ESI) calculated value calcd C 22 H 18 F5N2O9 + [M+H] +:549.0927. Measured value Found:549.0928.
[0267] S56 (4.0 mmol hydrolysis scale, 1.4263 g, 61% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3OD)δ7.90(d,J=8.0Hz,1H),7.68(s,1H),7.60-7.43(m,5H),7.43-7.3 3(m,2H),7.33-7.24(m,1H),7.18(d,J=7.2Hz,2H),4.85(t,J=12.2Hz,2H),3.78(s,2H). 13 CNMR(100MHz,CD3OD)δ170.4,166.6,151.0,143.6,141.8,141.4,140.1,136.0,131. 6,129.8,128.3,127.9,127.8,126.8,122.3,115.8,69.1,66.8(t,J=28.6Hz),38.3. 19 F NMR(376MHz,CD3OD)δ-84.8(s),-124.6(t,J=11.8Hz).IR(neat,cm -1 )3385,3074,1760,1510,1193. HRMS (ESI) calculated value calcd C 26 H 20 F5N2O8 + [M+H] + :583.1134. Measured value Found:583.1138.
[0268] S57 (6.0 mmol hydrolysis scale, 2.0061 g, 61% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89(d,J=8.0Hz,1H),7.61(s,1H),7.52-7.42(m,2H),7. 10(d,J=7.6Hz,2H), 6.96(d,J=7.6Hz,2H), 4.81(t,J=12.2Hz,2H), 3.63(s,2H). 13C NMR (100MHz, CD3CN) δ169.0,165.5,150.6,143.2,140.3,139.4,132.7,132.5,126.6,122.2,120.0,115.8,68.0,66.7(t,J=27.8Hz),37.9. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3381,2929,2117,1734,1510,1209. HRMS (ESI) calculated value calcdC 20 H 15 F5N5O8 + [M+H] + :548.0835. Measured value Found:548.0832.
[0269] S58 (4.0 mmol hydrolysis scale, 1.3662 g, 56% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ7.87(d,J=8.0Hz,1H),7.77-7.59(m,6H),7.57-7.43(m,4H),7.24(d,J=6.8Hz,2H),4.80(t,J=12.0Hz,2H),3.77(s,2H). 13 C NMR(100MHz,CD3CN)δ197.1,168.8,165.6,150.6,143.2,141.1,139.4,138.5,137.6,1 33.5,131.1,130.9,130.7,129.4,126.6,122.3,115.8,68.0,66.7(t,J=27.8Hz),38.4. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.6Hz).IR(neat,cm -1 )3400,3056,1735,1528,1195. HRMS (ESI) calculated value calcd C 27 H 20 F5N2O9 + [M+H] + :611.1083. Measured value Found:611.1084.
[0270] S59 (4.7 mmol hydrolysis scale, 1.0209 g, 41% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ7.88(d,J=8.4Hz,1H),7.68-7.56(m,3H),7.51-7.42(m,2H),7.25(d,J=8.0Hz,2H),4.81(t,J=12.6Hz,2H),3.73(s,2H). 13 C NMR (100MHz, CD3CN) δ168.6,165.5,150.6,143.2,141.9,139.3,133.2,132.0,126.6,122.3,119.6,115.8,112.0,67.9,66.7(t,J=27.5Hz),38.5. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3380,2959,1730,1531,1199. HRMS (ESI) calculated value calcd C 21 H 15 F5N3O8 + [M+H] + :532.0774. Measured value Found:532.0773.
[0271] S60 (8.3 mmol hydrolysis scale, 2.8275 g, 65% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.88(d,J=8.4Hz,1H),7.61(s,1H),7.56-7.43(m,2H),7.37(d, J=7.6Hz,2H),7.08(d,J=8.0Hz,2H),4.81(t,J=12.6Hz,2H),3.66(s,2H),3.37(s,1H). 13CNMR(100MHz,CD3CN)δ168.9,165.5,150.6,143.2,139.4,137.2,132.9,131 .3,126.6,122.2,122.0,115.7,83.8,79.2,68.0,66.7(t,J=27.8Hz),38.3. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.1(t,J=12.6Hz).IR(neat,cm -1 )3298,2939,1743,1534,1199. HRMS (ESI) calculated value calcd C 22 H 16 F5N2O8 + [M+H] + :531.0821. Measured value Found:531.0824.
[0272] S61 (5.1 mmol hydrolysis scale, 1.5484 g, 46% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.88(d,J=7.6Hz,1H),7.78-7.62(m,7H),7.62-7.54(m,3H),7.52-7 .42(m,3H),7.41-7.33(m,1H),7.19(d,J=6.4Hz,2H),4.80(t,J=12.2Hz,2H),3.72(s,2H). 13 C NMR(100MHz,CD3CN)δ169.1,165.5,150.6,143.2,141.2,140.9,140.23,140.20,139.5,135.3,131 .7,129.9,128.5,128.4,128.2,127.8,127.7,126.7,122.2,115.8,68.1,66.7(t,J=27.8Hz),38.3. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.6Hz).IR(neat,cm -1 )3385,2924,1739,1530,1204. HRMS (ESI) calculated value calcd C 32 H 24 F5N2O8 + [M+H]+ :659.1447. Measured value Found:659.1443.
[0273] S62 (5.0 mmol hydrolysis scale, 1.6554 g, 61% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89(d,J=8.0Hz,1H),7.62(s,1H),7.55-7.43(m,2H),7.19-7 .11(m,1H),6.99(t,J=8.6Hz,1H),6.89(s,1H),4.81(t,J=12.2Hz,2H),3.63(s,2H). 13 C NMR (100MHz, CD3CN) δ168.7, 165.5, 150.7 (ddd, J1=244.1, J2=19.9, J3=12.6Hz), 150.6, 143.2, 139.3, 133.6 (dd, J1=5.5, J2=4 .0Hz), 127.7 (dd, J1=6.2, J2=3.3Hz), 126.6, 122.3, 119.0 (dd, J1=156.0, J2=16.6Hz), 115.8, 68.0, 66.7 (t, J=27.8Hz), 37.7. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.6Hz),-140.1--140.3(m),-142.0--142.2(m).IR(neat,cm -1 )3381,2987,1743,152251204.HRMS(ESI)calcd C 20 H 14 F7N2O8 + [M+H] + :543.0633. Measured value Found:543.0634.
[0274] S63 (4.8 mmol hydrolysis scale, 0.9836 g, 33% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1HNMR(400MHz,CD3CN)δ7.92-7.80(m,2H),7.66(s,1H),7.56(s,1H),7.52(d,J=8.4Hz,1H),7.29(t ,J=7.4Hz,1H),7.23(d,J=7.2Hz,1H),6.96(t,J=7.4Hz,1H),4.81(t,J=12.6Hz,2H),3.83(s,2H). 13 C NMR (100MHz, CD3CN) δ169.0,165.5,150.6,143.1,141.2,139.5,139.4,132. 0,130.2,129.4,126.5,122.4,116.0,102.5,67.6,66.7(t,J=27.8Hz),42.5. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3394,2926,1729,1525,1193. HRMS (ESI) calculated value calcd C 20 H 15 F5N2O8I + [M+H] + :632.9788. Measured value Found:632.9789.
[0275] S64 (4.7 mmol hydrolysis scale, 1.5007 g, 57% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89-7.82(m,2H),7.80-7.72(m,2H),7.59(d,J=13.2Hz,2 H),7.53-7.41(m,4H),7.23(d,J=8.0Hz,1H),4.72(t,J=12.2Hz,2H),3.83(s,2H). 13 C NMR(100MHz,CD3CN)δ169.0,165.6,150.6,143.1,139.5,134.3,133.7,133.6,129.9,129.1 ,128.9,128.53,128.48,127.3,127.0,126.6,122.3,115.7,68.2,66.6(t,J=27.8Hz),38.7. 19FNMR(376MHz,CD3CN)δ-84.1(s),-124.0(t,J=12.6Hz).IR(neat,cm -1 )3411,3061,1729,1512,1193. HRMS (ESI) calculated value calcd C 24 H 18 F5N2O8 + [M+H] + :557.0978. Measured value Found:557.0980.
[0276] S65 (4.3 mmol hydrolysis scale, 0.8075 g, 34% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ8.82(d,J=8.4Hz,1H),7.88-7.75(m,3H),7.43-7.30(m,6H),7.25(d,J=8.0Hz,1H),4.68(t,J=12.6Hz,2H),4.17(s,2H). 13 C NMR (100MHz, CD3CN) δ169.2,166.0,150.4,143.0,139.4,134.8,134.0,132.5,129.6,129. 5,129.1,127.1,126.6,126.5,126.3,124.8,122.2,115.6,68.3,66.6(t,J=27.5Hz),34.7. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3385,2945,1738,1526,1197. HRMS (ESI) calculated value calcd C 24 H 18 F5N2O8 + [M+H] + :557.0978. Measured value Found:557.0979.
[0277] S66 (5.1 mmol hydrolysis scale, 1.8568 g, 71% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1HNMR(400MHz,CD3CN)δ7.89(d,J=8.0Hz,1H),7.62(s,1H),7.56(s,1H),7.48(d,J=8.4Hz, 1H),7.31(s,1H),7.08(s,1H),7.85(d,J=4.8Hz,1H),4.82(t,J=12.4Hz,2H),3.70(s,2H). 13 C NMR (100MHz, CD3CN) δ169.1,165.5,150.6,143.2,139.4,135.9,130.0,126.9,126.7,125.2,122.2,115.8,67.8,66.7(t,J=27.8Hz),33.3. 19 F NMR(376MHz,CD3CN)δ-84.1(s),-124.1(t,J=12.6Hz).IR(neat,cm -1 )3385,3062,1730,1527,1193. HRMS (ESI) calculated value calcd C 18 H 14 F5N2O8S + [M+H] + :513.0386. Measured value Found:513.0387.
[0278] S67 (6.8 mmol hydrolysis scale, 2.2831 g, 68% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.89(d,J=8.0Hz,1H),7.68-7.57(m,2H),7.47(d,J=8.4Hz,1H) ,7.37(s,1H),6.31(s,1H),6.13(d,J=2.0Hz,1H),4.82(t,J=12.6Hz,2H),3.73(s,2H). 13 CNMR(100MHz,CD3CN)δ168.8,165.5,150.65,150.60,143.7,143.1,139.5,126.7,122.2,115.7,111.5,109.9,66.9,66.7(t,J=27.5Hz),31.9. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1)3392,3075,1731,1530,1194.HRMS (ESI) calculated value calcdC 18 H 14 F5N2O9 + [M+H] + :497.0614. Measured value Found:497.0617.
[0279] 1 H NMR (400MHz, DMSO-d6) δ8.55(s,1H),8.03(d,J=8.0Hz,1H),7.87(s,1H),7.66(d,J=8.0Hz,1H),5.19(t,J=12.6Hz,2H),1.69(s,3H). 13 C NMR (100MHz, DMSO-d6) δ170.0 (d, J = 57.8Hz), 163.7, 149.0, 141.4, 138.6, 125.3, 121.7, 115.0, 65.1 (t, J = 27.8Hz), 63.2, 21.0 (d, J = 36.9Hz). 19 F NMR(376MHz, DMSO-d6)δ-82.6(s),-122.5(t,J=13.2Hz).IR(neat,cm -1 )3385,2977,1743,1534,1199. HRMS (ESI) calculated value calcd C 13 13 CH 12 F5N2O8 + [M+H] + :432.0542. Measured value Found:432.0546.
[0280] 15 N-68 (1.6 mmol hydrolysis scale, 0.6461 g, 91% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 H NMR (400MHz, CD3CN) δ7.92(d,J=8.4Hz,1H),7.91(d,J=93.2Hz,1H),7.70(s,1H),7.61(d,J=8.4Hz,1H),4.83(t,J=12.4Hz,2H),1.79(s,3H). 13C NMR(100MHz,CD3CN)δ171.0,165.8(d,J=15.9Hz),150.6,143.1,139.1(d,J= 8.6Hz), 126.6, 122.3, 115.8, 66.7 (t, J = 27.8Hz), 63.5 (d, J = 12.3Hz), 21.7. 19 F NMR (376MHz, CD3CN) δ-84.2 (s), -124.1 (t, J = 12.4Hz). 15 N NMR(40MHz,CD3CN)δ121.9.IR(neat,cm -1 )3390,2943,1739,1539,1194. HRMS (ESI) calculated value calcd C 14 H 12 F5N 15 NO8 + [M+H] + :432.0479. Found:432.0477.
[0281] S71 (4.0 mmol hydrolysis scale, 1.5972 g, 92% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (400MHz, CD3CN) δ8.01-7.84(m,2H),7.70(s,1H),7.61(d,J=8.4Hz,1H),4.83(t,J=12.6Hz,2H). 13 C NMR (150MHz, CD3CN) δ171.0,165.8,150.6,143.1,139.1,126.6,122.3,119.6 (qt, J1=283.9Hz, J2=34 .6Hz), 115.8, 113.6 (tq, J1=253.1Hz, J2=37.8Hz), 66.7 (t, J=27.5Hz), 63.4, 20.9 (hept, J=19.7Hz). 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.4Hz).IR(neat,cm -1 )3395,2987,1734,1530,1194.HRMS (ESI) calculated value calcdC 14 H9D3F5N2O8 + [M+H] +:434.0697. Measured value Found:434.0693.
[0282] S73 (10.0 mmol hydrolysis scale, 2.5373 g, 68% yield, 4 steps) white solid. f =0.7 (DCM / MeOH 5:1). 1 H NMR (400MHz, CDCl3) δ8.16(d,J=7.2Hz,2H),7.78(d,J=8.0Hz,1H),7.58-7.48(m,1H),7.47-7.34(m,2H),6.41(d,J=8.0Hz,1H),6.37-6.26 (m,1H),5,26(s,1H),4.92(s,2H),4.09-3.94(m,1H),3.92-3.77(m,1H),3.57-3.38(m,2H),3.13(dd,J1=12.0,J2=3.6Hz,1H),2.28(s,1H). 13 C NMR (100MHz, CDCl3) δ177.4,153.9,149.3,136.4,135.4,132.7,129.8,128.2,98.0,87.1,86.6,78.0,71.0,63.1,37.6,32.2.IR(neat,cm -1 )3417,3289,2927,2248,1646,1555,1250,1263. HRMS (ESI) calculated value calcd C 18 H 18 N3O4S + [M+H] + :372.1013. Measured value Found:372.1009.
[0283] 76 (9.3 mmol hydrolysis scale, 2.9922 g, 94% yield) was prepared according to the general procedure by using isopropyl alcohol instead of 2,2,3,3,3-pentafluoropropan-1-ol as a white solid. f =0.1 (DCM / MeOH 5:1). 1H NMR(400MHz,CD3CN)δ9.38(br,2H),7.98(s,1H),7.73(d,J=8.4Hz,1H),7.58(s,1 H),7.40(d,J=8.4Hz,1H),4.90-4.71(m,1H),1.77(s,3H),1.28(d,J=6.0Hz,6H). 13 C NMR(100MHz,CD3CN)δ171.2,167.0,151.5,144.1,138.4,126.0,120.0,116.4,74.0,63.6,22.0,21.6.IR(neat,cm -1 )3395,2977,1734,1525,1253. HRMS (ESI) calculated value calcd C 14 H 17 N2O8 + [M+H] + :341.0979. Found:341.0981.
[0284] (±)-80 (3.0 mmol hydrolysis scale, 0.3556 g, 26% yield) white solid. f =0.3 (DCM / MeOH 5:1). 1 H NMR (400MHz, DMSO-d6) δ8.71(s,1H),8.03(d,J=8.4Hz,1H),7.86(s,1H),7.66(d,J=8.4H z,1H),5.19(t,J=12.8Hz,2H),4.15(q,J=7.1Hz,2H),1.70(s,3H),1.16(t,J=7.0Hz,3H). 13 C NMR (100MHz, DMSO-d6) δ169.7,168.2,163.9,148.9,141.4,138.4,125.2,121.7,115.0,65.1(t,J=27.8Hz),63.3,61.5,21.1,13.9. 19 F NMR(376MHz,DMSO-d6)δ-82.6(s),-122.5(t,J=12.4Hz).IR(neat,cm -1 )3400,2924,1739,1539,1194. HRMS (ESI) calculated value calcd C 16 H 16 F5N2O8 + [M+H]+ :459.0821. Found:459.0824.
[0285] 83 (8.5 mmol hydrolysis scale, 1.4693 g, 89% yield) was prepared according to the reported procedure as a white solid. f =0.1 (DCM / MeOH 5:1). 1 H NMR (400MHz, CD3OD) δ7.43 (d, J = 8.0Hz, 2H), 7.37-7.23 (m, 3H), 5.08 (br, 2H), 1.83 (s, 3H). 13 C NMR (100MHz, CD3OD) δ175.3,140.4,129.0,128.6,128.4,59.9,23.0.
[0286] 84 (2.0 mmol hydrolysis scale, 0.2127 g, 24% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR (500MHz, DMSO-d6) δ8.02(d,J=8.0Hz,1H),7.49(s,1H),7.23(d,J=8.0Hz,1H),5.17(t,J=13.0Hz,2H),2.88(s,3H),1.71(s,3H). 13 C NMR (125MHz, DMSO-d6) δ170.0,169.1,149.3,141.7,140.2,125.6,120.9,114.3,68.0,65.0(t,J=27.6Hz),35.1,20.4. 19 F NMR(376MHz, DMSO-d6)δ-82.6(s),-122.5(t,J=13.2Hz).IR(neat,cm -1 )2929,1748,1593,1530,1199. HRMS (ESI) calculated value calcd C 15 H 14 F5N2O8 + [M+H] + :445.0665. Measured value Found:445.0664.
[0287] 85 (3.6 mmol hydrolysis scale, 1.2227 g, 74% yield) white solid. f =0.1 (DCM / MeOH 5:1). 1 HNMR(400MHz,CD3CN)δ7.93(d,J=8.0Hz,1H),7.41(s,1H),7.33(d,J=8.4Hz,1H),4.8 0(t,J=12.6Hz,2H),3.67(t,J=6.6Hz,2H),2.50(t,J=6.8Hz,2H),2.09-1.99(m,2H). 13 C NMR (100MHz, CD3CN) δ171.7, 169.7, 150.7, 142.2, 141.2, 126.9, 121.9, 115.2, 72.5, 66.7 (t, J = 27.5Hz), 52.2, 36.9, 25.6. 19 F NMR(376MHz,CD3CN)δ-84.2(s),-124.1(t,J=12.6Hz).IR(neat,cm -1 )3463,2977,1753,1530,1442,1194. HRMS (ESI) calculated value calcd C 16 H 14 F5N2O8 + [M+H] + :457.0665. Measured value Found:457.0664.
[0288] Product characterization
[0289] (+)-17 was obtained by asymmetric decarboxylation of malonic acid S17 (86.1 mg, 0.2 mmol) according to the general procedure for 10 h to give a white solid (71.9 mg, 90% yield). f =0.3 (hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=8.59min,t r (major) = 11.56 min) gave the isomeric composition of the product: 94% ee, []17D = +21.7 (c = 1.05, CHCl3). 1H NMR (400MHz, CDCl3) δ7.93(d,J=8.4Hz,1H),7.64(d,J=1.6Hz,1H),7.49(dd,J1=8.4,J2=1.6Hz,1H) ,6.84(d,J=7.2Hz,1H),4.86-4.71(m,1H),4.61(t,J=11.8,2H),3.83(s,3H),1.56(d,J=7.2Hz,3H). 13 C NMR (150MHz, CDCl3) δ173.8,164.2,149.9,141.9,138.6,125.7,120.5,118.3(qt,J1=284.3Hz, J2=34.3Hz), 114.4, 111.8 (tq, J1=254.6Hz, J2=37.8Hz), 65.9 (t, J=28.7Hz), 52.7, 48.8, 17.7. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3373,2964,1711,1529,1193. HRMS (ESI) calculated value calcd C 14 H 14 F5N2O6 + [M+H] + :401.0767. Measured value Found:401.0768.
[0290] (-)-17 was obtained by asymmetric decarboxylation of malonic acid S17 (86.2 mg, 0.2 mmol) using (S)-CPA-8 as catalyst according to the general procedure for 10 hours to obtain a white solid (73.1 mg, 91% yield). f =0.3 (hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (major)=8.54min,t r (minor) = 11.80min) gives the isomer composition of the product: 93% ee, 1H NMR (400MHz, CDCl3) δ7.81(d,J=8.4Hz,1H),7.57(s,1H),7.47(d,J=8.4Hz,1H),7.32(d,J= 6.8Hz,1H),4.85-4.72(m,1H),4.59(t,J=12.0Hz,2H),3.83(s,3H),1.54(d,J=7.6Hz,3H). 13 C NMR (100MHz, CDCl3) δ174.0, 164.1, 150.0, 142.0, 138.6, 125.7, 120.5, 114.5, 66.0 (t, J = 28.2Hz), 52.8, 48.8, 17.9. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.3(t,J=11.8Hz).IR(neat,cm -1 )3332,2968,1739,1530,1199. HRMS (ESI) calculated value calcd C 14 H 14 F5N2O6 + [M+H] + :401.0767. Measured value Found:401.0766.
[0291] HPLC analysis of the above-derivatized (+)-18 (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=7.17min,t r (major) = 8.01min) gives the isomer composition of the product: 97% ee, (Amino acid hydrochloride (+)-18, c = 1.00, MeOH). 1 H NMR (400MHz, DMSO-d6) δ8.38 (br, 2H), 3.92 (q, J = 7.1Hz, 1H), 1.40 (d, J = 7.2Hz, 3H). 13 C NMR(100MHz,DMSO-d6)δ171.6,47.8,15.8.IR(neat,cm -1 )3356,2929,1734,1623,1121. HRMS (ESI) calculated for C3H8NO2 + [M+H] +:90.0550. Measured value Found:90.0551.
[0292] (+)-19 was obtained from malonic acid S19 (88.9 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 10 hours to obtain a white solid (71.7 mg, 86% yield). f =0.3 (hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=8.02min,t r (major) = 11.44min) gives the isomer composition of the product: 93% ee, 1 H NMR (400MHz, CDCl3) δ7.89 (d, J = 8.4Hz, 1H), 7.62 (s, 1H), 7.49 (d, J = 8.4, 1H), 6.96 (d, J = 7.2Hz, 1H), 4.83-4. 71(m,1H),4.61(t,J=11.8Hz,2H),3.82(s,3H),2.12-1.97(m,1H),1.93-1.78(m,1H),0.99(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ173.2, 164.4, 150.1, 142.0, 138.8, 125.8, 120.4, 114.7, 66.1 (t, J = 28.6Hz), 54.1, 52.7, 25.3, 9.7. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.2(t,J=11.7Hz).IR(neat,cm -1 )3312,2974,1737,1531,1199. HRMS (ESI) calculated value calcd C 15 H 16 F5N2O6 + [M+H] + :415.0923. Measured value Found:415.0926.
[0293] (+)-20 was obtained by asymmetric decarboxylation of malonic acid S20 (91.8 mg, 0.2 mmol) according to the general procedure for 8 hours to obtain a white solid (72.5 mg, 85% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=7.47min,t r (major) = 11.24min) gives the isomer composition of the product: 93% ee, 1 HNMR (400MHz, CDCl3) δ7.88(d,J=8.4Hz,1H),7.61(s,1H),7.48(d,J=8.4,1H),6.94(d,J=7.6Hz,1H),4.87-4.74(m,1H ),4.60(t,J=11.8Hz,2H),3.82(s,3H),2.03-1.87(m,1H),1.85-1.71(m,1H),1.51-1.33(m,2H),0.97(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ173.4, 164.3, 150.2, 142.1, 138.8, 125.9, 120.4, 114.8, 66.2 (t, J = 28.5Hz), 52.8, 52.7, 34.3, 18.7, 13.6. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3303,2968,1748,1539,1194. HRMS (ESI) calculated value calcd C 16 H 18 F5N2O6 + [M+H] + :429.1080. Found:429.1079.
[0294] (+)-21 was obtained as a colorless oil (72.8 mg, 82% yield) by asymmetric decarboxylation of malonic acid S21 (94.6 mg, 0.2 mmol) according to the general procedure for 8 hours. f=0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=7.56min,t r (major) = 10.98 min) gives the isomer composition of the product: 91% ee, 1 HNMR (400MHz, CDCl3) δ7.90(d,J=8.4Hz,1H),7.64(s,1H),7.49(d,J=8.4,1H),6.90(d,J=7.2Hz,1H),4.84-4.75(m,1H ),4.61(t,J=11.8Hz,2H),3.81(s,3H),2.04-1.91(m,1H),1.87-1.74(m,1H),1.45-1.27(m,4H),0.91(t,J=6.6Hz,3H). 13 C NMR (100MHz, CDCl3) δ173.1, 164.3, 150.3, 142.2, 139.1, 126.0, 120.3, 115.1, 66.3 (t, J = 28.6Hz), 53.0, 52.7, 32.1, 27.4, 22.2, 13.8. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3393,2959,1742,1532,1195. HRMS (ESI) calculated value calcdC 17 H 20 F5N2O6 + [M+H] + :443.1236. Measured value Found:443.1234.
[0295] (+)-22 was obtained as a colorless oil (120.3 mg, 80% yield) by asymmetric decarboxylation of malonic acid S22 (158.5 mg, 0.3 mmol) according to the general procedure for 8 hours. f =0.6 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r(minor)=7.10min,t r (major) = 8.92min) gives the isomer composition of the product: 92% ee, 1 HNMR (400MHz, CDCl3) δ7.92(d,J=8.4Hz,1H),7.64(s,1H),7.49(d,J=8.4Hz,1H),6.83(d,J=8.0Hz,1H),4.85-4.75(m,1H ),4.61(t,J=11.8Hz,2H),3.81(s,3H),2.03-1.92(m,1H),1.85-1.75(m,1H),1.42-1.21(m,12H),0.87(t,J=6.8Hz,3H). 13 C NMR (100MHz, CDCl3) δ173.6,164.3,150.1,142.1,138.7,125.8,120.4,114.7,6 6.1(t,J=28.2Hz),53.0,52.7,32.1,31.7,29.3,29.11,29.09,25.4,22.6,14.0. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.2(t,J=12.6Hz).IR(neat,cm -1 )3260,2928,1744,1533,1196.HRMS (ESI) calculated value calcdC 21 H 28 F5N2O6 + [M+H] + :499.1862. Measured value Found:499.1860.
[0296] (+)-23 was obtained as a colorless oil (75.9 mg, 86% yield) by asymmetric decarboxylation of malonic acid S23 (94.0 mg, 0.2 mmol) according to the general procedure for 14 hours. f =0.6 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=8.94min,t r (major) = 13.33min) gives the isomer composition of the product: 91% ee, 1 HNMR (400MHz, CDCl3) δ7.93(d,J=8.4Hz,1H),7.65(s,1H),7.50(d,J=7.6Hz,1H),6.98(d,J=7.6Hz,1H),4.95-4.81(m, 1H), 4.61 (t, J = 11.8Hz, 2H), 3.82 (s, 3H), 1.96-1.74 (m, 2H), 0.80-0.66 (m, 1H), 0.60-0.44 (m, 2H), 0.18-0.06 (m, 2H). 13 C NMR (100MHz, CDCl3) δ173.0, 164.1, 150.2, 142.1, 139.0, 125.9, 120.3, 114.9, 66.2 (t, J = 28.5Hz), 53.4, 52.6, 36.8, 6.9, 4.2, 4.1. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.7Hz).IR(neat,cm -1 )3233,3050,1750,1538,1197. HRMS (ESI) calculated value calcd C 17 H 18 F5N2O6 + [M+H] + :441.1080. Found:441.1081.
[0297] (+)-24 was obtained from malonic acid S24 (91.6 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 8 hours to obtain a white solid (74.8 mg, 87% yield). f =0.3 (Hexane / EtOAc 4:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=7.57min,t r (major) = 11.69 min) gives the isomer composition of the product: 84% ee, 1HNMR (400MHz, CDCl3) δ7.93(d,J=8.4Hz,1H),7.65(s,1H),7.50(d,J=8.4Hz,1H),6.76(d,J=8.4Hz,1H),4.82-4. 71(m,1H),4.62(t,J=11.8Hz,2H),3.81(s,3H),2.38-2.23(m,1H),1.02(d,J=7.2Hz,3H),1.00(d,J=6.8Hz,3H). 13 C NMR (125MHz, CDCl3) δ172.4, 164.6, 150.3, 142.2, 139.3, 126.0, 120.2, 115.2, 66.3 (t, J = 28.0Hz), 57.9, 52.5, 31.5, 18.9, 17.9. 19 F NMR(471MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.3Hz).IR(neat,cm -1 )3369,2968,1743,1530,1199. HRMS (ESI) calculated value calcd C 16 H 18 F5N2O6 + [M+H] + :429.1080. Found:429.1078.
[0298] (+)-25 was obtained as a colorless oil (71.5 mg, 84% yield) by asymmetric decarboxylation of malonic acid S25 (91.5 mg, 0.2 mmol) according to the general procedure for 6 hours. f =0.4 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=8.41min,t r (major) = 14.32min) gives the isomer composition of the product: 92% ee, 1HNMR (400MHz, CDCl3) δ7.90(d,J=8.4Hz,1H),7.62(d,J=0.8Hz,1H),7.46(dd,J1=8.2,J2=1.4Hz,1H),6.87(d,J=7.6Hz ,1H),5.84-5.63(m,1H),5.25-5.10(m,2H),4.94-4.78(m,1H),4.61(t,J=11.8Hz,2H),3.82(s,3H),2.83-2.55(m,2H). 13 C NMR (100MHz, CDCl3) δ172.0, 164.2, 150.3, 142.2, 139.1, 131.8, 126.0, 120.3, 119.8, 115.1, 66.3 (t, J = 28.2Hz), 52.7, 52.3, 36.3. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3228,2961,1748,1641,1534,1195. HRMS (ESI) calculated value calcd C 16 H 16 F5N2O6 + [M+H] + :427.0923. Measured value Found:427.0921.
[0299] (+)-26 was obtained as a yellow oil (90.9 mg, 90% yield) by asymmetric decarboxylation of malonic acid S26 (106.7 mg, 0.2 mmol) according to the general procedure for 10 hours. f =0.3 (Hexane / EtOAc 4:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=16.08min,t r (major) = 16.67 min) gave the isomeric composition of the product: 93% ee, []21 D = +44.0 (c = 1.00, CHCl3). 1H NMR (400MHz, CDCl3) δ7.88(d,J=8.4Hz,1H),7.55(s,1H),7.44(d,J=8.4Hz,1H),7.36-7.28(m,4H),7.27-7.22(m,1H),6.81(d,J=7.2Hz,1H ),6.48(d,J=16.0Hz,1H),6.17-6.01(m,1H),5.01-4.87(m,1H),4.51(t,J=11.8Hz,2H),3.84(s,3H),2.97-2.86(m,1H),2.84-2.74(m,1H). 13 C NMR (100MHz, CDCl3) δ172.1,164.4,150.2,142.1,139.1,136.5,134.6,128.6,1 27.9,126.2,126.0,123.0,120.3,114.8,66.1(t,J=28.6Hz),52.8,52.6,35.7. 19 FNMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3225,2961,1750,1642,1538,1197. HRMS (ESI) calculated value calcd C 22 H 20 F5N2O6 + [M+H] + :503.1236. Measured value Found:503.1235.
[0300] (+)-27 was obtained by asymmetric decarboxylation of malonic acid S27 (107.2 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a white solid (83.7 mg, 83% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=9.89min,t r (major) = 17.82min) gives the isomer composition of the product: 93% ee, 1HNMR (500MHz, CDCl3) δ7.92(d,J=8.5Hz,1H),7.64(d,J=1.5Hz,1H),7.50(dd,J1=8.5,J2=1.5Hz,1H),6.96(d,J=7.0Hz,1H),5.69(s,1H),5.59 (d,J=1.5Hz,1H),5.06-5.92(m,1H),4.61(t,J=12.0Hz,2H),3.84(s,3H),3.20(dd,J1=14.5,J2=5.0Hz,1H),3.08(dd,J1=14.8,J2=6.3Hz,1H). 13 C NMR (125MHz, CDCl3) δ171.5,164.4,150.2,142.2,138.6,127.2,125.9,121.3,120.4,114.9,66.2(t,J=28.4Hz),52.9,51.8,42.8. 19 F NMR(471MHz, CDCl3)δ-83.4(s),-123.2(t,J=12.0Hz).IR(neat,cm -1 )3240,3065,1753,1540,1194. HRMS (ESI) calculated value calcd C 16 H 15 F5N2O6 79 Br + [M+H] + :505.0028. Found:505.0027.
[0301] (+)-28 was obtained as a yellow oil (80.3 mg, 88% yield) by asymmetric decarboxylation of malonic acid S28 (96.9 mg, 0.2 mmol) according to the general procedure for 10 hours. f =0.3 (Hexane / EtOAc 4:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=7.88min,t r (major) = 12.60 min) gives the isomer composition of the product: 91% ee, 1HNMR (500MHz, CDCl3) δ7.92(d,J=8.5Hz,1H),7.63(s,1H),7.45(d,J=6.5Hz,1H),6.80(d,J=7.0Hz,1H),5.06(t,J=7.5Hz,1 H),4.87-4.76(m,1H),4.61(t,J=11.8Hz,2H),3.81(s,3H),2.78-2.67(m,1H),2.64-2.54(m,1H),1.72(s,3H),1.62(s,3H). 13 C NMR (125MHz, CDCl3) δ172.3, 164.2, 150.4, 142.2, 139.3, 137.2, 126.1, 120.2, 116.9, 115.2, 66.3 (t, J = 27.9Hz), 52.8, 52.7, 30.5, 25.8, 17.9. 19 F NMR(471MHz, CDCl3)δ-83.3(s),-123.1(t,J=12.0Hz).IR(neat,cm -1 )3251,3051,1748,1647,1534,1194. HRMS (ESI) calculated value calcdC 18 H 20 F5N2O6 + [M+H] + :455.1236. Measured value Found:455.1237.
[0302] (+)-29 was obtained from malonic acid S29 (91.2 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 6 hours to obtain a white solid (72.4 mg, 85% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=12.33min,t r (major) = 24.54min) gives the isomer composition of the product: 92% ee, 1HNMR (400MHz, CDCl3) δ7.95(d,J=8.4Hz,1H),7.65(s,1H),7.54(d,J=8.4Hz,1H),7.04(d,J=6.8Hz,1 H),4.98-4.86(m,1H),4.62(t,J=11.8Hz,2H),3.87(s,3H),3.04-2.81(m,2H),2.09(t,J=2.4Hz,1H). 13 C NMR (100MHz, CDCl3) δ170.6, 164.4, 150.3, 142.3, 138.8, 126.0, 120.5, 115.2, 77.9, 72.1, 66.2 (t, J = 28.5Hz), 53.1, 51.3, 22.2. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.7Hz).IR(neat,cm -1 )3306,2973,1732,1524,1198. HRMS (ESI) calculated value calcd C 16 H 14 F5N2O6 + [M+H] + :425.0767. Measured value Found:425.0771.
[0303] (+)-30 was obtained as a colorless oil (88.5 mg, 88% yield) by asymmetric decarboxylation of malonic acid S30 (106.3 mg, 0.2 mmol) according to the general procedure for 5 hours. f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (major)=12.71min,t r (minor) = 14.87min) gives the isomer composition of the product: 90% ee, 1HNMR(400MHz, CDCl3)δ7.91(d,J=8.4Hz,1H),7.63(s,1H),7.53(d,J=8.4Hz,1H),7.40-7.25(m,5H) ,7.11(d,J=7.2Hz,1H),5.05-4.92(m,1H),4.57(t,J=11.8Hz,2H),3.88(s,3H),3.25-3.03(m,2H). 13 C NMR (100MHz, CDCl3) δ170.7,164.3,150.3,142.3,139.1,131.6,128.5,128.4, 126.1,122.5,120.5,115.2,84.2,83.0,66.3(t,J=28.2Hz),53.1,51.6,23.4. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3313,2953,1753,1534,1199. HRMS (ESI) calculated value calcd C 22 H 18 F5N2O6 + [M+H] + :501.1080. Found:501.1076.
[0304] (+)-31 was obtained as a yellow oil (66.5 mg, 64% yield) by asymmetric decarboxylation of malonic acid S31 (110.4 mg, 0.2 mmol) according to the general procedure for 8 hours. f =0.6 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=6.62min,t r (major) = 10.41min) gives the isomer composition of the product: 88% ee, 1HNMR (400MHz, CDCl3) δ7.92(d,J=8.4Hz,1H),7.63(s,1H),7.43(d,J=8.4Hz,1H),6.77(d,J=7.2Hz,1H),5.15-4.96(m,2H),4.89-4.78(m, 1H),4.60(t,J=11.8Hz,2H),3.81(s,3H),2.81-2.68(m,1H),2.66-2.55(m,1H),2.12-1.95(m,4H),1.65(s,3H),1.62(s,3H),1.58(s,3H). 13 C NMR (100MHz, CDCl3) δ172.4,164.1,150.3,142.1,140.6,139.1,131.8,126.0,123.6,1 20.2,117.0,115.0,66.2(t,J=28.2Hz),52.8,52.6,39.7,30.3,26.4,25.6,17.6,16.1. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3224,2961,1750,1643,1538,1196. HRMS (ESI) calculated value calcd C 23 H 28 F5N2O6 + [M+H] + :523.1862. Measured value Found:523.1859.
[0305] (+)-32 was obtained by asymmetric decarboxylation of malonic acid S32 (111.2 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (85.7 mg, 81% yield). f =0.6 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=9.12min,t r (major) = 19.17min) gives the isomer composition of the product: 93% ee, 1HNMR(400MHz, CDCl3) δ7.69(d,J=8.4Hz,1H),7.57(s,1H),7.42(d,J=8.4Hz,1H),7.35-7.27(m,5H),7.10(d,J=7.2Hz,1H),5.59(s,1H),5 .40(s,1H),5.09-4.98(m,1H),4.46(t,J=11.8Hz,2H),3.81(s,3H),3.01(dd,J1=14.0,J2=4.8Hz,1H),2.89(dd,J1=14.0,J2=5.6Hz,1H). 13 C NMR (100MHz, CDCl3) δ171.5,164.2,150.1,142.1,138.9,131.4,128.8,128.4,125.8,1 25.73,125.67,122.2,120.3,114.8,90.7,88.8,66.0(t,J=28.6Hz),52.8,52.6,38.6. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3230,3056,2960,2150,1746,1531,1199. HRMS (ESI) calculated value calcd C 24 H 20 F5N2O6 + [M+H] + :527.1236. Measured value Found:527.1238.
[0306] (+)-33 was obtained from malonic acid S33 (107.0 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 8 hours to obtain a white solid (91.4 mg, 91% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=11.72min,t r (major) = 13.77min) gives the isomer composition of the product: 92% ee, 1H NMR (400MHz, CDCl3) δ7.89(d,J=8.4Hz,1H),7.61(s,1H),7.45(d,J=8.4Hz,1H),7.31-7.25(m,2H),7.24-7.06(m,3H),6.80(d, J=7.6Hz,1H),4.90-4.75(m,1H),4.60(t,J=11.8Hz,2H),3.79(s,3H),2.76-2.56(m,2H),2.08-1.93(m,1H),1.90-1.64(m,3H). 13 C NMR (100MHz, CDCl3) δ173.2,164.3,150.1,142.1,141.3,138.7,128.4,128.3, 126.1,125.8,120.4,114.8,66.1(t,J=28.6Hz),52.8,52.7,35.2,31.7,27.2. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3338,2956,1741,1531,1194. HRMS (ESI) calculated value calcd C 22 H 22 F5N2O6 + [M+H] + :505.1393. Measured value Found:505.1394.
[0307] (+)-34 was obtained as a yellow oil (89.7 mg, 83% yield) by asymmetric decarboxylation of malonic acid S34 (114.2 mg, 0.2 mmol) according to the general procedure for 12 hours. f =0.4 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=14.09min,t r (major) = 18.80min) gives the isomer composition of the product: 90% ee, 1HNMR (400MHz, CDCl3) δ7.67(d,J=8.4Hz,1H),7.57(d,J=8.0Hz,1H),7.38(s,1H),7.27-7.20(m,2H),7.14-7.06(m,1H),6.86(s,1H),6.85- 6.71(m,2H),4.95-4.78(m,1H),4.49(t,J=12.0Hz,2H),3.78(s,3H), 3.65(s,3H),2.99-2.80(m,2H),2.49-2.38(m,1H),2.32-2.21(m,1H). 13 C NMR (100MHz, CDCl3) δ172.8,164.0,150.0,141.9,138.7,137.2,127.2,126.8,125.6,121.9, 119.9,119.1,118.8,114.6,112.9,109.4,66.1(t,J=28.6Hz),53.3,52.6,32.5,31.8,21.5. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3342,2963,1748,1530,1199. HRMS (ESI) calculated value calcd C 24 H 23 F5N3O6 + [M+H] + :544.1502. Measured value Found:544.1500.
[0308] (+)-35 was obtained by asymmetric decarboxylation of malonic acid S35 (117.8 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (87.5 mg, 78% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak ID-3, hexane / i PrOH=70 / 30,0.8mL / min,230nm; t r (minor)=49.50min,t r(major) = 136.27 min) gave the isomeric composition of the product: 72% ee, (57% yield, 99% ee, single cleavage from DCM / hexane, Chiralpak IB-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (major)=28.09min,t r (minor)=32.20min), 1 H NMR(400MHz, CDCl3) δ7.97(d,J=8.4Hz,1H),7.91-7.81(m,3H),7.81-7.68(m,3H),7.55(d,J=8.0Hz,1H),4.9 9-4.89(m,1H),4.75(t,J=12.2Hz,2H),3.97-3.76(m,2H),3.49(s,3H),2.64-2.48(m,1H),2.40-2.31(m,1H). 13 C NMR (100MHz, CDCl3) δ171.8,168.6,164.3,150.2,142.0,138.9,134.5,131 .7,126.2,123.4,121.2,114.4,66.1(t,J=28.2Hz),52.6,50.1,33.5,29.2. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3245,3065,1714,1534,1204. HRMS (ESI) calculated value calcd C 23 H 19 F5N3O8 + [M+H] + :560.1087. Measured value Found:560.1083.
[0309] (+)-36 was obtained as a colorless oil (77.9 mg, 86% yield) by asymmetric decarboxylation of malonic acid S36 (96.7 mg, 0.2 mmol) according to the general procedure for 18 hours. f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak ID-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (minor)=12.48min,t r (major) = 21.42 min) gives the isomer composition of the product: 91% ee, 1 HNMR (400MHz, CDCl3) δ7.90(d,J=8.0Hz,1H),7.62(s,1H),7.51(d,J=8.0Hz,1H),7.10(d,J=7.6Hz,1H),4.89-4.76(m,1 H),4.62(t,J=11.8Hz,2H),3.84(s,3H),2.46(t,J=7.0Hz,2H),2.24-2.10(m,1H),2.02-1.90(m,1H),1.88-1.75(m,2H). 13 C NMR (100MHz, CDCl3) δ172.4, 164.6, 150.1, 142.2, 138.5, 125.9, 120.5, 119.1, 114.8, 66.1 (t, J = 28.2Hz), 53.0, 52.2, 31.2, 21.7, 16.8. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.7Hz).IR(neat,cm -1 )3337,2958,2180,1743,1530,1199. HRMS (ESI) calculated value calcd C 17 H 17 F5N3O6 + [M+H] + :454.1032. Measured value Found:454.1036.
[0310] (+)-37 was obtained as a colorless oil (85.9 mg, 88% yield) by asymmetric decarboxylation of malonic acid S37 (103.5 mg, 0.2 mmol) according to the general procedure for 18 hours. f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=25.48min,t r(major) = 33.43min) gives the isomer composition of the product: 90% ee, 1 HNMR (400MHz, CDCl3) δ7.88 (d, J = 8.4Hz, 1H), 7.65 (s, 1H), 7.61-7.47 (m, 2H), 4.98-4.89 (m,1H),4.80-4.69(m,1H),4.61(t,J=11.8Hz,2H),4.05-3.75(m,7H),2.17-1.80(m,4H). 13 CNMR(100MHz, CDCl3)δ172.6,164.5,150.2,142.1,139.0,125.9,120.4,115.0,103.3,66.2(t,J=28.6Hz),65.0,52.8,52.6,29.0,25.1. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3314,2968,1743,1534,1194.HRMS (ESI) calculated value calcdC 18 H 20 F5N2O8 + [M+H] + :487.1134. Measured value Found:487.1132.
[0311] (+)-38 was obtained as a colorless oil (84.3 mg, 90% yield) by asymmetric decarboxylation of malonic acid S38 (99.9 mg, 0.2 mmol) according to the general procedure for 12 hours. f =0.4 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=14.33min,t r (major) = 16.43min) gives the isomer composition of the product: 92% ee, 1HNMR (400MHz, CDCl3) δ7.89(d,J=8.0Hz,1H),7.61(s,1H),7.49(d,J=8.4Hz,1H),7.08(d,J=7.6Hz,1H),4.90-4.76(m, 1H), 4.60 (t, J = 11.8Hz, 2H), 3.84 (s, 3H), 3.45-3.28 (m, 2H), 2.16-2.03 (m, 1H), 1.97-1.84 (m, 1H), 1.77-1.66 (m, 2H). 13 C NMR (100MHz, CDCl3) δ172.8, 164.5, 150.1, 142.1, 138.6, 125.9, 120.4, 114.8, 66.1 (t, J = 28.2Hz), 52.9, 52.5, 50.6, 29.4, 24.9. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.2(t,J=12.6Hz).IR(neat,cm -1 )3245,2968,2103,1739,1534,1194. HRMS (ESI) calculated value calcd C 16 H 17 F5N6O6 + [M+H] + :470.1094. Measured value Found:470.1093.
[0312] (+)-39 was obtained by asymmetric decarboxylation of malonic acid S39 (167.0 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a colorless oil (137.0 mg, 86% yield). The crude product was quenched with CH2Br2 (14 μL) as an internal standard. 1 HNMR analysis confirmed dr>20:1.R f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak ID-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=11.35min,t r (major) = 18.56min) gives the isomer composition of the product: 91% ee, 1H NMR (400MHz, CDCl3) δ7.85(d,J=8.0Hz,1H),7.60(s,1H),7.49(d,J=8.4Hz,1H),7.13( d,J=7.2Hz,1H),4.82-4.71(m,1H),4.60(t,J=11.8Hz,2H),3.82(s,3H),3.39-3.28(m, 4H),3.24(s,3H),3.20(s,3H),3.14(s,1H),3.05-2.93(m,1H),2.24-1.64(m,13H),1. 63-1.56(m,1H),1.55-1.38(m,4H),1.32-0.96(m,8H),0.92-0.84(m,6H),0.64(s,3H). 13 C NMR (100MHz, CDCl3) δ173.6,164.3,150.1,142.1,138.8,125.8,120.4,114.8,82.0,80.7,76.9,66.1(t,J=28.3Hz),55.8,55.6,55.3,5 3.2,52.6,46.4,46.0,42.7,41.9,39.5,35.4,35.3,35.2,34.8,34.4,32.6,27.9,27.7,27.5,26.7,23.1,22.8,22.0,21.9,17.6,12.4. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )2939,2866,1739,1539,1194,1102. HRMS (ESI) calculated value calcd C 40 H 58 F5N2O9 + [M+H] + :805.4057. Measured value Found:805.4055.
[0313] (+)-40 was obtained by asymmetric decarboxylation of malonic acid S40 (148.0 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a colorless oil (120.4 mg, 85% yield). The crude product was quenched with CH2Br2 (14 μL) as an internal standard. 1 HNMR analysis confirmed dr>20:1.R f=0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=29.47min,t r (major) = 37.40min) gives the isomer composition of the product: 94% ee, 1 H NMR(400MHz, CDCl3)δ7.84(d,J=8.4Hz,1H),7.61(s,1H),7.49(d,J=7.2Hz,1H), 7.24-7.10(m,2H),6.67(d,J=8.8Hz,1H),6.60(s,1H),4.89-4.76(m,1H),4.58(t ,J=11.8Hz,2H),3.94(t,J=5.8Hz,2H),3.81(s,3H),2.94-2.79(m,2H),2.55-2.4 5(m,1H),2.43-2.33(m,1H),2.28-1.78(m,10H),1.67-1.42(m,7H),0.90(s,3H). 13 C NMR (100MHz, CDCl3) δ221.0,173.1,164.4,156.8,150.1,142.0,138.8,137.8,132.1,126.3,125.8,120.5,114.8,114.4,111 .9,67.2,66.1(t,J=28.3Hz),52.9,52.7,50.3,47.9,43.9,38.3,35.8,31.7,31.5,29.6,28.6,26.4,25.8,22.2,21.5,13.7. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3351,2943,1729,1534,1194. HRMS (ESI) calculated value calcd C 35 H 40 F5N2O8 + [M+H] + :711.2699. Found:711.2700.
[0314] (+)-41 was obtained as a colorless oil (104.4 mg, 92% yield) by asymmetric decarboxylation of malonic acid S41 (118.9 mg, 0.2 mmol) according to the general procedure for 5 hours. f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=16.08min,t r (major) = 22.40min) gives the isomer composition of the product: 91% ee, 1 HNMR(500MHz, CDCl3)δ7.78-7.63(m,2H),7.55(s,1H),7.29(d,J=8.5Hz,1H ),7.22(d,J=8.0Hz,2H),6.81(d,J=8.0Hz,2H),4.77-4.67(m,1H),4.54(t,J =11.8Hz,2H),4.47(d,J=11.0Hz,1H),4.40(d,J=11.5Hz,1H),3.79(s,3H),3 .77(s,3H),3.56(t,J=5.3Hz,2H),2.06(q,J=6.5Hz,2H),1.80-1.68(m,2H). 13 C NMR (125MHz, CDCl3) δ172.6,164.6,159.4,150.0,141.8,139.0,129.6,129.5,125.8 ,120.4,114.9,113.8,73.0,69.7,66.1(t,J=28.4Hz),55.2,52.8,52.5,28.9,25.2. 19 F NMR(471MHz, CDCl3)δ-83.3(s),-123.2(t,J=12.0Hz).IR(neat,cm -1 )3356,2929,1661,1632,1277.HRMS (ESI) calculated value calcdC 24 H 26 F5N2O8 + [M+H] + :565.1604. Measured value Found:565.1606.
[0315] HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=12.82min,t r (major) = 22.73min) gives the isomer composition of the product: 91% ee, 1 H NMR (400MHz, CDCl3) δ8.03(d,J=6.8Hz,1H),7.83(d,J=8.4Hz,1H),7.64(s,1H),7.54(d,J=8.4Hz,1H),4.76- 4.67(m,1H),4.62(t,J=12.0Hz,2H),3.88-3.60(m,5H),2.87(br,1H),2.12-1.94(m,2H),1.77-1.59(m,2H). 13 C NMR (100MHz, CDCl3) δ172.8, 164.8, 150.0, 141.8, 138.9, 125.8, 120.6, 114.7, 66.0 (t, J = 28.6Hz), 61.9, 52.8, 52.6, 28.7, 27.9. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.3(t,J=12.6Hz).IR(neat,cm -1 )3308,2943,1743,1539,1194. HRMS (ESI) calculated value calcd C 16 H 18 F5N2O7 + [M+H] + :445.1029. Measured value Found:445.1031.
[0316] HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=13.92min,t r (major) = 15.77min) gives the isomer composition of the product: 91% ee, 1H NMR (400MHz, CDCl3) δ7.89(d,J=8.4Hz,1H),7.62(s,1H),7.49(d,J=8.4Hz,1H),7.05(d,J=7.6Hz,1H),4.87 -4.76(m,1H),4.61(t,J=11.8Hz,2H),3.84(s,3H),3.30-3.15(m,2H),2.20-2.05(m,1H),2.03-1.84(m,3H). 13 C NMR (100MHz, CDCl3) δ172.6, 164.4, 150.2, 142.2, 138.7, 126.0, 120.3, 115.0, 66.2 (t, J = 28.2Hz), 52.9, 52.1, 33.2, 29.2, 5.1. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3393,2958,1748,1530,1199. HRMS (ESI) calculated value calcd C 16 H 17 F5N2O6I + [M+H] + :555.0046. Measured value Found:555.0048.
[0317] HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (major)=14.90min,t r (minor) = 17.46min) gives the isomer composition of the product: 91% ee, 1 H NMR(400MHz, CDCl3)δ7.98-7.84(m,1H),7.42-7.29 and 7.21-7.13(m,2H),4.73-4.48(m,3H),3.80(s,3H),3.68-3.58(m,1H),3.55-3.40(m,1H),2.44-2.24(m,1H),2.15-1.89(m,3H). 13C NMR (100MHz, CDCl3) δ172.1,166.6,150.2,141.8,141.1,126.0,125.9,121.2,120.6,115 .0,114.7,66.4(t,J=28.6Hz),61.1,59.2,52.5,52.4,49.8,46.7,31.3,29.2,25.2,22.4. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.2(t,J=11.7Hz).IR(neat,cm -1 )2958,1743,1632,1531,1437,1194.HRMS (ESI) calculated value calcdC 16 H 16 F5N2O6 + [M+H] + :427.0923. Measured value Found:427.0926.
[0318] (+)-45 was obtained from malonic acid S45 (101.3 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 8 hours to obtain a white solid (83.4 mg, 87% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=12.37min,t r (major) = 20.38min) gives the isomer composition of the product: 92% ee, 1 HNMR (400MHz, CDCl3) δ7.87(d,J=8.4Hz,1H),7.54(s,1H),7.37-7.26(m,4H),7.12(d,J=7.6Hz,2H),6.69(d,J=7.6Hz,1H),5 .13-5.00(m,1H),4.58(t,J=12.0Hz,2H),3.82(s,3H),3.32(dd,J1=14.0,J2=5.6Hz,1H),3.23(dd,J1=13.8,J2=5.4Hz,1H). 13C NMR (100MHz, CDCl3) δ171.8,164.1,150.3,142.2,139.1,135.4,129.2,128.8,127.5,126.1,120.3,115.0,66.3(t,J=28.2Hz),53.7,52.7,37.6. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3230,2973,1748,1535,1195.HRMS (ESI) calculated value calcdC 20 H 18 F5N2O6 + [M+H] + :477.1080. Found:477.1082.
[0319] (+)-46 was obtained from malonic acid S46 (104.7 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 8 hours to obtain a white solid (88.9 mg, 90% yield). f =0.3 (Hexane / EtOAc 4:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=19.09min,t r (major) = 23.31min) gives the isomer composition of the product: 92% ee, 1 HNMR (400MHz, CDCl3) δ7.85(d,J=8.4Hz,1H),7.55(s,1H),7.35(d,J=8.4Hz,1H),7.15-7.05(m,2H),7.04-6.95(m,2H),6.86(d,J=6.4 Hz,1H),5.11-4.95(m,1H),4.59(t,J=11.8Hz,2H),3.81(s,3H),3.29(dd,J1=14.2,J2=5.8Hz,1H),3.18(dd,J1=14.0,J2=6.0Hz,1H). 13C NMR (100MHz, CDCl3) δ171.8, 164.2, 162.1 (d, J = 244.9Hz), 150.2, 142.2, 138.8, 131.2 (d, J = 3.6Hz), 130.7(d,J=8.0Hz),126.0,120.2,115.6(d,J=21.7Hz),115.0,66.2(t,J=28.5Hz),53.9,52.7,36.8. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-114.9--114.0(m),-123.2(t,J=11.7Hz).IR(neat,cm -1 )3227,2963,1748,1536,1194. HRMS (ESI) calculated value calcd C 20 H 17 F6N2O6 + [M+H] + :495.0985. Found:495.0988.
[0320] (+)-47 was obtained from malonic acid S47 (108.0 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 8 hours to obtain a white solid (90.1 mg, 88% yield). f =0.3 (Hexane / EtOAc 4:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (major)=15.82min,t r (minor) = 20.62min) gives the isomer composition of the product: 91% ee, 1 H NMR (400MHz, CDCl3) δ7.85(d,J=8.4Hz,1H),7.55(s,1H),7.35(d,J=8.4Hz,1H),7.27(d,J=8.4Hz,2H),7.06(d,J=8.4Hz,2H),6.86(d,J= 6.8Hz,1H),5.10-4.97(m,1H),4.59(t,J=11.8Hz,2H),3.81(s,3H),3.29(dd,J1=14.0,J2=5.6Hz,1H),3.18(dd,J1=14.0,J2=6.0Hz,1H). 13C NMR (100MHz, CDCl3) δ171.1,164.1,150.2,142.2,138.8,134.0,133.4,130.5,128.9,126.0,120.2,115.0,66.2(t,J=28.6Hz),53.7,52.8,37.0. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=12.4Hz).IR(neat,cm -1 )3226,2963,1748,1536,1195. HRMS (ESI) calculated value calcd C 20 H 17 F5N2O6 35 Cl + [M+H] + :511.0690. Found:511.0688.
[0321] (+)-48 was obtained from malonic acid S48 (117.1 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 8 hours to obtain a white solid (104.2 mg, 94% yield). f =0.3 (Hexane / EtOAc 4:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (major)=16.95min,t r (minor) = 24.54min) gives the isomer composition of the product: 93% ee, 1 HNMR (400MHz, CDCl3) δ7.85(d,J=8.0Hz,1H),7.55(s,1H),7.42(d,J=8.0Hz,2H),7.35(d,J=8.4Hz,1H),7.01(d,J=8.0Hz,2H),6.87(d,J= 7.6Hz,1H),5.12-4.95(m,1H),4.59(t,J=11.8Hz,2H),3.81(s,3H),3.28(dd,J1=14.0,J2=5.6Hz,1H),3.16(dd,J1=14.0,J2=6.0Hz,1H). 13C NMR (100MHz, CDCl3) δ171.7,164.2,150.2,142.2,138.7,134.5,131.8,130.8,126.0,121.4,120.2,114.9,66.2(t,J=28.5Hz),53.7,52.8,37.0. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=12.6Hz).IR(neat,cm -1 )3222,2964,1750,1538,1195. HRMS (ESI) calculated value calcd C 20 H 17 F5N2O6 79 Br + [M+H] + :555.0185. Measured value Found:555.0181.
[0322] (+)-49 was obtained by asymmetric decarboxylation of malonic acid S49 (107.3 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (92.9 mg, 92% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=19.69min,t r (major) = 26.99 min) gives the isomer composition of the product: 92% ee, 1 HNMR (400MHz, CDCl3) δ7.88(d,J=8.4Hz,1H),7.56(s,1H),7.35(dd,J1=8.4,J2=1.6Hz,1H),7.02(d,J=8.4Hz,2H),6.83(d,J=8.4Hz,2H),6.88(d,J=6 .8Hz,1H),5.07-4.97(m,1H),4.59(t,J=11.8Hz,2H),3.81(s,3H),3.78(s ,3H),3.25(dd,J1=14.0,J2=5.6Hz,1H),3.17(dd,J1=14.0,J2=5.6Hz,1H). 13C NMR (100MHz, CDCl3) δ172.0,164.1,158.9,150.2,142.1,139.0,130.2,127 .2,126.0,120.3,114.9,114.1,66.2(t,J=28.2Hz),55.2,53.9,52.7,36.7. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3222,3049,1751,1539,1197. HRMS (ESI) calculated value calcd C 21 H 20 F5N2O7 + [M+H] + :507.1185. Measured value Found:507.1182.
[0323] (+)-50 was obtained as a colorless oil (102.5 mg, 88% yield) by asymmetric decarboxylation of malonic acid S50 (122.7 mg, 0.2 mmol) according to the general procedure for 14 hours. f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=24.25min,t r (major) = 38.49 min) gives the isomer composition of the product: 94% ee, 1 HNMR (400MHz, CDCl3) δ7.88(d,J=8.0Hz,1H),7.58(s,1H),7.50-7.27(m,6H),7.02(d,J=8.0Hz,2H),6.91(d,J =8.4Hz,2H),6.62(d,J=6.8Hz,1H),5.16-4.91(m,3H),4.59(t,J=11.6Hz,2H),3.81(s,3H),3.31-3.12(m,2H). 13C NMR (100MHz, CDCl3) δ172.0,164.1,158.1,150.2,142.1,138.9,136.7,130.2,128.6,128 .0,127.6,127.4,125.9,120.2,115.1,114.9,69.9,66.1(t,J=28.2Hz),53.9,52.7,36.7. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3230,3060,1748,1539,1199.HRMS(ESI)calcdC 27 H 24 F5N2O7 + [M+H] + :583.1498. Measured value Found:583.1497.
[0324] (+)-51 was obtained as a white solid (94.3 mg, 88% yield) after asymmetric decarboxylation of malonic acid S51 (112.8 mg, 0.2 mmol) using 1,4-dioxane as solvent according to the general procedure for 20 hours. f =0.4 (Hexane / EtOAc 1:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.9mL / min,254nm; t r (minor)=17.07min,t r (major) = 21.99 min) gives the isomer composition of the product: 90% ee, 1 H NMR (400MHz, CDCl3) δ7.86(d,J=8.4Hz,1H),7.56(s,1H),7.42(d,J=8.0Hz,2H),7.36(d,J=8.0Hz,1H),7.27(s,1H),7.05(d,J=8.0Hz,2H),6.75(d,J= 7.6Hz,1H),5.11-4.94(m,1H),4.59(t,J=11.8Hz,2H),3.81(s,3H),3.28(d d, J1=13.8, J2=5.4Hz, 1H), 3.18 (dd, J1=14.2, J2=5.4Hz, 1H), 2.15 (s, 3H). 13C NMR (100MHz, CDCl3) δ171.7,168.5,164.3,150.2,142.1,139.0,137.1,131.4, 129.7,126.0,120.3,120.2,114.9,66.2(t,J=28.2Hz),53.8,52.7,37.0,24.4. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3264,3065,1743,1530,1194. HRMS (ESI) calculated value calcd C 22 H 21 F5N3O7 + [M+H] + :534.1294. Measured value Found:534.1296.
[0325] (+)-52 was obtained by asymmetric decarboxylation of malonic acid S52 (110.1 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (94.9 mg, 91% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.9mL / min,254nm; t r (major)=18.83min,t r (minor) = 51.69min) gives the isomer composition of the product: 95% ee, 1 H NMR (400MHz, CDCl3) δ8.16(d,J=8.4Hz,2H),7.91(d,J=8.4Hz,1H),7.61(s,1H),7.39(d,J=8.0Hz,1H),7.31(d,J=8.4Hz,2H),6.80(d,J= 6.8Hz,1H),5.16-5.04(m,1H),4.61(t,J=11.8Hz,2H),3.83(s,3H),3.45(dd,J1=14.0,J2=6.0Hz,1H),3.32(dd,J1=13.6,J2=5.6Hz,1H). 13C NMR (100MHz, CDCl3) δ171.3,164.2,150.4,147.3,143.4,142.4,138.5,130.1,126.1,123.8,120.2,115.2,66.3(t,J=28.6Hz),53.6,53.0,37.6. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3225,2962,1751,1539,1197. HRMS (ESI) calculated value calcd C 20 H 17 F5N3O8 + [M+H] + :522.0930. Measured value Found:522.0932.
[0326] (+)-53 was obtained by asymmetric decarboxylation of malonic acid S53 (116.7 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a white solid (102.9 mg, 93% yield). f =0.2(Hexane / EtOAc 1:1). HPLC analysis (Chiralpak IC-3,hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (minor)=57.51min,t r (major) = 63.89 min) gives the isomer composition of the product: 90% ee, 1 HNMR(500MHz, CDCl3)δ7.92-7.76(m,3H),7.59(s,1H),7.44-7.32(m,3H),7.03(d,J=7.5Hz,1H),5.14-5.03(m,1H),4 .61(t,J=11.8Hz,2H),3.81(s,3H),3.43(dd,J1=14.0,J2=5.5Hz,1H),3.30(dd,J1=14.0,J2=6.5Hz,1H),3.04(s,3H). 13C NMR (100MHz, CDCl3) δ171.3,164.4,150.2,142.4,142.2,139.4,138.6,130 .2,127.6,126.0,120.3,115.0,66.2(t,J=28.6Hz),53.6,52.9,44.3,37.4. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3351,2962,1748,1530,1151. HRMS (ESI) calculated value calcd C 21 H 20 F5N2O8 + [M+H] + :555.0855. Measured value Found:555.0857.
[0327] (+)-54 was obtained by asymmetric decarboxylation of malonic acid S54 (115.0 mg, 0.2 mmol) according to the general procedure for 10 hours to obtain a white solid (96.4 mg, 88% yield). f =0.4 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (major)=24.44min,t r (minor) = 32.15min) gives the isomer composition of the product: 92% ee, 1 HNMR (400MHz, CDCl3) δ7.87(d,J=8.0Hz,1H),7.66-7.49(m,3H),7.37(d,J=8.4Hz,1H),7.26(d,J=8.4Hz,2H),6.85(d,J=7.2Hz,1 H),5.17-5.01(m,1H),4.59(t,J=11.8Hz,2H),3.82(s,3H),3.39(dd,J1=13.6,J2=5.6Hz,1H),3.27(dd,J1=13.8,J2=5.8Hz,1H). 13CNMR (100MHz, CDCl3) δ171.5,164.2,150.3,142.3,139.7,138.7,129.7(q,J=32.3Hz),129.6,126 .1,125.6(q,J=3.6Hz),124.0(q,J=270.4Hz),120.2,115.0,66.3(t,J=28.6Hz),53.6,52.9,37.4. 19 F NMR(376MHz, CDCl3)δ-62.6(s),-83.4(s),-123.2(t,J=11.7Hz).IR(neat,cm -1 )3223,3049,1751,1539,1197. HRMS (ESI) calculated value calcd C 21 H 17 F8N2O6 + [M+H] + :545.0953. Measured value Found:545.0956.
[0328] (+)-55 was obtained by asymmetric decarboxylation of malonic acid S55 (109.7 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a white solid (92.9 mg, 90% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (major)=36.17min,t r (minor) = 57.45min) gives the isomer composition of the product: 95% ee, 1 H NMR (400MHz, CDCl3) δ7.88(d,J=8.4Hz,2H),7.82(d,J=8.0Hz,1H),7.57(s,1H),7.37(d,J=8.4Hz,1H),7.25(d,J=8.0Hz,2H),7.06(d,J=7.6Hz, 1H),5.14-5.02(m,1H),4.59(t,J=11.8Hz,2H),3.82(s,3H),3.39(dd,J1=14.0,J2=5.6Hz,1H),3.26(dd,J1=14.0,J2=6.4Hz,1H),2.57(s,3H). 13C NMR (100MHz, CDCl3) δ197.7,171.6,164.2,150.2,142.1,141.2,138.7,136.2, 129.4,128.7,125.9,120.3,115.0,66.2(t,J=28.5Hz),53.7,52.8,37.6,26.5. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.7Hz).IR(neat,cm -1 )3240,3060,1753,1534,1194. HRMS (ESI) calculated value calcd C 22 H 20 F5N2O7 + [M+H] + :519.1185. Measured value Found:519.1186.
[0329] (+)-56 was obtained by asymmetric decarboxylation of malonic acid S56 (116.4 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (99.7 mg, 90% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (minor)=11.38min,t r (major) = 16.59 min) gives the isomer composition of the product: 94% ee, 1 H NMR (400MHz, CDCl3) δ7.89(d,J=8.4Hz,1H),7.63-7.50(m,5H),7.44(t,J=7.4Hz,2H),7.40-7.32(m,2H),7.18(d,J=8.0Hz,2H),6.71(d,J =7.2Hz,1H),5.16-5.04(m,1H),4.59(t,J=11.8Hz,2H),3.84(s,3H),3.36(dd,J1=14.0,J2=5.6Hz,1H),3.28(dd,J1=14.0,J2=5.2Hz,1H). 13C NMR (100MHz, CDCl3) δ171.9,164.2,150.2,142.2,140.30,140.26,138.9,134.4,129.6, 128.8,127.5,127.4,126.9,126.0,120.3,115.0,66.2(t,J=28.2Hz),53.8,52.7,37.2. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3222,2962,1751,1539,1197. HRMS (ESI) calculated value calcd C 26 H 22 F5N2O6 + [M+H] + :553.1393. Measured value Found:553.1390.
[0330] (+)-57 was obtained by asymmetric decarboxylation of malonic acid S57 (109.7 mg, 0.2 mmol) according to the general procedure for 18 hours to obtain a white solid (95.7 mg, 92% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak ID-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (minor)=9.16min,t r (major) = 10.78min) gives the isomer composition of the product: 94% ee, 1 HNMR (500MHz, CDCl3) δ7.85(d,J=8.0Hz,1H),7.56(s,1H),7.35(d,J=8.0Hz,1H),7.12(d,J=7.6Hz,2H),6.96(d,J=8.0Hz,2H),6.88(d,J= 7.2Hz,1H),5.12-4.96(m,1H),4.59(t,J=12.0Hz,2H),3.82(s,3H),3.30(dd,J1=14.0,J2=5.6Hz,1H),3.18(dd,J1=14.0,J2=6.0Hz,1H). 13C NMR (100MHz, CDCl3) δ171.8,164.1,150.2,142.2,139.3,138.8,132.1,130.5,126.0,120.2,119.3,115.0,66.2(t,J=28.2Hz),53.9,52.7,37.0. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3235,3035,2122,1748,1534,1199. HRMS (ESI) calculated value calcd C 20 H 17 F5N5O6 + [M+H] + :518.1094. Measured value Found:518.1093.
[0331] (+)-58 was obtained by asymmetric decarboxylation of malonic acid S58 (122.3 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (107.4 mg, 92% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (minor)=16.01min,t r (major) = 28.66min) gives the isomer composition of the product: 93% ee, 1 HNMR (400MHz, CDCl3) δ7.89-7.81(m,1H),7.81-7.66(m,4H),7.65-7.53(m,2H),7.47(t,J=7.4Hz,2H),7.38(d,J=8.0Hz,1H),7.26(d,J=8.4Hz,2H ),7.04-6.87(m,1H),5.19-5.02(m,1H),4.59(t,J=11.8Hz,2H),3.82(s, 3H), 3.42 (dd, J1=13.6, J2=5.6Hz, 1H), 3.30 (dd, J1=13.8, J2=5.8Hz, 1H). 13C NMR (100MHz, CDCl3) δ196.3,171.6,164.2,150.2,142.2,140.5,138.7,137.3,136.6,132. 6,130.5,129.9,129.2,128.3,126.0,120.2,115.0,66.2(t,J=28.5Hz),53.7,52.8,37.6. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3223,3049,1750,1539,1197. HRMS (ESI) calculated value calcd C 27 H 22 F5N2O7 + [M+H] + :581.1342. Measured value Found:581.1343.
[0332] (+)-59 was obtained by asymmetric decarboxylation of malonic acid S59 (106.2 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (82.5 mg, 82% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (major)=17.91min,t r (minor) = 30.23min) gives the isomer composition of the product: 94% ee, 1 HNMR(500MHz, CDCl3) δ7.90(d,J=8.5Hz,1H),7.66-7.53(m,3H),7.39(dd,J1=8.5,J2=1.5Hz,1H),7.26(d,J=7.5Hz,2H),6.91-6.80( m,1H),5.12-5.03(m,1H),4.61(t,J=12.0Hz,2H),3.82(s,3H),3.39(dd,J1=14.0,J2=6.0Hz,1H),3.27(dd,J1=13.8,J2=5.8Hz,1H). 13C NMR (125MHz, CDCl3) δ171.3,164.1,150.4,142.4,141.3,138.6,132.4,130. 0,126.1,120.2,118.4,115.2,111.4,66.3(t,J=28.0Hz),53.6,52.9,37.9. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3224,2962,1751,1539,1197. HRMS (ESI) calculated value calcd C 21 H 17 F5N3O6 + [M+H] + :502.1032. Measured value Found:502.1031.
[0333] (+)-60 was obtained by asymmetric decarboxylation of malonic acid S60 (106.1 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a white solid (90.8 mg, 91% yield). f =0.6 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=18.46min,t r (major) = 29.46min) gives the isomer composition of the product: 93% ee, 1 HNMR (400MHz, CDCl3) δ7.84(d,J=8.4Hz,1H),7.53(s,1H),7.42(d,J=7.6Hz,2H),7.33(d,J=8.0Hz,1H),7.09(d,J=7.6Hz,2H),6.83(d,J=7.6Hz ,1H),5.12-4.98(m,1H),4.58(t,J=12.0Hz,2H),3.81(s,3H),3.32(dd, J1=14.0, J2=5.6Hz, 1H), 3.20(dd, J1=13.6, J2=6.0Hz, 1H), 3.09(s, 1H). 13C NMR (100MHz, CDCl3) δ171.7,164.2,150.2,142.2,138.8,136.3,132.4,129.2, 126.0,121.3,120.2,114.9,83.0,77.8,66.2(t,J=28.6Hz),53.7,52.8,37.5. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3303,3055,1753,1355,1199. HRMS (ESI) calculated value calcd C 22 H 18 F5N2O6 + [M+H] + :501.1080. Found:501.1078.
[0334] (+)-61 was obtained by asymmetric decarboxylation of malonic acid S61 (131.8 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a white solid (120.3 mg, 96% yield). f =0.4 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=25.60min,t r (major) = 33.12min) gives the isomer composition of the product: 93% ee, 1 HNMR (400MHz, CDCl3) δ7.88(d,J=8.4Hz,1H),7.72-7.53(m,9H),7.46(t,J=7.4Hz,2H),7.37(d,J=7.2Hz,2H),7.20(d,J=8.0Hz,2H),6.75(d ,J=7.6Hz,1H),5.17-5.04(m,1H),4.59(t,J=11.8Hz,2H),3.85(s,3H),3.37(dd,J1=14.0,J2=5.6Hz,1H),3.29(dd,J1=13.8,J2=5.4Hz,1H). 13C NMR (100MHz, CDCl3) δ171.8,164.2,150.3,142.2,140.5,140.3,139.8,139.1,139.0,134.5,129.7,1 28.8,127.5,127.4,127.3,127.2,127.0,126.1,120.3,115.1,66.3(t,J=28.5Hz),53.8,52.7,37.3. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3070,1748,1530,1267,1204.HRMS(ESI)calcdC 32 H 26 F5N2O6 + [M+H] + :629.1706. Measured value Found:629.1707.
[0335] (+)-62 was obtained by asymmetric decarboxylation of malonic acid S62 (108.4 mg, 0.2 mmol) according to the general procedure for 15 hours to obtain a white solid (96.6 mg, 94% yield). f =0.4 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=18.66min,t r (major) = 20.58min) gives the isomer composition of the product: 95% ee, 1 HNMR (400MHz, CDCl3) δ7.82(d,J=8.0Hz,1H),7.55(s,1H),7.36(d,J=8.4Hz,1H),7.15-6.94(m,3H),6.92-6.83(m,1H),5. 11-4.93(m,1H),4.59(t,J=12.0Hz,2H),3.82(s,3H),3.28(dd,J1=14.0,J2=5.6Hz,1H),3.15(dd,J1=14.0,J2=6.4Hz,1H). 13C NMR (100MHz, CDCl3) δ171.7,164.3,150.2,149.9(ddd,J1=247.2,J2=54.6,J3=12.7Hz),142.1,138.6,132.6(dd,J1=5.0,J2=4.4 Hz), 125.9, 125.2 (dd, J1=6.3, J2=3.3Hz), 120.2, 117.7 (dd, J1=54.9, J2=17.4Hz), 114.8, 66.1 (t, J=28.5Hz), 53.8, 52.8, 36.8. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.2(t,J=11.8Hz),-137.0--137.3(m),-139.4--137.6(m).IR(neat,cm -1 )3230,3055,1753,1525,1204. HRMS (ESI) calculated value calcd C 20 H 16 F7N2O6 + [M+H] + :513.0891. Measured value Found:513.0894.
[0336] (+)-63 was obtained by asymmetric decarboxylation of malonic acid S63 (126.4 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (112.3 mg, 93% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=70 / 30,0.8mL / min,254nm; t r (minor)=8.43min,t r (major) = 15.19 min) gave the isomeric composition of the product: 82% ee (76% yield, 98% ee, single cleavage from acetone / hexane), 1HNMR (400MHz, CDCl3) δ7.96-7.87(m,2H),7.54(s,1H),7.44(d,J=8.4Hz,1H),7.31(t,J=7.4Hz,1H),7.24(d,J=7.6Hz,1H),6.96(t,J=7.6Hz,1H),6 .79(d,J=8.0Hz,1H),5.20-5.00(m,1H),4.57(t,J=11.8Hz,2H),3.81(s, 3H), 3.47 (dd, J1=14.0, J2=6.0Hz, 1H), 3.32 (dd, J1=14.2, J2=8.6Hz, 1H). 13 C NMR (100MHz, CDCl3) δ171.9,164.4,150.1,142.1,139.8,139.0,138.7,130.3,1 29.2,128.7,125.9,120.5,114.9,101.1,66.2(t,J=28.5Hz),53.5,52.9,42.2. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.2(t,J=11.8Hz).IR(neat,cm -1 )3222,3050,1751,1539,1198. HRMS (ESI) calculated value calcd C 20 H 17 F5N2O6I + [M+H] + :603.0046. Measured value Found:603.0047.
[0337] (+)-64 was obtained from malonic acid S64 (111.3 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 10 hours to give a white solid (95.5 mg, 91% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=16.71min,t r (major) = 22.30min) gives the isomer composition of the product: 91% ee, 1H NMR (400MHz, CDCl3) δ7.89-7.67(m,4H),7.58(s,1H),7.53-7.39(m,3H),7.31-7.20(m,2H),6.82(d,J=7.6Hz,1H),5.21 -5.06(m,1H),4.48(t,J=11.8Hz,2H),3.82(s,3H),3.48(dd,J1=13.8,J2=5.8Hz,1H),3.37(dd,J1=14.0,J2=6.0Hz,1H). 13 C NMR (100MHz, CDCl3) δ171.9,164.3,150.1,142.1,139.0,133.4,132.9,132.5,128.5,128.1,1 27.7,127.4,127.0,126.5,126.1,126.0,120.3,114.7,66.1(t,J=28.6Hz),53.8,52.7,37.8. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3232,2975,1753,1538,1198. HRMS (ESI) calculated value calcd C 24 H 20 F5N2O6 + [M+H] + :527.1236. Measured value Found:527.1237.
[0338] (+)-65 was obtained by asymmetric decarboxylation of malonic acid S65 (111.1 mg, 0.2 mmol) according to the general procedure for 10 hours to obtain a white solid (99.2 mg, 94% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=12.04min,t r (major) = 21.71 min) gave the isomeric composition of the product: 81% ee (81% yield, 97% ee, single cleavage from DCM / hexane), 1H NMR (400MHz, CDCl3) δ8.16-8.02(m,1H),7.93-7.83(m,1H),7.83-7.67(m,2H),7.60-7.45(m,2H),7.40(t,J=7.4Hz,1H),7. 36-7.26(m,2H),7.17(d,J=8.4Hz,1H),6.79(d,J=7.2Hz,1H),5.26-5.13(m,1H),4.47(t,J=11.6Hz,2H),3.85-3.56(m,5H). 13 C NMR (100MHz, CDCl3) δ172.1,164.4,150.0,142.0,138.9,133.9,132.2,131.9,129.1,128.3,12 7.5,126.5,125.93,125.87,125.3,123.2,120.4,114.6,66.1(t,J=28.2Hz),53.8,52.6,34.6. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3230,2973,1750,1538,1196.HRMS (ESI) calculated value calcd C 24 H 20 F5N2O6 + [M+H] + :527.1236. Measured value Found:527.1234.
[0339] (+)-66 was obtained from malonic acid S66 (102.5 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 8 h to give a white solid (90.7 mg, 94% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=14.05min,t r (major) = 25.09 min) gives the isomer composition of the product: 93% ee, 1H NMR (400MHz, CDCl3) δ7.85(d,J=8.4Hz,1H),7.55(s,1H),7.35(d,J=8.0Hz,1H),7.30(dd,J1=5.0,J2=3.0Hz,1H),7.02(d,J=1.6Hz,1H),6.9 3-6.77(m,2H),5.09-4.95(m,1H),4.59(t,J=12.0Hz,2H),3.82(s,3H),3.36(dd,J1=14.4,J2=5.2Hz,1H),3.27(dd,J1=14.6,J2=5.8Hz,1H). 13 C NMR (100MHz, CDCl3) δ171.9,164.2,150.2,142.2,138.9,135.6,128.0,126.5,126.0,123.0,120.3,114.9,66.2(t,J=28.6Hz),53.3,52.8,32.0. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3228,2962,1750,1538,1197. HRMS (ESI) calculated value calcd C 18 H 16 F5N2O6S + [M+H] + :483.0644. Measured value Found:483.0645.
[0340] (+)-67 was obtained by asymmetric decarboxylation of malonic acid S67 (99.2 mg, 0.2 mmol) according to the general procedure for 10 hours to obtain a white solid (84.4 mg, 91% yield). f =0.4 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=19.53min,t r (major) = 20.81min) gives the isomer composition of the product: 92% ee, 1HNMR (400MHz, CDCl3) δ7.92(d,J=8.4Hz,1H),7.60(s,1H),7.43(d,J=8.4Hz,1H),7.34(d,J=1.2Hz,1H),6.87(d,J=7.2Hz,1 H), 6.31 (t, J = 2.6Hz, 1H), 6.11 (d, J = 2.8Hz, 1H), 5.07-4.96 (m, 1H), 4.60 (t, J = 11.8Hz, 2H), 3.83 (s, 3H), 3.42-3.26 (m, 2H). 13 C NMR (125MHz, CDCl3) δ171.3,164.3,150.3,150.0,142.5,142.2,139.1,126.0,120.4,115.1,110.5,108.3,66.3(t,J=28.0Hz),52.9,52.3,30.3. 19 F NMR(471MHz, CDCl3)δ-83.3(s),-123.1(t,J=12.2Hz).IR(neat,cm -1 )3225,2962,1750,1539,1197.HRMS (ESI) calculated value calcdC 18 H 16 F5N2O7 + [M+H] + :467.0872. Measured value Found:467.0871.
[0341] Characterization in synthetic applications
[0342] (+)-69 was obtained from malonic acid S69 (86.2 mg, 0.2 mmol) by asymmetric decarboxylation according to the general procedure for 10 hours to obtain a white solid (73.3 mg, 91% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=8.80min,t r (major) = 11.89 min) gives the isomer composition of the product: 94% ee, 1HNMR (400MHz, CDCl3) δ7.86(d,J=8.4Hz,1H),7.60(s,1H),7.48(d,J=8.0Hz,1H),7.12(d,J=6.0Hz,1H),4.78 (dquintet,J1=147.2,J1=7.1Hz,1H),4.60(t,J=11.6Hz,2H),3.83(s,3H),1.54(dd,J1=6.6,J2=4.6Hz,3H). 13 C NMR (100MHz, CDCl3) δ173.7 (d, J = 61.4Hz), 164.0, 150.1, 142.1, 138.8, 125.9, 120.4, 114.8, 66.2 (t, J = 28.6Hz), 52.8, 48.8, 18.1 (d, J = 34.7Hz). 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.3(t,J=11.7Hz).IR(neat,cm -1 )3366,2963,1714,1530,1194.HRMS (ESI) calculated value calcdC 13 13 CH 14 F5N2O6 + [M+H] + :402.0800. Found:402.0799.
[0343] (+)-70 was obtained by asymmetric decarboxylation of malonic acid S70 (86.2 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (72.6 mg, 90% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=8.84min,t r (major) = 12.07min) gives the isomer composition of the product: 94% ee, 1HNMR (400MHz, CDCl3) δ7.83(d,J=8.4Hz,1H),7.58(d,J=1.2Hz,1H),7.48(dd,J1=8.2,J2=1.4Hz,1H),7.26(dd,J 1=91.7,J2=7.2Hz,1H),4.85-4.72(m,1H),4.59(t,J=11.8Hz,2H),3.83(s,3H),1.54(dd,J1=7.2,J2=2.8Hz,3H). 13 C NMR (100MHz, CDCl3) δ173.9, 164.0 (d, J = 16.6Hz), 150.0, 142.0, 138.6 (d, J = 8. 7Hz), 125.8, 120.5, 114.6, 66.1 (t, J = 28.6Hz), 52.8, 48.8 (d, J = 12.3Hz), 18.0. 19 F NMR(376MHz, CDCl3)δ-83.4(s),-123.2(t,J=11.8Hz). 15 N NMR(40MHz,CDCl3)δ116.9.IR(neat,cm -1 )3356,1709,1543,1228,1190. HRMS (ESI) calculated value calcd C 14 H 14 F5N 15 NO6 + [M+H] + :402.0737. Measured value Found:402.0740.
[0344] (+)-71 was obtained by asymmetric decarboxylation of malonic acid S71 (86.7 mg, 0.2 mmol) according to the general procedure for 12 hours to obtain a white solid (72.1 mg, 89% yield). f =0.3 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (minor)=8.72min,t r (major) = 11.84min) gives the isomer composition of the product: 94% ee, 1HNMR(500MHz,CDCl3)δ7.87(d,J=8.5Hz,1H),7.61(s,1H),7.48(d,J=8.0Hz,1H),7.08(d,J=7.0Hz,1H),4.76(d,J=7.0Hz,1H),4.60(t,J=12.0Hz,2H),3.82(s,3H). 13 C NMR(125MHz,CDCl3)δ173.8,164.2,149.9,141.9,138.7,125.7,120.5,118.3(qt,J1=284.4Hz,J2=34.1Hz),114.5,111.9(tq,J1=254.5Hz,J2=38.0Hz),66.0(t,J=27.9Hz),52.7,48.6,16.9(hept,J=19.8Hz). 19 F NMR(376MHz,CDCl3)δ-83.3(s),-123.2(t,J=11.1Hz).IR(neat,cm -1 )3361,2938,1717,1530,1194.HRMS(ESI) calculated for C 14 H 11 D3F5N2O6 + [M+H] + :404.0955. Found:404.0958.
[0345] 1 H NMR(400MHz,CD3OD)δ8.00(s,1H),7.90(d,J=8.4Hz,1H),7.86(s,1H),7.76(s,1H),7.57(d,J=8.0Hz,1H),6.43(t,J=6.0Hz,1H),5.47 - 5.32(m,1H),5.05 - 4.75(m,5H),4.35 - 4.25(m,1H),3.86(d,J=12.4Hz,1H),3.80 - 3.66(m,4H),3.43(dd,J1=15.0,J2=4.6Hz,1H),3.34 - 3.24(m,1H),2.96 - 2.80(m,1H),2.77 - 2.63(m,1H),1.87(s,3H). 13C NMR (100MHz, CD3OD) δ172.7,167.5,166.3,152.2,150.9,144.8,143.3,140.2,138.2,126.6,124. 2,122.5,115.8,111.7,86.6,86.3,66.9(t,J=28.3Hz),62.1,61.0,54.4,53.1,38.9,28.4,12.5. 19 F NMR(376MHz,CD3OD)δ-84.7(s),-124.6(t,J=12.4Hz).IR(neat,cm -1 )3293,3050,1670,1530,1267,1199.HRMS (ESI) calculated value calcdC 26 H 27 F5N7O 10 + [M+H] + :692.1734. Measured value Found:692.1735.
[0346] 1 H NMR (400MHz, CDCl3) δ8.09(d,J=7.2Hz,2H),8.02(s,1H),7.82(d,J=8.0Hz,1H),7.69(d,J=8.4Hz,1H),7.64-7.55(m,3H),7.50(t,J=7.4H z,1H),7.45-7.34(m,3H),7.25(s,1H),7.15(d,J=7.2Hz,1H),6.39-6.28(m,2H),5.63-5.42(m,2H),5.26(t,J=3.2Hz,1H),5.12-5.00(m,1 H),4.58(t,J=11.8Hz,2H),4.00(dd,J1=12.4,J2=2.0Hz,1H),3.85(dd,J1=12.6,J2=3.8Hz,1H),3.80(s,3H),3.45(dd,J1=12.2,J2=5.4Hz ,1H),3.37(dd,J1=14.0,J2=5.6Hz,1H),3.26(dd,J1=14.0,J2=6.0Hz,1H),3.11(dd,J1=12.0,J2=4.8Hz,1H),2.95(br,1H),1.85(br,1H). 13C NMR (150MHz, CDCl3) δ177.6,171.6,164.6,154.5,150.0,149.7,143.4,141.9,138.6,136.9,136.6,135.8,135.3,132.7,1 30.4,129.7,128.2,125.8,121.6,120.5,114.9,98.0,87.1,86.7,66.0(t,J=28.3Hz),63.1,53.9,52.7,37.7,37.5,36.8. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.8Hz).IR(neat,cm -1 )3318,3045,1648,1541,1204. HRMS (ESI) calculated value calcd C 38 H 34 F5N8O 10 S + [M+H] + :889.2033. Measured value Found:889.2030.
[0347] 1 H NMR (400MHz, CDCl3) δ8.10(s,1H),7.85(d,J=8.4Hz,1H),7.67(d,J=7.6Hz,2H),7.61(s,1H),7.40(d,J=8.4H z,1H),7.32(d,J=8.0Hz,2H),7.10-6.98(m,1H),5.89(d,J=2.8Hz,1H),5.17-5.04(m,1H),4.88(q,J=12.8Hz ,2H),4.70-4.52(m,3H),4.43-4.30(m,1H),4.18-4.06(m,3H),4.06-3.98(m,1H),3.83(s,3H),3.41(dd,J1= 14.0,J2=5.6Hz,1H),3.28(dd,J1=13.8,J2=6.2Hz,1H),1.49(s,3H),1.40(s,3H),1.34(s,3H),1.32(s,3H). 13C NMR (150MHz, CDCl3) δ171.5,164.2,150.2,145.8,142.2,138.7,136.7,136.1,130.5,126.0,120.6,120.2,115.1,11 1.9,109.1,105.2,82.5,81.6,81.0,72.2,67.4,66.2(t,J=28.7Hz),63.8,53.8,52.8,37.2,26.8,26.7,26.1,25.4. 19 F NMR(376MHz, CDCl3)δ-83.3(s),-123.1(t,J=11.7Hz).IR(neat,cm -1 )3254,2982,1748,1539,1204. HRMS (ESI) calculated value calcd C 35 H 39 F5N5O 12 + [M+H] + :816.2510. Measured value Found:816.2509.
[0348] (+)-77 was obtained by asymmetric decarboxylation of malonic acid S77 (340.5 mg, 1 mmol) using (S)-CPA-8 as catalyst according to the general procedure for 12 hours to obtain a white solid (294.5 mg, 95% yield). f =0.5 (Hexane / EtOAc 2:1). HPLC analysis (Chiralpak IA-3, hexane / i PrOH=80 / 20,0.8mL / min,254nm; t r (major)=8.06min,t r (minor) = 10.33 min) gave the isomeric composition of the product: 88% ee, (81% yield, 94% ee, single recrystallized from DCM / hexane), 1 HNMR (400MHz, CDCl3) δ7.78(d,J=8.0Hz,1H),7.60(s,1H),7.29(d,J=8.4Hz,1H),6.86(d,J =6.0Hz,1H),4.87-4.68(m,2H),3.82(s,3H),1.55(d,J=7.2Hz,3H),1.40(d,J=5.6Hz,6H).13 C NMR (100MHz, CDCl3) δ173.4,164.9,151.1,142.6,138.3,125.2,117.6,115.3,72.9,52.6,48.6,21.7,21.6,18.0.IR(neat,cm -1 )3313,2987,1743,1530,1262.HRMS (ESI) calculated value calcd C 14 H 19 N2O6 + [M+H] + :311.1238. Measured value Found:311.1240.
[0349] 1 H NMR(400MHz,CD3OD)δ7.64(s,1H),7.57-7.45(m,2H),6.84(s,1H),4.83-4.78(m,1H),4.49-4 .39(m,1H),2.33(s,3H),1.48(d,J=7.2Hz,3H),1.44(d,J=6.0Hz,3H),1.32(d,J=6.0Hz,3H). 13 C NMR (150MHz, CD3OD) δ179.8,168.1,159.1,154.8,137.0,129.2,128.6,125.8,12 0.4,120.1,115.0,114.4,109.4,72.6,52.5,22.4,22.2,19.2,10.1.IR(neat,cm -1 )3351,2982,1700,1500,1107.HRMS(ESI)calcdC 14 H 22 N3O5Cl2 + [M+H] + :442.0931. Measured value Found:442.0930.
[0350] Crystal structure and crystallographic data of (+)-17
[0351] The crystal structure of (+)-17 is as follows Figure 6 The crystal data of (+)-17 are as follows: C 14 H 13F5N2O6, Mw = 400.26, orthorhombic, space group P21,21,2, final R factor [I>2σ(I)], R1 = 0.0588, wR2 = 0.2027; R factor (all data), R1 = 0.0612, wR2 = 0.2083, α=90°, β=90°, γ=90°, T = 295K, Z = 4, collected reflections / unique 17002 / 3594 [R int =0.0186], number of observations [>2σ(I)] 3284, parameters: 266. Radiation Cu Kα (λ = 1.54184), ρ calc =1.553g / cm 3 ,flack parameter 0.07(5).CCDC-2206851.
[0352] Decarboxylation conditions
[0353] Compared with enzyme catalysis, the research on asymmetric decarboxylation by chemical catalysis is still lacking. Chiral organic bases (such as 6) have been used as catalysts, but the enantioselectivity of amino acids is low. This method can complete asymmetric decarboxylation, especially chiral phosphoric acid ( Figure 1 , CPA, 7). These acids not only have high acidity that allows for rapid protonation, but also can achieve stereocontrol by forming a rich hydrogen bond network within their pockets, especially when used with heteroatom-rich substrates or intermediates (e.g. Figure 1 , 8 and 9). Therefore, this approach can not only act as a proton donor, but also solve a long-standing problem by forming a rich hydrogen bond network with diacid substrates or enol intermediates. It is speculated that the CPA-catalyzed pathway can outperform the background self-decarboxylation by intercepting intramolecular CO2 extrusion (8) or enol protonation (9). For example, chiral acids can interrupt the internal hydrogen bonds of malonic acid (8) and trigger decarboxylation via intermolecular proton transfer (10). Alternatively, the self-decarboxylation of the enol intermediate 9 can also be directly intercepted. Figure 1 As shown, in either case, stereoselective protonation within the chiral pocket (11) can produce the chiral amino acid (12).
[0354] The chiral pocket of the phosphate is shown in Scheme 19 below. Chiral phosphates can induce enantioselective decarboxylation. However, both the backbone and side chains of the acid must be fully functional. Optimal enantiocontrol can be achieved by combining a spirocyclic backbone with a pair of mesityl substituents.
[0355] Scheme 19. Example of enantioselective decarboxylation using chiral phosphoric acid.
[0356] As shown in Scheme 19, although the decarboxylation of diacid 13 using the pocket-free BINOL-derived CPA-1 gave a nearly racemic mixture of benzoylated alanine (14), moderate enantiomeric control was achieved using a pair of bulky side arms (CPA-2 to CPA-5). Furthermore, the backbone of the acid is equally important for modulating the microenvironment. In particular, the combination of a spirocyclic scaffold (CPA-6 to CPA-10) and a mesityl substituent (CPA-8) greatly enhanced the enantioselectivity of the decarboxylation. Several other phosphate backbones, including H8-BINOL (CPA-11) and TADDOL (CPA-12), were also investigated (Table 1).
[0357] Decarboxylation is affected by solvent ( Figure 2A and Table 2). In general, polar solvents have higher decarboxylation rates than non-polar solvents. Compared with non-polar solvents, highly polar solvents tend to produce higher decarboxylation rates due to the stabilization of the polar transition state. This acceleration may be due to the stabilization of the polar transition state during the decarboxylative CC cleavage process. However, these polar solvents also destroy the interactions (such as hydrogen bonds) between phosphoric acid and substrates or intermediates, resulting in lower enantioselectivity. For example, water and alcohols destroy the organized hydrogen bonds and other weaker interactions of phosphoric acid, thereby reducing enantioselectivity. In contrast, the ether solvent family can strike a balance between decarboxylation reaction activity and enantioselectivity, among which cyclopentylmethyl ether (CPME) is an emerging process solvent with good safety and sustainability, slightly better than other members. The effects of reaction temperature and concentration on the decarboxylation reaction are shown in Table 3.
[0358] Table 1. Screening of chiral phosphates Unless otherwise stated, the reaction conditions were: 1 (0.1 mmol), (R)-CPA (10 mol%), in THF (0.5 mL), 80°C, 3 hours. Dibromomethane was used as an internal standard. 1 The yield was determined by H NMR analysis, and the ee was determined by HPLC analysis of the isolated product.
[0359] Table 2. Effect of solvent on decarboxylation Unless otherwise stated, the reaction conditions were: 1 (0.1 mmol), (R)-CPA-8 (10 mol%), in solvent (0.5 mL), 80°C, 2 hours. Dibromomethane was used as an internal standard. 1 The yield was determined by H NMR analysis, and the ee was determined by HPLC analysis of the isolated product.
[0360] Table 3. Effects of reaction temperature and concentration on decarboxylation reactions. Unless otherwise stated, the reaction conditions were: 1 (0.1 mmol), (R)-CPA-8 (10 mol%), dissolved in CPME, °T °C, t hours. Dibromomethane was used as an internal standard and the crude 1 H NMR analysis confirmed The yield and ee were determined by HPLC analysis of the isolated products. "c(M)" is the concentration of malonate substrate 1.
[0361] Amine protecting groups provide another avenue for improving enantioselectivity. Screening different amine protecting groups further improved enantioselectivity, suggesting that the amine protecting groups interact with the chiral phosphoric acid during enantioselective induction ( Figure 2B As shown in Table 4, benzamide (Bz) was selected as the protecting group for further derivatization compared with other protecting groups including acetyl, pivalate and benzyl carbamate. Figure 2B As shown, further derivatization of the benzoyl group showed that the para-nitro (Bz 1 ) and meta-methoxy (Bz 2 ) groups can work together to improve enantioselectivity. Both substituents can enhance the acidity of the amide proton, thereby acting as a stronger hydrogen bond donor and strengthening the substrate-catalyst interaction. In addition, geometrically, the extended side chain of the meta-alkoxyl group may further help anchor the substrate or intermediate in the acid pocket. Although the simple extension of the alkyl chain has only a negligible benefit (Bz 3 and Bz 5 ), but various fluorides (Bz 4 and Bz 6 -Bz 8) was introduced, which improved the enantiomeric control to an excellent level. 7 ) is the most important substituent ( Figure 2B The enhanced enantiocontrol of the fluorinated chain may be due to its weak interactions with the phosphate group, such as dispersion interactions, and the C-H bond-rich backbone of the phosphate group serving as an additional anchor to fix the intermediate conformation.
[0362] Table 4. Effect of amine protecting groups. Unless otherwise stated, the reaction conditions were: 1 (0.1 mmol), (R)-CPA-8 (10 mol%), in CPME (2.0 mL), at 80°C for 2 hours. Dibromomethane was used as an internal standard. 1 The yield was determined by H NMR analysis. The ee was determined by HPLC analysis of the isolated product. aThe reaction was carried out for 5 hours. Stereoscopic effect Electronic effect
[0363] Synthesis of asymmetric malonic esters
[0364] With customized protecting groups (Bz 7Aminomalonic acids can be prepared in a variety of modular ways (Figure 3). Starting from the inexpensive aminomalonate hydrochloride 15, and then proceeding to the hectogram-scale benzoyl unit 16, a structurally diverse diacid can be generated for decarboxylation under uniform alkylation and hydrolysis conditions. At the same time, since phosphoric acid is commercially available, such as CPA-8 with opposite configurations, both enantiomers of the product can be obtained, such as natural and unnatural alanine derivatives (+) / (-)-17. In addition to simple methylation with trimethylsilyldiazomethane, amino acid hydrochloride salts can also be obtained by hydrolysis. When decarboxylation is carried out on a larger scale by acid treatment at lower catalyst loadings, analytically pure alanine hydrochloride (18) can be obtained by simple extraction. Alanine hydrochloride salt (18) can be directly prepared on a large scale using relatively little catalyst, which shows the high practicality of this method. This protocol also provides a method for recovering the tailor-made benzoic acid (Bz) remaining in the organic phase. 7 OH) and phosphoric acid catalysts provide opportunities.
[0365] Structurally diverse amino acids possess unique functions, and this method allows for the preparation of a wide variety of amino acids. Chiral phosphates can tolerate alkyl groups of varying shapes (19-24). Chiral phosphates can accommodate extended alkyl chains (19-22) and cycloalkyl (23) groups, thereby generating unnatural amino acids, including those isomeric proteolytic amino acids such as norvaline (20) and norleucine (21). This method can also tolerate more crowded secondary alkyl substituents (24), but with slightly lower enantioselectivity. A wide variety of functional groups can be introduced into amino acids (25-40), which can serve as tools for further modification of amino acids or for imparting diverse functions to peptides or proteins. When unsaturated motifs are present in the side chains, they not only diversify the shape of the amino acids but also allow for further modification of the amino acids. Thus, various types of olefins can be incorporated, including monosubstituted olefins (25), 1,1 / 1,2-disubstituted olefins (26 and 27), and trisubstituted olefins (28), as well as terminal alkynes (29) and internal alkynes (30). Chains with multiple such motifs, including dienes derived from geraniol (31) and enynes (32), are also compatible. Further transformations of these alkenes and alkynes, such as coupling and oxidation reactions, can generate more complex amino acids. These functional groups can also facilitate the chemical modification of peptides and proteins through metathesis or click reactions. These functional groups extend beyond unsaturated moieties. When phenyl, indole, or phthalimide are attached to the alkyl chain, unnatural analogs of phenylalanine (33), tryptophan (34), and ornithine (35) are formed, respectively. The reduced enantioselectivity of 35 may be due to the fact that the imide carbonyls may interfere with the hydrogen bonding between the phosphate and the enol intermediate. Malonic acids bearing nitrile (36), acetal (37), or azide (38) groups can also participate in the generation of amino acids, thereby inheriting their multifunctional reactivity. Furthermore, acid catalysts operate smoothly on substrates with multifunctional skeletons derived from cholic acid (39) and estrone (40), and despite their large size, stereocontrol is still excellent.
[0366] Cyclic amino acids (such as 44) can also be obtained from decarboxylation products (such as 41) through a sequence involving a pair of multifunctional intermediates (42 and 43). Figure 3DA route from p-methoxybenzyl ether 41 to proline 44 is presented, which can be generally applied to obtain natural or unnatural cyclic amino acids. In addition, considering the high reactivity of alcohol (42) and alkyl iodide (43), this pair of intermediates in the sequence has high synthetic value in obtaining functionalized acyclic amino acids.
[0367] Non-protein derivatives of phenylalanines are particularly prevalent in bioactive peptide pharmaceuticals and have been widely used in various fields to introduce various functionalities into proteins via their aromatic substituents. Asymmetric synthesis has enabled the preparation of a library of such compounds, which takes advantage of the abundant supply of benzyl bromides and their facile substitution in the preparation of aminomalonic acids, as well as the catalyst's tolerance to substituents of varying shapes and electronic properties. As a result, phenylalanines with a rich variety of functionalities can be obtained, including fluorophores (59-61), NMR-active nuclei (46 and 54), and photosensitizers (58). Due to the ubiquity of functionalized phenylalanines in pharmaceuticals and their role as vessels for delivering various functionalities to peptides and proteins, the synthesis of functionalized phenylalanines has been further investigated. The availability of various benzyl bromides and their facile substitution reactions provide a reliable source for the synthesis of asymmetric malonates of functionalized phenylalanines. In fact, as shown in Figure 4, substituents of different shapes and electronic properties (i.e., electron-donor, -acceptor, and -neutral) on the benzylic substrate can be converted into the corresponding phenylalanine derivatives along the route (46-56). A wide variety of functional groups can be introduced. In addition to NMR-active fluorinated compounds (46 and 54) that are helpful for protein structure studies, the two partners (57 and 60) of the azide-alkyne cycloaddition reaction are also compatible. In addition to the enolizable methylketone, an amino acid with a benzophenone motif (58) was also obtained, which can achieve enzymatic photocatalysis. The catalyst's tolerance to aryl nitrile and alkyne as well as large terphenyl groups allows the preparation of atypical fluorescent amino acids (59-61). In addition to these para-substituted phenyl groups (46-61), other substitution patterns (62 and 63) and aromatic rings (64-67) are also suitable. The fluorine substituent in 62 strengthens the CH-π interaction within the peptide by enhancing the acidity of the aromatic hydrogen. At the same time, the ortho-iodide motif (63) can help derivatize the phenylalanine core through cross-coupling. Malonic acid with fused naphthalene (64-65) or heterocycles (66-67) can also be decarboxylated to produce non-proteinogenic amino acids. When ortho-substituents are present (such as 63 and 65), a slight decrease in stereocontrol is observed, which may be due to steric repulsion within the confined catalyst pocket.However, simple recrystallization can enhance the enantioselectivity without a significant loss of yield.
[0368] Synthetic Applications
[0369] Isotope-labeled amino acids can also be obtained (Scheme 20). Given the wide range of applications of these structures in various fields such as proteomics, pharmacokinetics and radiodiagnostics, they are in great demand, and asymmetric malonate synthesis can provide a modular approach with high flexibility in the identity of isotopes and the target position of amino acids. Bottom-up synthesis can easily produce isotope-labeled amino acids. By using a unified synthetic sequence, 13 C and 15 N isotopes can be introduced by early oxime formation, while labeled side chains can be introduced by later substitution. For example, oximes can be generated by condensation reaction with labeled diethyl malonate or sodium nitrite, followed by reduction and benzoylation to generate α- 13 C- or 15 N-16, thereby introducing α- 13 C and 15 On the other hand, labeled side chains can be easily attached by substitution, as demonstrated by the preparation of d3-68 (which has the structure of 68 but with CD3 replacing CH3, i.e., all H in CH3 of 68 are replaced by deuterium). Subsequently, all three labeled malonates undergo acid-catalyzed decarboxylation to provide enantiomerically and isotopically enriched alanines (69-71).
[0370] Scheme 20. Representative applications of asymmetric malonate synthesis
[0371] Non-proteinogenic amino acids with alkyne or azide motifs can be conjugated to other biomolecules via click chemistry. Amino acid-antiretroviral drug and -saccharide conjugates are readily prepared. For example, the alkyne- or azide-substituted amino acids generated herein (29, 38, 57, and 60) can be rapidly conjugated to bioactive cores, demonstrating their utility in the discovery of amino acid- or peptide-based therapeutics (Scheme 21). Using a universal copper catalyst, the cycloaddition reaction between the propargyl group in 29 and the azide motif of zidovudine proceeds smoothly (72). Another amino acid-antiretroviral drug conjugate was prepared from the azide-containing product 57 and propargyl-tethered lamivudine (73). In addition, sugars and amino acids can also be linked using the same strategy (74). Biomolecules
[0372] Scheme 21. Conjugation of non-proteinogenic amino acids with alkyne or azide motifs to other biomolecules
[0373] In addition to being protective groups, 3-alkoxy-4-nitrobenzamides, once reduced to the corresponding anilines, can also serve as α-helix mimetics, which are common in biologically active small molecules and peptides (75, Figure 5 Therefore, we designed a representative decarboxylation / reduction sequence to achieve these motifs (e.g., a DNA gyrase B inhibitor containing a non-natural alanine residue (79)). Starting from the customized aminomalonic acid 76, asymmetric decarboxylation using (S)-CPA-8 resulted in a non-natural alanine motif (77) as the C-terminus of the helix mimetic. Subsequently, hydrogenation of the nitro group exposed the N-terminus (78). Subsequent acylation and ester hydrolysis produced the DNA gyrase B inhibitor 79.
[0374] in conclusion
[0375] Excellent enantiostatic control of acid-catalyzed decarboxylation is achieved using tailored protecting groups (e.g., fluorinated benzoyl) on chiral phosphoric acid and aminomalonic acid. A diverse range of interactions between the two components, particularly the numerous dispersing forces, helps anchor the enol intermediate and enables stereoselective protonation of the phosphoric acid. Enantioselective decarboxylation has made the long-standing elusive synthesis of malonate-based chiral α-amino acids possible. The synthetic scheme disclosed herein introduces amino acid side chains via a simple alkylation of aminomalonic acid esters. Subsequent hydrolysis and decarboxylation yield amino acids with diverse shapes and side chain substituents, thereby providing diverse properties and functionalities.
[0376] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The publications cited herein and the materials cited therein are incorporated herein by reference. In addition, unless otherwise indicated, "wt%" means "wt / wt%."
[0377] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the appended claims.
[0378] References J. Wislicenus, Liebigs Ann. Chem. 186, 161-228 (1877). ACCope,et al.,Org.React.107-331(1957). HOHouse, Modern Synthetic Reactions (The Organic Chemistry Monograph Series). 2nd ed (WA Benjamin, inc., 1972) pp. 492-623. S.Gabriel,Ber.20,2224-2236(1887). MS Gibson and RW Radshaw, Angew. Chem., Int. Ed. Engl. 7, 919-930 (1968). SK Mitra, J. Ind. Chem. Soc. 7, 799-802 (1930). C. Fehr, Angew. Chem. Int. Ed. Engl. 35, 2566-2587 (1996). K.Miyamoto andKourist,R.Appl.Microbiol.Biotechnol.100,8621-8631(2016). M.Wilding,et al.,Comprehensive Chirality,H.Yamamoto,&E.M.Carreira,Eds.(Elsevier,2012)pp.402-409. W.H.Richardson and H.E.O’Neal,Comprehensive Chemical Kinetics:Decomposition and Isomerization of Organic Compounds,C.H.Bamford&C.F.H.TipperEds.(Elsevier,1972)pp.381-565. K.Okrasa,et al.,Angew.Chem.Int.Ed.48,7691-7694(2009). J.Blanchet,et al.,Eur.J.Org.Chem.5493-5506(2008). H.Brunner and M.A.Baur,Eur.J.Org.Chem.2854-2862(2003). M.Rueping,et al.,Chem.Soc.Rev.40,4539-4549(2011). C.Min and D.Seidel,Chem.Soc.Rev.46,5889-5902(2017). T.Akiyama,Chem.Rev.107,5744-5758(2007). T.Akiyama and K.Mori,Chem.Rev.115,9277-9306(2015). M.Terada,Chem.Commun.4097-4112(2008). D.Parmar,et al.,Chem.Rev.114,9047-9153(2014). R.Maji,et al.,Chem.Soc.Rev.47,1142-1158(2018). A.G.Doyle and E.N.Jacobsen,Chem.Rev.107,5713-5743(2007). J.-H.Xie and Q.-L.Zhou,Acc.Chem.Res.41,581-593(2008). A.Rahman and X.Lin,Org.Biomol.Chem.16,4753-4777(2018). G.G.Midyana,et al.,Russ.J.Gen.Chem.80,944-947(2010). I.A.Koppel and V.A.Palm,Advances in Linear Free Energy Relationships(eds.Chapman,N.B.&Shorter,J.)203-280(Springer,1972). K.Watanabe,et al.,Org.Process Res.Dev.11,2,251-258(2007). M.S.Messina and H.D.Maynard,Mater.Chem.Front.4,1040-1051(2020). C.G.Parker and M.R.Pratt,Cell 180,605-632,(2020). D.R.Liu and P.G.Schultz,Proc.Natl.Acad.Sci.USA 96,4780-4785(1999). C.C.Liu and P.G.Schultz,Annu.Rev.Biochem.79,413-444(2010). C.H.Kim,et al.,Curr.Opin.Chem.Biol.17,412-419(2013). M.A.Danielson and J.J.Falke,Annu.Rev.Biophys.Biomol.Struct.25,163-195(1996). K.E.Arntson and W.C.K.Pomerantz,J.Med.Chem.59,5158-5171(2016). J.S.Trimble,et al.,Nature 611,709-714(2022). N.Sun,et al.,Nature 611,715-720(2022). Z.Cheng,et al.,Nat.Rev.Chem.4,275-290(2020). T.Fujita,et al.,Tetrahedron Lett.41,923-927(2000). M.Mann,Nat.Rev.Mol.Cell.Biol.7,952-958(2006). F.Castellani,et al.,Nature 420,99-102(2002). M.T.Lin,et al.,J.Am.Chem.Soc.130,15768-15769(2008). A.Ullah,et al.,Eur.J.Med.Chem.145,140-153(2018). H.Arifian,et al.,Molecules 27,7631-7664(2022). A.Shaginian,et al.,J.Am.Chem.Soc.131,5564-5572(2009). M.Durcik,et al.,Eur.J.Med.Chem.154,117-132(2018). W.H.Richardson and H.E.O’Neal,Comprehensive Chemical Kinetics:Decomposition and Isomerization of Organic Compounds;Bamford C.H.,TipperC.F.H.,Eds.;Elsevier:Amsterdam,The Netherlands,1972;Vol.5,Chapter 4,p381-565. W.Huang,et al.,Org.Lett.2020,22,3245-3250. C.J.Easton,et al.,J.Aust.J.Chem.1997,50,451-456. RHVerschueren,et al.,Org.Biomol.Chem.,2021,19,5782-5787. J.Mao,et al.,J.Am.Chem.Soc.2014,136,17622-17668.
Claims
1. A method for preparing a chiral amino acid, include: (i) maintaining a first reaction mixture at a first temperature for a first period of time sufficient to form a product, wherein the first reaction mixture comprises a substrate, a catalyst, and a solvent, wherein the catalyst is chiral phosphoric acid, and wherein the product comprises a chiral amino acid.
2. The method of claim 1, wherein the substrate is malonate.
3. The method according to claim 2, wherein the malonic acid has a structure of Formula I or Formula I': The chiral amino acid in the product has a structure of Formula II or Formula II': Where P 1 is an amino protecting group, R 1 It is a functional group or part of a biomolecule.
4. The method according to claim 1, further comprising: include: (ii) adding an alkylating reactant or an acid to the product to form a second reaction mixture, and (iii) maintaining the second reaction mixture at a second temperature for a second period of time sufficient to form an alkylated product or a hydrolyzed product, The alkylation product or hydrolysis product comprises an alkylated chiral amino acid or a hydrolyzed chiral amino acid.
5. The method according to claim 4, wherein the alkylated chiral amino acid has a structure of Formula VIII or Formula VIII', and the hydrolyzed chiral amino acid has a structure of Formula V or Formula V': Where P 1 is an amino protecting group, R 1 is a functional group or biomolecule moiety, R 26 is a substituted or unsubstituted alkyl group, such as C 1 -C 12 Unsubstituted alkyl, C 1 -C 10 Unsubstituted alkyl, C 1 -C 8 Unsubstituted alkyl, C 1 -C 6 Unsubstituted alkyl, or C 1 -C 4 unsubstituted alkyl, such as methyl or ethyl, A1 is an acid molecule (such as HCl), optionally, wherein the alkylated chiral amino acid is a methylated chiral amino acid having a structure of Formula IV or Formula IV': Where P 1 is an amino protecting group, R 1 It is a functional group or part of a biomolecule.
6. The method of claim 4, wherein the alkylating reactant in the second reaction mixture is a methylating reactant (such as trimethylsilylated diazomethane), and the acid in the second reaction mixture is HCl.
7. The method according to claim 3, wherein P 1 yes Where L 1 yes: R 2 is hydrogen, hydroxy, halide, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, alkoxy, thiol, amino, amido, carbonyl, cyano, isocyano, nitro, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphonyl; R 3 -R 10 are independently hydrogen, or substituted or unsubstituted alkyl (e.g., unsubstituted alkyl, such as C 1 -C 10 Unsubstituted alkyl, C 1 -C 8 Unsubstituted alkyl, C 1 -C 6 Unsubstituted alkyl, or C 1 -C 4 unsubstituted alkyl); and When present, the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono, optionally wherein L 1 yes 8. The method according to claim 7, wherein R 2 is a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted aryl, a substituted or unsubstituted polyaryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteropolyaryl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aralkyl, an alkoxyl group, a thiol, an amino group, an amide group or a carbonyl group.
9. The method according to claim 7, wherein R 2 yes Where R 11 -R 15 and R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphono.
10. The method according to claim 9, wherein R 11 -R 15 are independently hydrogen, halide, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, unsubstituted phenyl, unsubstituted haloalkyl, unsubstituted aralkyl, cyano, isocyano, nitro, Where R 16 -R 18 are independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted phenyl, unsubstituted halogenated alkyl or unsubstituted aralkyl, R' 18 is an unsubstituted alkyl group.
11. The method according to claim 7, wherein R 2 yes: Where R 12 -R 14 are independently halide (such as F, Cl or I), unsubstituted alkyl, unsubstituted haloalkyl (such as fluoride substituted C 1 -C 6 Alkyl halide, such as -CF 3 ,-CH 2 -CF 3 ,-CH 2 -CH 2 -CF 3 ,-CH 2 -CF 2 -CF 3 ,-CH 2 -CF 2 -CF 2 -CF 3 ), cyano, isocyano, nitro, Where R 16 and R 18 are independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C 1 -C 6 Alkyl halide, such as -CF 3 ,-CH 2 -CF 3 ,-CH 2 -CH 2 -CF 3 ,-CH 2 -CF 2 -CF 3 ,-CH 2 -CF 2 -CF 2 -CF 3 ), or unsubstituted aralkyl (eg, benzyl), R' 18 is an unsubstituted alkyl group.
12. The method according to claim 3, wherein R 1 is a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, or a substituted or unsubstituted alkynyl, and wherein when the substituents are present, the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, nitro, amino, amido, azido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphino, phosphoryl or phosphonyl.
13. The method of claim 12, wherein the substituents, when present, are independently biomolecule moieties.
14. The method of claim 1, wherein the one or more carbons, one or more nitrogens and / or one or more hydrogens of the substrate are 13 C. 14 C. 15 N and / or D form.
15. The method of claim 1, wherein the chiral phosphoric acid is BINOL phosphoric acid or a derivative thereof, H8BINOL phosphoric acid or a derivative thereof, SPINOL phosphoric acid or a derivative thereof, Biphenol phosphoric acid or a derivative thereof, dithiophosphoric acids or a derivative thereof, TADDOL phosphoric acid or a derivative thereof, paracyclophane or a derivative thereof, TiPSY phosphoric acid or a derivative thereof, or TRIP phosphoric acid or a derivative thereof.
16. The method according to claim 1, wherein the chiral phosphoric acid has a structure of Formula III or Formula III': in: R 19 , R 20 , R' 19 , and R' 20 are independently substituted or unsubstituted aryl, or substituted or unsubstituted polyaryl; R 21 -R 24 and R' 21 -R' 24 are independently hydrogen, or unsubstituted alkyl; and When the substituents are present, the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted polyaryl (e.g., naphthyl), substituted or unsubstituted haloalkyl (e.g., fluoride-substituted C 1 -C 6 Alkyl halide, such as -CF 3 ,-CH 2 -CF 3 ,-CH 2 -CH 2 -CF 3 ,-CH 2 -CF 2 -CF 3 ,-CH 2 -CF 2 -CF 2 -CF 3 ),or R 25 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted haloalkyl group (e.g., a fluorine-substituted C 1 -C 6 Alkyl halide, such as -CF 3 ,-CH 2 -CF 3 ,-CH 2 -CH 2 -CF 3 ,-CH 2 -CF 2 -CF 3 ,-CH 2 -CF 2 -CF 2 -CF 3 ), substituted or unsubstituted aryl (e.g. phenyl), or substituted or unsubstituted aralkyl (e.g. benzyl).
17. The method according to claim 16, wherein R 19 and R 20 At least one of R' 19 and R' 20 At least one of the groups is independently a substituted aryl group or a substituted polyaryl group, and optionally, the substituted aryl group or polyaryl group has three or more substituents (such as 2,4,6-substituted phenyl).
18. The method of claim 1, wherein the chiral phosphoric acid has the following structure:
19. The method of claim 1, wherein the catalyst is present in the first reaction mixture in an amount ranging from about 1 mol% to about 20 mol%, about 1 mol% to about 10 mol%, about 2 mol% to about 20 mol%, about 2 mol% to about 10 mol%, or about 2.5 mol% to about 10 mol%, for example, about 10 mol% or about 2.5 mol%.
20. The method according to claim 1, wherein the solvent is ether, optionally, wherein the ether is ethyl acetate, t BuOMe, THF, 2-MeTHF, 1,4-dioxane, cyclopentyl methyl ether (CPME) or (MeOCH 2 CH 2 ) 2 O, or a combination thereof.
21. The method of claim 1, wherein the first reaction mixture is maintained at a temperature in the range of about 50°C to about 100°C, about 60°C to about 100°C, or about 70°C to about 100°C, such as at a temperature of about 80°C, for a duration in the range of about 1 hour to about 12 hours, about 1 hour to about 10 hours, about 1 hour to about 8 hours, about 1 hour to about 5 hours, or about 1 hour to about 3 hours, such as for about 2 hours.
22. The method of claim 4, wherein the second reaction mixture (e.g., for methylation reaction) is maintained at a temperature in the range of about 50°C to about 100°C, about 60°C to about 100°C, or about 70°C to about 100°C, for a time in the range of about 30 minutes to about 2 hours, or about 30 minutes to about 1 hour, or The second reaction mixture (for hydrolysis) is maintained at a temperature ranging from about 90°C to about 120°C, or about 90°C to about 110°C, for a time ranging from about 12 hours to about 36 hours, or about 12 hours to about 24 hours.
23. The process of claim 4, wherein after step (i), the product is cooled to room temperature or about 0°C before adding the alkylation reactant (eg, methylation reactant) or the acid.
24. The method of claim 1, wherein the chiral amino acid is obtained in an amount of at least 80%, or in an amount ranging from about 80% to about 99%, and / or in an enantiomeric excess (ee) of at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, in a range of about 70% to 100%, about 75% to 100%, about 80% to 100%, about 85% to 100%, about 90% to 100%, about 75% to 99%, about 80% to 99%, about 85% to 99%, or about 90% to 99%, as determined by chiral HPLC.
25. The method according to claim 1, further comprising: include: purifying the product after step (i), and / or purifying the alkylation or hydrolysis product after step (iii); The substrate is prepared before step (i); the amino protecting agent and the catalyst are recovered after step (i) and / or step (iii); and / or the chiral amino acid or the alkylated or hydrolyzed chiral amino acid is derivatized into a derivative compound after step (i) and / or step (iii), optionally, wherein the derivative compound is a cyclic amino acid, a drug-amino acid conjugate, or a DNA gyrase inhibitor.
26. A chiral amino acid having a structure of Formula VIII or Formula VIII': Where R 26 is a substituted or unsubstituted alkyl group, such as C 1 -C 12 Unsubstituted alkyl, C 1 -C 10 Unsubstituted alkyl, C 1 -C 8 Unsubstituted alkyl, C 1 -C 6 Unsubstituted alkyl, or C 1 -C 4 unsubstituted alkyl, such as methyl or ethyl; P 1 yes Where R 12 yes R 13 is cyano, isocyano, nitro, or R 16 and R 18 are independently hydrogen, hydroxyl, -OR' 18 , unsubstituted alkyl, unsubstituted haloalkyl (e.g., fluoride-substituted C 1 -C 6 Alkyl halide, such as -CF 3 ,-CH 2 -CF 3 ,-CH 2 -CH 2 -CF 3 ,-CH 2 -CF 2 -CF 3 ,-CH 2 -CF 2 -CF 2 -CF 3 ) or unsubstituted aralkyl (eg benzyl), wherein R' 18 is an unsubstituted alkyl group; R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl, wherein the substituents, when present, are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, carbonyl, alkoxy, halide, hydroxy, thiol, cyano, isocyano, nitro, amino, amido, azido, oxo, silyl, sulfinyl, sulfonyl, phosphonium, phosphonyl, phosphoryl, or phosphonyl.
27. The chiral amino acid according to claim 26, wherein R 26 is methyl or ethyl; R 13 is nitro; R 12 yes R 16 is an unsubstituted haloalkyl group (e.g., a fluoride-substituted C 1 -C 6 Alkyl halide, such as -CF 3 ,-CH 2 -CF 3 ,-CH 2 -CH 2 -CF 3 ,-CH 2 -CF 2 -CF 3 ,-CH 2 -CF 2 -CF 2 -CF 3 ), optionally, where R 16 Yes-CH 2 -CH 2 -CF 3 、-CH 2 -CF 2 -CF 3 , or -CH 2 -CF 2 -CF 2 -CF 3 .
28. The chiral amino acid of claim 26, wherein the substituents, when present, are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteropolyaryl, substituted or unsubstituted heterocyclyl, azido, carbonyl, alkoxy, halide, hydroxyl, thiol, cyano, isocyano, or nitro.
29. The chiral amino acid of claim 26, wherein said substituents, when present, are independently biomolecule moieties (eg, cholic acid moieties, estrone moieties, etc.).
30. The chiral amino acid according to claim 26, wherein R 26 is methyl; R 13 is nitro; R 12 yes R 16 Yes-CH 2 -CF 2 -CF 3 .
